Cameron J. Turtle, Laïla-Aïcha Hanafi, Carolina Berger, Theodore A. Gooley, Sindhu Cherian, Michael Hudecek, Daniel Sommermeyer, Katherine Melville, Barbara Pender, Tanya M. Budiarto, Emily Robinson, Natalia N. Steevens, Colette Chaney, Lorinda Soma, Xueyan Chen, Cecilia Yeung, Brent Wood, Daniel Li, Jianhong Cao, Shelly Heimfeld, Michael C. Jensen, Stanley R. Riddell, David G. Maloney
Title and authors | Publication | Year |
---|---|---|
Molecular dynamics at immune synapse lipid rafts influence the cytolytic behavior of CAR T cells
Gad AZ, Morris JS, Godret-Miertschin L, Montalvo MJ, Kerr SS, Berger H, Lee JC, Saadeldin AM, Abu-Arja MH, Xu S, Vasileiou S, Brock RM, Fousek K, Sheha MF, Srinivasan M, Li Y, Saeedi A, R. Levental K, Leen AM, Mamonkin M, Carisey A, Varadarajan N, Hegde M, Joseph SK, Levental I, Mukherjee M, Ahmed N |
Science Advances | 2025 |
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
Glaviano A, Lau HS, Carter LM, Lee EH, Lam HY, Okina E, Tan DJ, Tan W, Ang HL, Carbone D, Yee MY, Shanmugam MK, Huang XZ, Sethi G, Tan TZ, Lim LH, Huang RY, Ungefroren H, Giovannetti E, Tang DG, Bruno TC, Luo P, Andersen MH, Qian BZ, Ishihara J, Radisky DC, Elias S, Yadav S, Kim M, Robert C, Diana P, Schalper KA, Shi T, Merghoub T, Krebs S, Kusumbe AP, Davids MS, Brown JR, Kumar AP |
Journal of Hematology & Oncology | 2025 |
Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies
Zhang C, Liu H |
Journal of Immunology Research | 2025 |
LLT1 overexpression renders allogeneic-NK resistance and facilitates the generation of enhanced universal CAR-T cells
Zhu S, Zuo S, Li C, You X, Jiang E, Feng X, Luo Y |
Journal of Experimental & Clinical Cancer Research : CR | 2025 |
A multi-kinase inhibitor screen identifies inhibitors preserving stem-cell-like chimeric antigen receptor T cells
Song F, Tsahouridis O, Stucchi S, Walhart T, Mendell S, Hardy PB, Axtman M, Guduru SK, Gilbert TS, Graves LM, Herring LE, Savoldo B, Ma X, Woodcock M, Milner JJ, Ivanova A, Pearce KH, Xu Y, Dotti G |
Nature Immunology | 2025 |
Enforced E-selectin ligand installation enhances homing and efficacy of adoptively transferred T cells
Hou Y, Ye J, Qin K, Cui LA, Chung S, Chapla DG, Wang W, Shi Y, Chen M, Moremen KW, Sackstein R, Wu P |
bioRxiv | 2025 |
Taming Variability in T-Cell Mechanosensing
Schultheiss PJ, Pulkundwar A, Li W, Kam LC |
Cells | 2025 |
Leveraging Vector-Based Gene Disruptions to Enhance CAR T-Cell Effectiveness
Oliveira BC, Bari S, Melenhorst JJ |
Cancers | 2025 |
Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells
Sytsma BJ, Allain V, Bourke S, Faizee F, Fathi M, Ferreira LM, Brewer WJ, Li L, Pan FL, Rothrock AG, Nyberg WA, Li Z, Wilson LH, Berdeaux R, Eyquem J, Pawell RS |
Scientific Reports | 2025 |
CAR‐T Cell Manufacturing for Hematological and Solid Tumors: From the Preclinical to Clinical Point of View
Capolla S, Rasool M, Toffoli G, Dal Bo M |
Cancer Medicine | 2025 |
Clinical evidence of immunogenicity of CAR-T cell therapies and its implication in the clinical development of CAR-T drug products
Alfar HR, Chen C, Lachacz E, Tang W, Zhang Y |
Frontiers in Immunology | 2025 |
Influence of CAR T-cell therapy associated complications
Umair MM, Lai X, Xue Y, Yao H |
Frontiers in Oncology | 2025 |
IFN-gamma and donor leukocyte infusions for relapsed myeloblastic malignancies after allogeneic hematopoietic stem cell transplantation
Sawa Ito, Emily M Geramita, Kedwin Ventura, Biswas Neupane, Shruti S Bhise, Erika M. Moore, Scott N Furlan, Warren Shlomchik |
JCI Insight | 2025 |
Cytokine-mediated increase in endothelial-leukocyte interaction mediates brain capillary plugging during CAR T cell neurotoxicity
Park L, Tsai YT, Lim HK, Faulhaber LD, Burleigh K, Faulhaber EM, Bose M, Shih AY, Hirayama AY, Turtle CJ, Annesley CE, Gardner RA, Gustafson HH, Gust J |
bioRxiv | 2025 |
Emerging Frontiers in Colorectal Cancer Therapy: From Targeted Molecules to Immunomodulatory Breakthroughs and Cell-Based Approaches
Fatemi N, Mirbahari SN, Tierling S, Sanjabi F, Shahrivari S, AmeliMojarad M, Amelimojarad M, Mirzaei Rezaei M, Nobaveh P, Totonchi M, Nazemalhosseini Mojarad E |
Digestive Diseases and Sciences | 2025 |
The Changing Role of Allogeneic Stem Cell Transplantation in Adult B-ALL in the Era of CAR T Cell Therapy
van den Berg J, Meloni C, Halter J, Passweg JR, Holbro A |
Current Oncology | 2025 |
On-demand treatment of metabolic diseases by a synthetic drug-inducible exocytosis system
Si Y, He M, Li Y, Jiang J, Fan Y, Xue S, Qiu X, Xie M |
Nature Communications | 2025 |
Two-Stage CD8+ CAR T-Cell Differentiation in Patients with Large B-Cell Lymphoma
Cao G, Hu Y, Pan T, Tang E, Asby N, Althaus T, Wan J, Riedell PA, Bishop MR, Kline JP, Huang J |
bioRxiv | 2025 |
CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses
Nguyen KA, Liu Z, Davies JS, McIntosh CP, Draper LM, Norberg SM, Rae Z, Achar SR, Altan-Bonnet G, Zhang L, Wu X, Meyer TJ, Kelly MC, Taylor N, Hinrichs CS, Ishii K |
Science Advances | 2025 |
New player in CAR-T manufacture field: comparison of umbilical cord to peripheral blood strategies
Rassek K, Misiak J, Ołdak T, Rozwadowska N, Basak G, Kolanowski T |
Frontiers in Immunology | 2025 |
Strategies for Altering Delivery Technologies to Optimize CAR Therapy
Cao L, Liu Y, Lin G |
International Journal of Molecular Sciences | 2025 |
Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL
Gauthier J, Liang EC, Huang JJ, Kimble EL, Hirayama AV, Fiorenza S, Voutsinas JM, Wu Q(, Jaeger-Ruckstuhl CA, Pender BS, Kirchmeier DR, Torkelson A, Braathen K, Basom R, Shadman M, Kopmar NE, Cassaday RD, Riddell SR, Maloney DG, Turtle CJ |
Blood Advances | 2025 |
MARC, a novel modular chimeric antigen receptor, improves T cell-based cancer immunotherapies by preventing early T cell exhaustion and enhancing persistence
Tual M, Bellemare-Pelletier A, Moore S, Guipouy D, Farzam-Kia N, Jafarzadeh L, Quenneville J, Barrette B, Saba-El-Leil MK, Delisle JS, Gagnon E |
Journal for Immunotherapy of Cancer | 2025 |
Humanizing CAR T-cell therapy in B-ALL
Faramand R, Muffly L |
Blood Advances | 2025 |
Novel strategies to manage CAR-T cell toxicity.
Mulvey A, Trueb L, Coukos G, Arber C |
Nature reviews. Drug discovery | 2025 |
GPR65 Inactivation in Tumor Cells Drives Antigen-Independent CAR T-cell Resistance via Macrophage Remodeling.
Mavuluri J, Dhungana Y, Jones LL, Bhatara S, Shi H, Yang X, Lim SE, Reyes N, Chi H, Yu J, Geiger TL |
Cancer discovery | 2025 |
Two-stage CD8(+) CAR T-cell differentiation in patients with large B-cell lymphoma.
Cao G, Hu Y, Pan T, Tang E, Asby N, Althaus T, Wan J, Riedell PA, Bishop MR, Kline JP, Huang J |
Nature communications | 2025 |
Defining immune reset: achieving sustained remission in autoimmune diseases.
Junt T, Calzascia T, Traggiai E, da Costa AN, Gergely P, Schett G, Dörner T, Siegel RM |
Nature reviews. Immunology | 2025 |
Cellular Kinetics and Biodistribution of Adoptive T Cell Therapies: from Biological Principles to Effects on Patient Outcomes.
Li R, Grosskopf AK, Joslyn LR, Stefanich EG, Shivva V |
The AAPS journal | 2025 |
CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant.
Ikeda S, Hasegawa K, Kogue Y, Arimori T, Kawamoto R, Wibowo T, Yaga M, Inada Y, Uehara H, Matsubara M, Tachikawa M, Suga M, Kida S, Shibata K, Tsutsumi K, Fukushima K, Fujita J, Ueda T, Kusakabe S, Hino A, Ichii M, Hirose A, Nakamae H, Hino M, Nakao T, Inoue M, Yoshihara K, Yoshihara S, Ueda S, Tachi T, Kuroda H, Murakami K, Kijima N, Kishima H, Igashira E, Murakami M, Takiuchi T, Kimura T, Hiroshima T, Kimura T, Shintani Y, Imai C, Yusa K, Mori R, Ogino T, Eguchi H, Takeda K, Oji Y, Kumanogoh A, Takagi J, Hosen N |
Nature cancer | 2025 |
Mitigation and Management of Common Toxicities Associated with the Administration of CAR-T Therapies in Oncology Patients.
Renninger J, Kurz L, Stein H |
Drug safety | 2025 |
Revolutionizing Cancer Treatment: Unveiling the Power of CAR T-cell Therapy.
Barjasteh AH, Saebi M, Mahmoudi M, Kheder RK, Hashemy SI, Forouzanfar F, Esmaeili SA |
Current pharmaceutical design | 2025 |
An Analysis of Monitoring Solutions for CAR T Cell Production.
Shoshi A, Xia Y, Fieschi A, Baumgarten Y, Gaißler A, Ackermann T, Reimann P, Mitschang B, Weyrich M, Bauernhansl T, Miehe R |
Healthcare technology letters | 2025 |
BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells.
Müller F, Wirsching A, Hagen M, Völkl S, Tur C, Raimondo MG, Taubmann J, Bucci L, Zhang L, Kretschmann S, Aigner M, Eckstein M, Spörl S, Kharboutli S, Böltz S, Atzinger A, Munoz L, Schett G, Mackensen A, Grieshaber-Bouyer R |
Nature medicine | 2025 |
Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma
D'Angelo SP, Druta M, Van Tine BA, Liebner D, Schuetze SM, Tap WD, Preston J, Goodison S, D'Souza JW, Kapoor GS, Suchindran S, Zajic S, Bhaskar A, Kaczynski H, Kim J, Klohe E, Corigliano E, Eleftheriadou I, Nathenson MJ, Somaiah N |
Journal of Clinical Oncology | 2025 |
High-dimensional temporal mapping of CAR T cells reveals phenotypic and functional remodeling during manufacturing
Cadinanos-Garai A, Flugel CL, Cheung A, Jiang E, Vaissié A, Abou-el-Enein M |
Molecular Therapy | 2025 |
Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed/refractory B cell non-Hodgkin lymphoma
Wang H, Wang G, Li T, Zhang P, Mao Z, Luo H, Zhu X, Li D, Zhou J, Zhou X, Huang L |
Journal of Translational Medicine | 2025 |
CAR binders affect CAR T-cell tonic signaling, durability, and sensitivity to target
Shukla D, Gabunia K, McGettigan SE, Patel PR, Christensen S, Fan TJ, Song D, Luo Y, Wang Y, Wang H, Young RM, June CH, Scholler J, Riley JL |
Cancer immunology research | 2025 |
Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection
Guo Q, Parikh K, Zhang J, Brinkley A, Chen G, Jakramonpreeya N, Zhen A, An DS |
Molecular Therapy. Methods & Clinical Development | 2025 |
TMIGD2 is a new and effective costimulatory domain in CAR-T cells
treating human solid tumors
Christopher Nishimura, Devin Corrigan, Xiang Zheng, Phillip Galbo Jr, Shan Wang, Yao Liu, Yao Wei, Linna Suo, Wei Cui, Nadia Mercado, Deyou Zheng, Chengcheng Zhang, Xingxing Zang |
Science Advances | 2024 |
Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies.
Li YR, Halladay T, Yang L |
Journal of biomedical science | 2024 |
Endogenous Signaling Molecule Activating (ESMA) CARs: A Novel CAR Design Showing a Favorable Risk to Potency Ratio for the Treatment of Triple Negative Breast Cancer
Ebbinghaus M, Wittich K, Bancher B, Lebedeva V, Appelshoffer A, Femel J, Helm MS, Kollet J, Hardt O, Pfeifer R |
International journal of molecular sciences | 2024 |
CAR T cells for hematological malignancies
Savoldo B, Grover N, Dotti G |
Journal of Clinical Investigation | 2024 |
CAR-T Cell Therapy for Follicular Lymphomas.
Testa U, D'Alò F, Pelosi E, Castelli G, Leone G |
Mediterranean journal of hematology and infectious diseases | 2024 |
Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma.
Yang S, Xu J, Dai Y, Jin S, Sun Y, Li J, Liu C, Ma X, Chen Z, Chen L, Hou J, Mi JQ, Chen SJ |
Nature Communications | 2024 |
Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies.
Baguet C, Larghero J, Mebarki M |
Blood Advances | 2024 |
Nonactivated and IL-7 cultured CD19-specific CAR T cells are enriched in stem cell phenotypes and functionally superior.
Wang SY, Scurti GM, Dalheim AV, Quinn S, Stiff PJ, Nishimura MI |
Blood Advances | 2024 |
"Digital twins elucidate critical role of T(scm) in clinical persistence of TCR-engineered cell therapy".
Joslyn LR, Huang W, Miles D, Hosseini I, Ramanujan S |
npj Systems Biology and Applications | 2024 |
Cancer Nano-Immunotherapy: The Novel and Promising Weapon to Fight Cancer.
García-Domínguez DJ, López-Enríquez S, Alba G, Garnacho C, Jiménez-Cortegana C, Flores-Campos R, de la Cruz-Merino L, Hajji N, Sánchez-Margalet V, Hontecillas-Prieto L |
International journal of molecular sciences | 2024 |
Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma
Negishi S, Girsch JH, Siegler EL, Bezerra ED, Miyao K, Sakemura RL |
Frontiers in Pediatrics | 2024 |
Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation
Netsrithong R, Garcia-Perez L, Themeli M |
Frontiers in immunology | 2024 |
A CAR-T response prediction model for r/r B-NHL patients based on a T cell subset nomogram
Zhang X, Sun R, Zhang M, Zhao Y, Cao X, Guo R, Zhang Y, Liu X, Lyu C, Zhao M |
Cancer Immunology, Immunotherapy | 2024 |
CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies (Review).
Sun D, Shi X, Li S, Wang X, Yang X, Wan M |
Molecular medicine reports | 2024 |
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells.
Mueller J, Schimmer RR, Koch C, Schneiter F, Fullin J, Lysenko V, Pellegrino C, Klemm N, Russkamp N, Myburgh R, Volta L, Theocharides AP, Kurppa KJ, Ebert BL, Schroeder T, Manz MG, Boettcher S |
EMBO Molecular Medicine | 2024 |
Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy
Shishido SN, Hart O, Jeong S, Moriarty A, Heeke D, Rossi J, Bot A, Kuhn P |
Journal for ImmunoTherapy of Cancer | 2024 |
Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism.
Huang Y, Shao M, Teng X, Si X, Wu L, Jiang P, Liu L, Cai B, Wang X, Han Y, Feng Y, Liu K, Zhang Z, Cui J, Zhang M, Hu Y, Qian P, Huang H |
Cell reports. Medicine | 2024 |
GMP-manufactured CRISPR/Cas9 technology as an advantageous tool to support cancer immunotherapy
Caforio M, Iacovelli S, Quintarelli C, Locatelli F, Folgiero V |
Journal of experimental & clinical cancer research : CR | 2024 |
Mechanical forces amplify TCR mechanotransduction in T cell activation and function.
Jeffreys N, Brockman JM, Zhai Y, Ingber DE, Mooney DJ |
2024 | |
Understanding Mechanisms of Response to CAR T-cell Therapy through Single-Cell Sequencing: Insights and Challenges.
Haradhvala NJ, Maus MV |
2024 | |
Disruption of SUV39H1-Mediated H3K9 Methylation Sustains CAR T-cell Function.
Jain N, Zhao Z, Koche RP, Antelope C, Gozlan Y, Montalbano A, Brocks D, Lopez M, Dobrin A, Shi Y, Gunset G, Giavridis T, Sadelain M |
Cancer Discovery | 2024 |
CAR T therapies in multiple myeloma: unleashing the future.
Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, Poondla N, Tanzadehpanah H, Dirbaziyan A, Mahaki H, Manoochehri H, Kalhor N, Dama P |
Cancer Gene Therapy | 2024 |
Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?
Aggeletopoulou I, Kalafateli M, Triantos C |
International journal of molecular sciences | 2024 |
Worldwide research trends on tumor burden and immunotherapy: a bibliometric analysis
Zhang L, Zheng H, Jiang ST, Liu YG, Zhang T, Zhang JW, Lu X, Zhao HT, Sang XT, Xu YY |
International journal of surgery (London, England) | 2024 |
Key role of CD4+ T cells in determining CD8 function during CAR-T cell manufacture
Melenhorst JJ, Oliveira BC |
Journal for ImmunoTherapy of Cancer | 2024 |
CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit
Yi F, Cohen T, Zimmerman N, Dündar F, Zumbo P, Eltilib R, Brophy EJ, Arkin H, Feucht J, Gormally MV, Hackett CS, Kropp KN, Etxeberria I, Chandran SS, Park JH, Hsu KC, Sadelain M, Betel D, Klebanoff CA |
2024 | |
Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics.
Kirouac DC, Zmurchok C, Morris D |
npj Systems Biology and Applications | 2024 |
Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models.
Jamali A, Ho N, Braun A, Adabi E, Thalheimer FB, Buchholz CJ |
EMBO Molecular Medicine | 2024 |
Automated manufacture of ΔNPM1 TCR-engineered T cells for AML therapy
Yonezawa Ogusuku IE, Herbel V, Lennartz S, Brandes C, Argiro E, Fabian C, Hauck C, Hoogstraten C, Veld S, Hageman L, Teppert K, Koutsoumpli G, Griffioen M, Mockel-Tenbrinck N, Schaser T, de Groot R, Johnston IC, Lock D |
2024 | |
Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies
León-Román J, Iacoboni G, Bermejo S, Carpio C, Bolufer M, García-Carro C, Sánchez-Salinas M, Alonso-Martínez C, Bestard O, Barba P, Soler MJ |
Clinical Kidney Journal | 2024 |
Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives
Levstek L, Janžič L, Ihan A, Kopitar AN |
Frontiers in immunology | 2024 |
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy
Shao W, Yao Y, Yang L, Li X, Ge T, Zheng Y, Zhu Q, Ge S, Gu X, Jia R, Song X, Zhuang A |
Experimental Hematology and Oncology | 2024 |
Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
Chen T, Wang M, Chen Y, Liu Y |
Cancer Cell International | 2024 |
Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy
Lin MY, Nam E, Shih RM, Shafer A, Bouren A, Ayala Ceja M, Harris C, Khericha M, Vo KH, Kim M, Tseng CH, Chen YY |
Journal of Experimental Medicine | 2024 |
Tumor microenvironment reprogramming by nanomedicine to enhance the effect of tumor immunotherapy
Huang Y, Fan H, Ti H |
Asian Journal of Pharmaceutical Sciences | 2024 |
Torque Teno Virus DNA Load in Blood as an Immune Status Biomarker in Adult Hematological Patients: The State of the Art and Future Prospects
Albert E, Giménez E, Hernani R, Piñana JL, Solano C, Navarro D |
Viruses | 2024 |
Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy.
Gabelli M, Oporto-Espuelas M, Burridge S, Chu J, Farish S, Hedges E, Ware K, Williams L, Young L, Alajangi R, Ancliff P, Bartram J, Bonney D, Chenchara L, Chiesa R, Cugno C, Hodby K, Jalowiec KA, Lazareva A, Lucchini G, Mirci-Danicar OC, Mullanfiroze K, Pavasovic V, Rao A, Rao K, Riley L, Samarasinghe S, Shenton G, Silva J, Vora A, Hough R, Amrolia PJ, Ghorashian S |
Blood Advances | 2024 |
Therapeutic bacteria and viruses to combat cancer: double-edged sword in cancer therapy: new insights for future
Yarahmadi A, Zare M, Aghayari M, Afkhami H, Jafari GA |
Cell communication and signaling : CCS | 2024 |
Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system
Khaniya A, Rad SM, Halpin J, Tawinwung S, McLellan A, Suppipat K, Hirankarn N |
Journal for ImmunoTherapy of Cancer | 2024 |
Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes
Khvorost D, Kendall B, Jazirehi AR |
Cells | 2024 |
In vitro encapsulation and expansion of T and CAR-T cells using 3D synthetic thermo-responsive matrices
Lizana-Vasquez GD, Mendez-Vega J, Cappabianca D, Saha K, Torres-Lugo M |
RSC Advances | 2024 |
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial.
Hegde M, Navai S, DeRenzo C, Joseph SK, Sanber K, Wu M, Gad AZ, Janeway KA, Campbell M, Mullikin D, Nawas Z, Robertson C, Mathew PR, Zhang H, Mehta B, Bhat RR, Major A, Shree A, Gerken C, Kalra M, Chakraborty R, Thakkar SG, Dakhova O, Salsman VS, Grilley B, Lapteva N, Gee A, Dotti G, Bao R, Salem AH, Wang T, Brenner MK, Heslop HE, Wels WS, Hicks MJ, Gottschalk S, Ahmed N |
Nature cancer | 2024 |
Targeting senescent cells with NKG2D-CAR T cells
Deng Y, Kumar A, Xie K, Schaaf K, Scifo E, Morsy S, Li T, Ehninger A, Bano D, Ehninger D |
Cell Death Discovery | 2024 |
CAR-T cell manufacturing landscape—Lessons from the past decade and considerations for early clinical development
Dias J, Garcia J, Agliardi G, Roddie C |
2024 | |
Stealth transgenes enable CAR-T cells to evade host immune responses.
Grauwet K, Berger T, Kann MC, Silva H, Larson R, Leick MB, Bailey SR, Bouffard AA, Millar D, Gallagher K, Turtle CJ, Frigault MJ, Maus MV |
Journal for ImmunoTherapy of Cancer | 2024 |
CD20 CAR T cells safely and reversibly ablate B cell follicles in a non-human primate model of HIV persistence.
Bui JK, Starke CE, Poole NH, Rust BJ, Jerome KR, Kiem HP, Peterson CW |
Molecular Therapy | 2024 |
Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T
Ruggeri Barbaro N, Drashansky T, Tess K, Djedaini M, Hariri R, He S, van der Touw W, Karasiewicz K |
Journal for ImmunoTherapy of Cancer | 2024 |
Deleting the mitochondrial respiration negative regulator MCJ enhances the efficacy of CD8(+) T cell adoptive therapies in pre-clinical studies.
Wu MH, Valenca-Pereira F, Cendali F, Giddings EL, Pham-Danis C, Yarnell MC, Novak AJ, Brunetti TM, Thompson SB, Henao-Mejia J, Flavell RA, D'Alessandro A, Kohler ME, Rincon M |
Nature Communications | 2024 |
Engineered CAR‐T cells targeting the non‐functional P2X purinoceptor 7 (P2X7) receptor as a novel treatment for ovarian cancer
Bandara V, Niktaras VM, Willett VJ, Chapman H, Lokman NA, Macpherson AM, Napoli S, Gundsambuu B, Foeng J, Sadlon TJ, Coombs J, McColl SR, Barry SC, Oehler MK, Ricciardelli C |
IBMS BoneKEy | 2024 |
Preclinical evaluation of cyclophosphamide and fludarabine combined with CD19 CAR-T in the treatment of B-cell hematologic malignancies in vivo
XIA Z, TIAN M, CHENG Y, YI W, DU Z, LI T, WEN Y, LI L, LIU Y, CHEN C |
Oncology research | 2024 |
Chimeric antigen receptor T cell therapy for autoimmune disease.
Chung JB, Brudno JN, Borie D, Kochenderfer JN |
Nature reviews. Immunology | 2024 |
The Unprecedented Success of Chimeric Antigen Receptor T-Cell Therapy in the Treatment of Hematological Malignancies
Dhaliwal S, Gill FS, Hamid P |
Cureus | 2024 |
qPCR assay for detection of Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Elements from CAR-T and TCR-T cells in fresh and formalin-fixed tissue
Pullarkat S, Black G, Bleakley M, Buenrostro D, Chapuis AG, Hirayama AV, Jaeger-Ruckstuhl CA, Kimble EL, Lee BM, Maloney DG, Radich J, Seaton BW, Specht JM, Turtle CJ, Woolston DW, Wright JH, Yeung CC |
PloS one | 2024 |
Feasibility and optimization of 19F MRI on a clinical 3T with a large field-of-view torso coil
Lechuga LM, Cho MM, Vail DM, Captini CM, Fain SB, Begovatz P |
Physics in Medicine and Biology | 2024 |
Selective refueling of CAR T cells using ADA1 and CD26 boosts antitumor immunity
Hu Y, Sarkar A, Song K, Michael S, Hook M, Wang R, Heczey A, Song X |
Cell reports. Medicine | 2024 |
Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia
Oh BL, Vinanica N, Wong DM, Campana D |
Haematologica | 2024 |
Advances in research on factors affecting chimeric antigen receptor T‐cell efficacy
Zhou D, Zhu X, Xiao Y |
Cancer Medicine | 2024 |
Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies
Skeate JG, Pomeroy EJ, Slipek NJ, Jones BJ, Wick BJ, Chang JW, Lahr WS, Stelljes EM, Patrinostro X, Barnes B, Zarecki T, Krueger JB, Bridge JE, Robbins GM, McCormick MD, Leerar JR, Wenzel KT, Hornberger KM, Walker K, Smedley D, Largaespada DA, Otto N, Webber BR, Moriarity BS |
Molecular Therapy | 2024 |
The role of CD4+ CAR T cells in cancer immunotherapy
Bove C, Maher J, Glover M |
Translational cancer research | 2024 |
Overcoming the Challenges of Primary Resistance and Relapse after CAR-T cell Therapy
Dreyzin A, Rankin AW, Luciani K, Gavrilova T, Shah NN |
Expert Review of Clinical Immunology | 2024 |
Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia
Gamal W, Mediavilla-Varela M, Uriepero-Palma A, Pinilla-Ibarz J, Sahakian E |
International journal of molecular sciences | 2024 |
Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
Cordeiro AC, Durisek G, Batista MV, Schmidt J, de Lima M, Bezerra E |
Frontiers in Oncology | 2024 |
Universal CAR 2.0 to overcome current limitations in CAR therapy
Schlegel LS, Werbrouck C, Boettcher M, Schlegel P |
Frontiers in immunology | 2024 |
Updates on the mechanisms of toxicities associated with monoclonal antibodies targeting growth factor signaling and immune cells in cancer
Park M, Kim JW |
Toxicological Research | 2024 |
A bibliometric and knowledge-map study on the treatment of hematological malignancies with CAR-T cells from 2012 to 2023
Huang Q, Li H, Zhang Y |
Human Vaccines & Immunotherapeutics | 2024 |
CXCR4 has a dual role in improving the efficacy of BCMA-redirected CAR-NK cells in multiple myeloma
Moles MW, Erdlei H, Menzel L, Massaro M, Fiori A, Bunse M, Schrimpf M, Gerlach K, Gudipati V, Reiser J, Mathavan K, Goodrich JP, Huppa JB, Krönke J, Valamehr B, Höpken UE, Rehm A |
Frontiers in immunology | 2024 |
Streamlined measurement of chimeric antigen receptor T-cell concentration, size, viability and two-color phenotyping during manufacturing
Pajarillo R, Paruzzo L, Carturan A, Ugwuanyi O, White G, Guruprasad P, Ballard HJ, Patel RP, Zhang Y, Lee YG, Hong SJ, Dittami GM, Ruella M |
Cytotherapy | 2024 |
Overview of infectious complications among CAR T- cell therapy recipients
Arya S, Shahid Z |
Frontiers in Oncology | 2024 |
Optimization of preparation method and specificity verification of cat CD19 monoclonal antibody for disease diagnosis and treatment
Shen L, Yan S, Xu A, Lan D, Jiang X, Peng Y, Wang S, Wang Z, Chen Y |
Heliyon | 2024 |
Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells.
Sytsma BJ, Allain V, Bourke S, Faizee F, Fathi M, Berdeaux R, Ferreira LMR, Brewer WJ, Li L, Pan FL, Rothrock AG, Nyberg WA, Li Z, Wilson LH, Eyquem J, Pawell RS |
bioRxiv : the preprint server for biology | 2024 |
Humanization of the antigen-recognition domain does not impinge on the antigen-binding, cytokine secretion, and antitumor reactivity of humanized nanobody-based CD19-redirected CAR-T cells.
Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F |
Journal of Translational Medicine | 2024 |
Activated CD4(+) T Cell Proportion in the Peripheral Blood Correlates with the Duration of Cytokine Release Syndrome and Predicts Clinical Outcome after Chimeric Antigen Receptor T Cell Therapy.
Kitamura W, Asada N, Ikegawa S, Fujiwara H, Kamoi C, Ennishi D, Nishimori H, Fujii K, Fujii N, Matsuoka KI, Maeda Y |
Internal medicine (Tokyo, Japan) | 2024 |
The Kinetics of Inflammation-Related Proteins and Cytokines in Children Undergoing CAR-T Cell Therapy—Are They Biomarkers of Therapy-Related Toxicities?
Marschollek P, Liszka K, Mielcarek-Siedziuk M, Dachowska-Kałwak I, Haze N, Panasiuk A, Olejnik I, Jarmoliński T, Frączkiewicz J, Gamrot Z, Radajewska A, Bil-Lula I, Kałwak K |
Biomedicines | 2024 |
The Spectrum of CAR Cellular Effectors: Modes of Action in Anti-Tumor Immunity
Nguyen NT, Müller R, Briukhovetska D, Weber J, Feucht J, Künkele A, Hudecek M, Kobold S |
Cancers | 2024 |
A CAR enhancer increases the activity and persistence of CAR T cells.
Rakhshandehroo T, Mantri SR, Moravej H, Louis BBV, Salehi Farid A, Munaretto L, Regan K, Khan RMM, Wolff A, Farkash Z, Cong M, Kuhnast A, Nili A, Lee UJ, Allen HH, Berland L, Simkova E, Uslu SC, Tavakolpour S, Rowley JE, Codet E, Shahbazian H, Baral J, Pyrdol J, Jacobson CA, Nadeem O, Nia HT, Wucherpfennig KW, Rashidian M |
Nature Biotechnology | 2024 |
PD-L1(+) macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B-cell lymphoma microenvironment impact CD19 CAR-T cell immunotherapy efficacy.
Hirayama AV, Wright JH, Smythe KS, Fiorenza S, Shaw AN, Gauthier J, Maloney DG, Naresh KN, Yeung CCS, Turtle CJ |
HemaSphere | 2024 |
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial.
Wang L, Fang C, Kang Q, Huang W, Chen Z, Zhao W, Wang L, Wang Y, Tan K, Guo X, Xu Y, Wang S, Wang L, Qiao J, Tang Z, Yu C, Xu Y, Li Y, Yu L |
Blood Cancer Journal | 2024 |
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses.
Lertsumitkul L, Iliopoulos M, Wang SS, McArthur SJ, Ebert LM, Davenport AJ, Endersby R, Hansford JR, Drummond KJ, Cross R, Jenkins MR |
Journal for ImmunoTherapy of Cancer | 2024 |
Advanced strategies in improving the immunotherapeutic effect of CAR-T cell therapy.
Wang M, Jia L, Dai X, Zhang X |
Molecular Oncology | 2024 |
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma
Mejia Saldarriaga M, Pan D, Unkenholz C, Mouhieddine TH, Velez-Hernandez JE, Engles K, Fein JA, Monge J, Rosenbaum C, Pearse R, Jayabalan D, Gordillo C, Chan HT, Yamshon S, Thibaud S, Mapara M, Inghirami G, Lentzsch S, Reshef R, Rossi A, Parekh S, Jagannath S, Richard S, Niesvizky R, Bustoros M |
Blood Advances | 2024 |
Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma
Gong IY, Tran D, Saibil S, Laister RC, Kuruvilla J |
HemaSphere | 2024 |
Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy
Xia X, Yang Z, Lu Q, Liu Z, Wang L, Du J, Li Y, Yang DH, Wu S |
Molecular Cancer | 2024 |
Acute T-cell lymphoblastic leukemia: chimeric antigen receptor technology may offer a new hope
Jing J, Ma Y, Xie Z, Wang B, Chen Y, Chi E, Wang J, Zhang K, Wang Z, Li S |
Frontiers in Immunology | 2024 |
Strategies for Improving CAR T Cell Persistence in Solid Tumors
Wittling MC, Cole AC, Brammer B, Diatikar KG, Schmitt NC, Paulos CM |
Cancers | 2024 |
Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system
Chang PS, Chen YC, Hua WK, Hsu JC, Tsai JC, Huang YW, Kao YH, Wu PH, Wang PN, Chang YF, Chang MC, Chang YC, Jian SL, Lai JS, Lai MT, Yang WC, Shen CN, Wen KL, Wu SC |
PLOS ONE | 2024 |
Activation of Cell-Intrinsic Signaling in CAR-T Cells via a Chimeric IL7R Domain
Vorri SC, Holl NJ, Leeming M, Apostolova P, Marple A, Ravich JW, Canbaz A, Rahnama R, Choe J, Modi A, Fearnow AD, Walsh ST, Pearce EL, Varadhan R, Bonifant CL |
Cancer Research Communications | 2024 |
Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy
Fang M, Allen A, Luo C, Finn JD |
Frontiers in Immunology | 2024 |
Human plasma cells engineered to secrete bispecifics drive effective in vivo leukemia killing
Hill TF, Narvekar P, Asher GD, Edelstein JN, Camp ND, Grimm A, Thomas KR, Leiken MD, Molloy KM, Cook PJ, Arlauckas SP, Morgan RA, Tasian SK, Rawlings DJ, James RG |
Molecular Therapy | 2024 |
Development of an antigen-based approach to noninvasively image CAR T cells in real time and as a predictive tool
Fröse J, Rowley J, Farid AS, Rakhshandehroo T, Leclerc P, Mak H, Allen H, Moravej H, Munaretto L, Millan-Barea L, Codet E, Glockner H, Jacobson C, Hemann M, Rashidian M |
Science Advances | 2024 |
Chick Embryo Chorioallantoic Membrane as a Platform for Assessing the In Vivo Efficacy of Chimeric Antigen Receptor T-cell Therapy in Solid Tumors
Nipper AJ, Warren EA, Liao KS, Liu HC, Michikawa C, Porter CE, Wells GA, Villanueva M, Brasil da Costa FH, Veeramachaneni R, Villanueva H, Suzuki M, Sikora AG |
ImmunoHorizons | 2024 |
CAR T-cells for pediatric solid tumors: where to go from here?
Trautmann T, Yakobian N, Nguyen R |
Cancer metastasis reviews | 2024 |
Humoral Immunity and Antibody Responses against Diphtheria, Tetanus, and Pneumococcus after Immune Effector Cell Therapies: A Prospective Study
Angelidakis G, Chemaly RF, Sahasrabhojane PV, Morado-Aramburo O, Jiang Y, Bhatti MM, Shpall E, Hosing C, Jain P, Mahadeo KM, Khawaja F, Elhajj P, Wargo JA, Jenq RR, Ajami NJ, Kebriaei P, Ariza-Heredia EJ |
Vaccines | 2024 |
Identification of early predictive biomarkers for severe cytokine release syndrome in pediatric patients with chimeric antigen receptor T-cell therapy
Su M, Chen L, Xie L, Fleurie A, Jonquieres R, Cao Q, Li B, Liang J, Tang Y |
Frontiers in Immunology | 2024 |
Quantification of circulating TCR-engineered T cells targeting a human endogenous retrovirus post-adoptive transfer using nanoplate digital PCR
Barisic S, Cherkasova E, Nadal R, Tian X, Chen L, Parrizzi A, Reger RN, Scurti GM, Nishimura MI, Childs RW |
Molecular Therapy. Methods & Clinical Development | 2024 |
PD1CD28 chimeric molecule enhances EGFRvⅢ specific CAR-T cells in xenograft experiments in mouse models
Chen W, Xian N, Zhao N, Zhang Q, Xu Y |
PLOS ONE | 2024 |
Fratricide-resistant CD7-CAR T cells in T-ALL.
Oh BLZ, Shimasaki N, Coustan-Smith E, Chan E, Poon L, Lee SHR, Yeap F, Tan LK, Chai LYA, Le Bert N, Tan N, Bertoletti A, Chen SP, Del Bufalo F, Becilli M, Locatelli F, Yeoh AEJ, Campana D |
Nature medicine | 2024 |
Anti-BCMA CAR-T therapy for multiple myeloma with extramedullary disease: A case report and review of the literature.
Shi H, Zhang M, Su Y, Liu J, Guo J, Liu M, Ma Q |
Medicine | 2024 |
Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells.
Sytsma BJ, Allain V, Bourke S, Faizee F, Fathi M, Berdeaux R, Ferreira LMR, Brewer WJ, Li L, Pan FL, Rothrock AG, Nyberg WA, Li Z, Wilson LH, Eyquem J, Pawell RS |
Research square | 2024 |
Advancement and Challenges in Monitoring of CAR-T Cell Therapy: A Comprehensive Review of Parameters and Markers in Hematological Malignancies.
Ploch W, Sadowski K, Olejarz W, Basak GW |
Cancers | 2024 |
Generation of ex vivo autologous hematopoietic stem cell-derived T lymphocytes for cancer immunotherapy
Maneechai K, Khopanlert W, Noiperm P, Udomsak P, Viboonjuntra P, Julamanee J |
Heliyon | 2024 |
The influence of CRS and ICANS on the efficacy of anti-CD19 CAR-T treatment for B-cell acute lymphoblastic leukemia
Ma Y, Zhou H, Zhang J, Zhang Q, Li Y, Xie R, Zhang B, Shen Z, Li P, Liang A, Zhou K, Han L, Hu Y, Xu K, Sang W, Wang X |
Frontiers in Immunology | 2024 |
Revolutionizing the treatment for nasopharyngeal cancer: the impact, challenges and strategies of stem cell and genetically engineered cell therapies.
Looi CK, Loo EM, Lim HC, Chew YL, Chin KY, Cheah SC, Goh BH, Mai CW |
Frontiers in immunology | 2024 |
Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic review and meta-analysis
Han MW, Jeong SY, Suh CH, Park H, Guenette JP, Huang RY, Kim KW, Yoon DH |
Frontiers in Neurology | 2024 |
Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting.
Wan X, Wisskirchen K, Jin T, Yang L, Wang X, Wu X, Liu F, Wu Y, Ma C, Pang Y, Li Q, Zhang K, Protzer U, Du S |
Clinical and molecular hepatology | 2024 |
Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells.
Khaliulin M, Valiullina A, Petukhov A, Yuan Y, Spada S, Bulatov E |
Cancer immunology, immunotherapy : CII | 2024 |
Genetically modified and unmodified cellular approaches to enhance graft versus leukemia effect, without increasing graft versus host disease: the use of allogeneic cytokine-induced killer cells
Rambaldi B, Rizzuto G, Rambaldi A, Introna M |
Frontiers in Immunology | 2024 |
Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies.
Li S, Shi L, Zhao L, Guo Q, Li J, Liu ZL, Guo Z, Cao YJ |
Nature communications | 2024 |
Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I/II trial
Volkov J, Nunez D, Mozaffar T, Stadanlick J, Werner M, Vorndran Z, Ellis A, Williams J, Cicarelli J, Lam Q, Furmanak T, Schmitt C, Hadi-Nezhad F, Thompson D, Miller C, Little C, Chang D, Basu S |
Molecular Therapy | 2024 |
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study.
Ortí G, Peczynski C, Boreland W, O'Reilly M, von Bonin M, Balduzzi A, Besley C, Kalwak K, Ryhänen S, Güngör T, Wynn RF, Bader P, Mielke S, Blaise D, Amrolia P, Yakoub-Agha I, Calkoen F, Schubert ML, Potter V, Pichler H, Kröger N, Kwon M, Sengeloev H, Torrent A, Chalandon Y, van Gorkom G, Koenecke C, Graham C, Schoemans H, Moiseev I, Penack O, Peric Z |
Leukemia | 2024 |
Identification and Characterization of Fully Human FOLR1-Targeting CAR T Cells for the Treatment of Ovarian Cancer
Bethke M, Abramowski P, Droste M, Felsberger A, Kochsiek L, Kotter B, Plettig L, Antonova K, Baghdo S, Burzan N, Tomszak F, Martinez-Osuna M, Eckardt D, Herbel C |
Cells | 2024 |
Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects
Alidadi M, Barzgar H, Zaman M, Paevskaya OA, Metanat Y, Khodabandehloo E, Moradi V |
Frontiers in Cell and Developmental Biology | 2024 |
Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias
Guerrero-Murillo M, Rill-Hinarejos A, Trincado JL, Bataller A, Ortiz-Maldonado V, Benítez-Ribas D, Español-Rego M, González-Navarro EA, Martínez-Cibrián N, Marchese D, Martín-Martín L, Martín García-Sancho A, Rives S, Heyn H, Juan M, Urbano-Ispizúa Á, Delgado J, Orfao A, Mereu E, Bueno C, Menendez P |
Cell Reports Medicine | 2024 |
Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukemia in children and young adults
Feuchtinger T, Bader P, Subklewe M, Breidenbach M, Willier S, Metzler M, Gökbuget N, Hauer J, Müller F, Schlegel PG, Frühwald M, Schmid C, Troeger A, Baldus C, Meisel R, Künkele A, Topp M, Bourquin JP, Cario G, von Stackelberg A, Peters C |
Haematologica | 2024 |
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
Tao Z, Chyra Z, Kotulová J, Celichowski P, Mihályová J, Charvátová S, Hájek R |
Blood Cancer Journal | 2024 |
Advances in Induced Pluripotent Stem Cell-Derived Natural Killer Cell Therapy
Qiao W, Dong P, Chen H, Zhang J |
Cells | 2024 |
Cullin-5 deficiency promotes chimeric antigen receptor T cell effector functions potentially via the modulation of JAK/STAT signaling pathway
Adachi Y, Terakura S, Osaki M, Okuno Y, Sato Y, Sagou K, Takeuchi Y, Yokota H, Imai K, Steinberger P, Leitner J, Hanajiri R, Murata M, Kiyoi H |
Nature Communications | 2024 |
Chimeric antigen receptor T-cell therapy in autoimmune diseases
Liu J, Zhao Y, Zhao H |
Frontiers in Immunology | 2024 |
Breaking barriers: advancing cellular therapies in autoimmune disease management
Fu Y, Feng C, Qin S, Xing Z, Liu C, Liu Z, Yu H |
Frontiers in Immunology | 2024 |
肿瘤免疫疗法中细胞来源对治疗效果的影响
|
Chinese Journal of Hematology | 2024 |
Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection
Guo Q, Parikh K, Zhang J, Brinkley A, Chen G, Jakramonpreeya N, Zhen A, An DS |
bioRxiv | 2024 |
From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases
Bulliard Y, Freeborn R, Uyeda MJ, Humes D, Bjordahl R, de Vries D, Roncarolo MG |
Frontiers in Immunology | 2024 |
Acute Myeloid Leukaemia and Acute Lymphoblastic Leukaemia Classification and Metabolic Characteristics for Informing and Advancing Treatment
Wemyss C, Jones E, Stentz R, Carding SR |
Cancers | 2024 |
Increased functional potency of multi-edited CAR-T cells manufactured by a non-viral transfection system
O\u2019Sullivan A, Case S, McCrudden A, Hackett E, Gallagher L, Martin D, Johnson GP, Mahadik K, Kienzle T, Lim JK, Nashat A, Srinivasan K, Lowdell MW, O\u2019Flynn L, Frankish J |
Molecular Therapy. Methods & Clinical Development | 2024 |
How I treat postimmunotherapy relapsed B-ALL
Lamble AJ, Kovach AE, Shah NN |
Blood | 2024 |
Universal protection of allogeneic T-cell therapies from natural killer cells via CD300a agonism
Zhang SQ, Thomas F, Fang J, Austgen K, Cowan C, Welstead GG |
Blood Advances | 2024 |
Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Jaeger-Ruckstuhl CA, Specht JM, Voutsinas JM, MacMillan HR, Wu Q(, Muhunthan V, Berger C, Pullarkat S, Wright JH, Yeung CC, Hyun TS, Seaton B, Aicher LD, Song X, Pierce RH, Lo Y, Cole GO, Lee SM, Newell EW, Maloney DG, Riddell SR |
Clinical Cancer Research | 2024 |
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
Altan M, Lopes G, Hiltermann TJ, Govindan R, Villaruz LC, Calvo E, Edelman MJ, Furqan M, Neal J, Felip E, Carlisle JW, Heymach JV, O\u2019Cearbhaill RE, Zauderer M, Chisamore M, Corigliano E, Eleftheriadou I, Zajic S, Jenkins B, Goodison S, Suchindran S, Ramos-Hernandez N, Tarek N, Schoenfeld AJ |
Clinical Cancer Research | 2024 |
Development and validation of predictive models of early immune effector cell–associated hematotoxicity
Liang EC, Huang JJ, Portuguese AJ, Ortiz-Maldonado V, Albittar A, Wuliji N, Basom R, Jeon Y, Wu Q, Torkelson A, Kirchmeier D, Chutnik A, Pender B, Sorror M, Hill JA, Kopmar NE, Banerjee R, Cowan AJ, Green D, Gopal AK, Poh C, Shadman M, Hirayama AV, Till BG, Kimble EL, Iovino L, Chapuis AG, Otegbeye F, Cassaday RD, Milano F, Turtle CJ, Maloney DG, Gauthier J |
Blood Advances | 2024 |
Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
de Oliveira Canedo G, Roddie C, Amrolia PJ |
Blood Advances | 2024 |
Bioengineered therapeutic systems for improving antitumor immunity
Cao Y, Yan W, Yi W, Yin Q, Li Y |
National Science Review | 2024 |
Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia
Nair MS, Silbert SK, Rejeski K, Wilson KA, Lamble AJ, Valtis Y, Yates B, Morales Arana A, Shouval R, Curran K, Gardner RA, Shalabi H, Annesley C, Park JH, Subklewe M, Shah NN |
Blood | 2024 |
Inconsistent reporting and definitions of time-to-event endpoints in CAR T clinical trials: A review
Grady CB, Li Y, Maude SL, Hexner EO, Frey NV, Porter DL, Hwang WT |
Transplantation and cellular therapy | 2024 |
Depletion of Tregs from CD4 + CAR‐T cells enhances the tumoricidal effect of CD8 + CAR‐T cells in anti‐CD19 CAR‐T therapy
Sun Y, Liu J, Zhan D, Wei J, XianShi L, Zhang R, Duan C, Zhang D, Tang X, Lin T, Li L, Lai X |
The Febs Journal | 2024 |
Long-term remission following CAR-T therapy in a patient with transformed follicular lymphoma relapse after allogeneic stem cell transplantation.
Kubo R, Onodera K, Onishi Y, Fukuhara N, Harigae H |
Annals of hematology | 2024 |
CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses
Bove C, Arcangeli S, Falcone L, Camisa B, El Khoury R, Greco B, De Lucia A, Bergamini A, Bondanza A, Ciceri F, Bonini C, Casucci M |
Journal for ImmunoTherapy of Cancer | 2023 |
Development of HIV-Resistant CAR T Cells by CRISPR/Cas-Mediated CAR Integration into the CCR5 Locus
Rothemejer FH, Lauritsen NP, Juhl AK, Schleimann MH, König S, Søgaard OS, Bak RO, Tolstrup M |
Viruses | 2023 |
Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma?
Miyao K, Yokota H, Sakemura RL |
Frontiers in Oncology | 2023 |
The frequency of differentiated CD3+CD27-CD28- T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma
Worel N, Grabmeier-Pfistershammer K, Kratzer B, Schlager M, Tanzmann A, Rottal A, Körmöczi U, Porpaczy E, Staber PB, Skrabs C, Herkner H, Gudipati V, Huppa JB, Salzer B, Lehner M, Saxenhuber N, Friedberg E, Wohlfarth P, Hopfinger G, Rabitsch W, Simonitsch-Klupp I, Jäger U, Pickl WF |
Frontiers in immunology | 2023 |
CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory/relapsed acute B lymphocytic leukemia: Long-term follow-up results
Li Z, Yang K, Song Y, Zhao Y, Wu F, Wen X, Li J, Wang X, Xu T, Zheng X, Zheng Q, Wu T |
Frontiers in Oncology | 2023 |
Enhancing CAR-T cell functionality in a patient-specific manner
Zhang DK, Adu-Berchie K, Iyer S, Liu Y, Cieri N, Brockman JM, Neuberg D, Wu CJ, Mooney DJ |
Nature Communications | 2023 |
Germline T cell receptor exchange results in physiological T cell development and function
Rollins MR, Raynor JF, Miller EA, Butler JZ, Spartz EJ, Lahr WS, You Y, Burrack AL, Moriarity BS, Webber BR, Stromnes IM |
Nature Communications | 2023 |
Analysis of causes for poor persistence of CAR-T cell therapy in vivo
Kong Y, Tang L, You Y, Li Q, Zhu X |
Frontiers in immunology | 2023 |
Comparison of the efficacy of second and third generation lentiviral vector transduced CAR CD19 T cells for use in the treatment of acute lymphoblastic leukemia both in vitro and in vivo models
Sawaisorn P, Atjanasuppat K, Uaesoontrachoon K, Rattananon P, Treesuppharat W, Hongeng S, Anurathapan U |
PloS one | 2023 |
Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy
Liu Z, Shi M, Ren Y, Xu H, Weng S, Ning W, Ge X, Liu L, Guo C, Duo M, Li L, Li J, Han X |
Molecular Cancer | 2023 |
Assessment of anti-CD20 antibody pre-treatment for augmentation of CAR-T cell therapy in SIV-infected rhesus macaques
Pampusch MS, Sevcik EN, Quinn ZE, Davey BC, Berg JM, Gorrell-Brown I, Abdelaal HM, Rakasz EG, Rendahl A, Skinner PJ |
Frontiers in immunology | 2023 |
Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL
Song F, Hu Y, Zhang Y, Zhang M, Yang T, Wu W, Huang S, Xu H, Chang AH, Huang H, Wei G |
Journal for ImmunoTherapy of Cancer | 2023 |
The role of macrophages-mediated communications among cell compositions of tumor microenvironment in cancer progression
Li M, Jiang P, Wei S, Wang J, Li C |
Frontiers in immunology | 2023 |
Comparative Pre-Clinical Analysis of CD20-Specific CAR T Cells Encompassing 1F5-, Leu16-, and 2F2-Based Antigen-Recognition Moieties
Belovezhets T, Kulemzin S, Volkova O, Najakshin A, Taranin A, Gorchakov A |
International journal of molecular sciences | 2023 |
A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome
Butt OH, Zhou AY, Ances BM, DiPersio JF, Ghobadi A |
Frontiers in neurology | 2023 |
T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts
Nasiri F, Safarzadeh Kozani P, Rahbarizadeh F |
Frontiers in immunology | 2023 |
Modeling interaction of Glioma cells and CAR T-cells considering multiple CAR T-cells bindings
Li R, Sahoo P, Wang D, Wang Q, Brown CE, Rockne RC, Cho H |
2023 | |
T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications
Chi X, Luo S, Ye P, Hwang WL, Cha JH, Yan X, Yang WH |
Frontiers in immunology | 2023 |
CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naïve/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Larson SM, Walthers CM, Ji B, Ghafouri SN, Naparstek J, Trent J, Chen JM, Roshandell M, Harris C, Khericha M, Schweppe T, Berent-Maoz B, Gosliner SB, Almaktari A, Ceja MA, Allen-Auerbach MS, Said J, Nawaly K, Mead M, de Vos S, Young PA, Oliai C, Schiller GJ, Timmerman JM, Ribas A, Chen YY |
Cancer Discovery | 2023 |
Challenges of Anti-Mesothelin CAR-T-Cell Therapy
Zhai X, Mao L, Wu M, Liu J, Yu S |
Cancers | 2023 |
Myeloidcells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies
Huang B, Zhang J, Zong W, Chen S, Zong Z, Zeng X, Zhang H |
Frontiers in immunology | 2023 |
Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering
Michels KR, Sheih A, Hernandez SA, Brandes AH, Parrilla D, Irwin B, Perez AM, Ting HA, Nicolai CJ, Gervascio T, Shin S, Pankau MD, Muhonen M, Freeman J, Gould S, Getto R, Larson RP, Ryu BY, Scharenberg AM, Sullivan AM, Green S |
Journal for ImmunoTherapy of Cancer | 2023 |
Human A2-CAR T cells reject HLA-A2+ human islets transplanted into mice without inducing graft versus host disease
Ellis CE, Mojibian M, Ida S, Fung VC, Skovsø S, McIver E, O\u2019Dwyer S, Webber TD, Braam MJ, Saber N, Kieffer TJ, Levings MK |
2023 | |
Controlling therapeutic protein expression via inhalation of a butter flavor molecule.
Bertschi A, Stefanov BA, Xue S, Charpin-El Hamri G, Teixeira AP, Fussenegger M |
Nucleic Acids Research | 2023 |
Mesenchymal stem cell suppresses the efficacy of CAR-T toward killing lymphoma cells by modulating the microenvironment through stanniocalcin-1.
Zhang R, Liu Q, Zhou S, He H, Zhao M, Ma W |
eLife | 2023 |
Combining chemotherapy with CAR-T cell therapy in treating solid tumors
Wang AX, Ong XJ, D\u2019Souza C, Neeson PJ, Zhu JJ |
Frontiers in immunology | 2023 |
Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells
Hiltensperger M, Krackhardt AM |
Frontiers in immunology | 2023 |
Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Li W, Ding L, Shi W, Wan X, Yang X, Yang J, Wang T, Song L, Wang X, Ma Y, Luo C, Tang J, Gu L, Chen J, Lu J, Tang Y, Li B |
Journal of Translational Medicine | 2023 |
Advancing CAR T cell therapy through the use of multidimensional omics data.
Yang J, Chen Y, Jing Y, Green MR, Han L |
Nature reviews. Clinical oncology | 2023 |
Advances in CAR-T Cell Therapy in Head and Neck Squamous Cell Carcinoma
Wang HQ, Fu R, Man QW, Yang G, Liu B, Bu LL |
Journal of Clinical Medicine | 2023 |
The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies
Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, Mardi A, Aghebati-Maleki A, Aghebati-Maleki L, Baradaran B |
Frontiers in immunology | 2023 |
Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
Hamieh M, Mansilla-Soto J, Rivière I, Sadelain M |
Cancer Discovery | 2023 |
The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors
Del Baldo G, Del Bufalo F, Pinacchio C, Carai A, Quintarelli C, De Angelis B, Merli P, Cacchione A, Locatelli F, Mastronuzzi A |
Frontiers in immunology | 2023 |
Long-term outcomes following CAR T cell therapy: what we know so far
Cappell KM, Kochenderfer JN |
Nature reviews. Clinical oncology | 2023 |
Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas.
Xu H, Li N, Wang G, Cao Y |
Frontiers in immunology | 2023 |
Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway.
Althaus J, Nilius-Eliliwi V, Maghnouj A, Döring S, Schroers R, Hudecek M, Hahn SA, Mika T |
Cancer Immunology, Immunotherapy | 2023 |
Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy.
Yan Z, Li L, Fu D, Wu W, Qiao N, Huang Y, Jiang L, Wu D, Hu Y, Zhang H, Xu P, Cheng S, Wang L, Lacin S, Muftuoglu M, Zhao W |
Frontiers of Medicine | 2023 |
Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis
Moreno-Castaño AB, Fernández S, Ventosa H, Palomo M, Martinez-Sanchez J, Ramos A, Ortiz-Maldonado V, Delgado J, Fernández de Larrea C, Urbano-Ispizua A, Penack O, Nicolás JM, Téllez A, Escolar G, Carreras E, Fernández-Avilés F, Castro P, Diaz-Ricart M |
Journal for ImmunoTherapy of Cancer | 2023 |
Preliminary assessment of cardiotoxicity in chimeric antigen receptor T cell therapy: a systematic review and meta-analysis.
Guo M, Wang X, Xiao S, Liu A, Xu T, Huan C, Wu H, Hu Y, Zhou S, Zhu H, Pan D |
Clinical and Experimental Medicine | 2023 |
DC vaccine enhances CAR-T cell antitumor activity by overcoming T cell exhaustion and promoting T cell infiltration in solid tumors.
Zhang M, Wang Y, Chen X, Zhang F, Chen J, Zhu H, Li J, Chen Z, Wang A, Xiao Y, Chen Z, Dong Y, Yin X, Ji F, Liu J, Liang J, Pan F, Guo Z, He L |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2023 |
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
Liu S, Zhang X, Dai H, Cui W, Yin J, Li Z, Yang X, Yang C, Xue S, Qiu H, Miao M, Chen S, Jin Z, Fu C, Li C, Sun A, Han Y, Wang Y, Yu L, Wu D, Cui Q, Tang X |
Blood Cancer Journal | 2023 |
Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes
Mohty R, Kharfan-Dabaja MA, Chavez JC |
Cancer management and research | 2023 |
Mutated Flt3Lg Provides Reduced Flt3 Recycling Compared to Wild-Type Flt3Lg and Retains the Specificity of Flt3Lg-Based CAR T-Cell Targeting in AML Models
Maiorova V, Mollaev MD, Vikhreva P, Chudakov DM, Kibardin A, Maschan MA, Larin S |
International journal of molecular sciences | 2023 |
Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies
García-Calderón CB, Sierro-Martínez B, García-Guerrero E, Sanoja-Flores L, Muñoz-García R, Ruiz-Maldonado V, Jimenez-Leon MR, Delgado-Serrano J, Molinos-Quintana Á, Guijarro-Albaladejo B, Carrasco-Brocal I, Lucena JM, García-Lozano JR, Blázquez-Goñi C, Reguera-Ortega JL, González-Escribano MF, Reinoso-Segura M, Briones J, Pérez-Simón JA, Caballero-Velázquez T |
Frontiers in immunology | 2023 |
A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells
Liu Y, Jie X, Nian L, Wang Y, Wang C, Ma J, Jiang J, Wu Q, Qiao J, Chen W, Cao J, Yan Z, Shi M, Cheng H, Zhu F, Sang W, Li D, Chen C, Xu K, Li Z |
Frontiers in immunology | 2023 |
Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies
Huang S, Wang X, Wang Y, Wang Y, Fang C, Wang Y, Chen S, Chen R, Lei T, Zhang Y, Xu X, Li Y |
Molecular Cancer | 2023 |
Advancing Cell-Based Cancer Immunotherapy Through Stem Cell Engineering
Li YR, Dunn ZS, Yu Y, Li M, Wang P, Yang L |
Cell Stem Cell | 2023 |
Rational Alternatives to Fludarabine and Cyclophosphamide-Based Pre-CAR Lymphodepleting Regimens in the Pediatric and Young Adult B-ALL Setting.
Green S, Schultz L |
Current Oncology Reports | 2023 |
Prognostic value of prelymphodepletion absolute lymphocyte counts in relapsed/refractory diffuse large B-cell lymphoma patients treated with chimeric antigen receptor T cells
Lu Y, Zhu H, Liu Y, Wang Y, Sun Y, Cheng H, Yan Z, Cao J, Sang W, Zhu F, Li D, Sun H, Zheng J, Xu K, Li Z |
Frontiers in immunology | 2023 |
Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T
Shiqi L, Jiasi Z, Lvzhe C, Huailong X, Liping H, Lin L, Qianzhen Z, Zhongtao Y, Junjie S, Zucong C, Yingzi Z, Meiling W, Yunyan L, Linling W, Lihua F, Yingnian C, Wei Z, Yu L, Le L, Youcheng W, Dingsong Z, Yancheng D, Ping Y, Lihua Z, Xiaoping L, Xiaozhuang H, Zhongzheng Z, Zhi Y, Cheng Q, Sanbin W |
2023 | |
Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor
Lainšček D, Golob-Urbanc A, Mikolič V, Pantović-Žalig J, Malenšek Š, Jerala R |
2023 | |
The Interplay between T Cells and Cancer: The Basis of Immunotherapy
Chen C, Liu X, Chang CY, Wang HY, Wang RF |
Genes & development | 2023 |
CAR T-cell detection scoping review: an essential biomarker in critical need of standardization.
Turicek DP, Giordani VM, Moraly J, Taylor N, Shah NN |
Journal for ImmunoTherapy of Cancer | 2023 |
Activation-inducible CAR expression enables precise control over engineered CAR T cell function
Fraessle SP, Tschulik C, Effenberger M, Cletiu V, Gerget M, Schober K, Busch DH, Germeroth L, Stemberger C, Poltorak MP |
Communications biology | 2023 |
Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies
Wang H, Tang L, Kong Y, Liu W, Zhu X, You Y |
International journal of molecular sciences | 2023 |
A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy.
Hirayama AV, Chou CK, Miyazaki T, Steinmetz RN, Di HA, Fraessle SP, Gauthier J, Fiorenza S, Hawkins RM, Overwijk WW, Riddell SR, Marcondes MQ, Turtle CJ |
Blood Advances | 2023 |
Insights in the host response towards biomaterial-based scaffolds for cancer therapy
Schluck M, Weiden J, Verdoes M, Figdor CG |
Frontiers in Bioengineering and Biotechnology | 2023 |
Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia
Hodroj MH, Abou Dalle I, Moukalled N, El Cheikh J, Mohty M, Bazarbachi A |
Frontiers in immunology | 2023 |
Enhancing Anticancer Efficacy of Chemotherapeutics Using Targeting Ligand-Functionalized Synthetic Antigen Receptor-Mesenchymal Stem Cells
Nethi SK, Li X, Bhatnagar S, Prabha S |
Pharmaceutics | 2023 |
Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, Nikiforow S, Ombrello AK, Shah NN, Talleur AC, Turicek D, Vatsayan A, Wong SW, Maus MV, Komanduri KV, Berliner N, Henter JI, Perales MA, Frey NV, Teachey DT, Frank MJ, Shah NN |
2023 | |
Multi-Targeted Immunotherapeutics to Treat B Cell Malignancies
Gambles MT, Yang J, Kopeček J |
Journal of Controlled Release | 2023 |
Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma
Rejeski K, Jain MD, Smith EL |
2023 | |
Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy
Mulgaonkar A, Udayakumar D, Yang Y, Harris S, Öz OK, Ramakrishnan Geethakumari P, Sun X |
Frontiers in Medicine | 2023 |
Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy
Zheng Z, Li S, Liu M, Chen C, Zhang L, Zhou D |
Cancers | 2023 |
Acute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond
Aureli A, Marziani B, Venditti A, Sconocchia T, Sconocchia G |
Cancers | 2023 |
Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead.
Pasvolsky O, Kebriaei P, Shah BD, Jabbour E, Jain N |
Blood Advances | 2023 |
Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors
Neeser A, Ramasubramanian R, Wang C, Ma L |
2023 | |
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial.
Schubert ML, Schmitt A, Hückelhoven-Krauss A, Neuber B, Kunz A, Waldhoff P, Vonficht D, Yousefian S, Jopp-Saile L, Wang L, Korell F, Keib A, Michels B, Haas D, Sauer T, Derigs P, Kulozik A, Kunz J, Pavel P, Laier S, Wuchter P, Schmier J, Bug G, Lang F, Gökbuget N, Casper J, Görner M, Finke J, Neubauer A, Ringhoffer M, Wolleschak D, Brüggemann M, Haas S, Ho AD, Müller-Tidow C, Dreger P, Schmitt M |
Journal of Hematology & Oncology | 2023 |
Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality
Smith R, Shen R |
Journal of Translational Medicine | 2023 |
Ginsenoside Rg1 improves anti-tumor efficacy of adoptive cell therapy by enhancing T cell effector functions
Liu Y, An L, Yang C, Wang X, Huang R, Zhang X |
2023 | |
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects.
Tang L, Huang Z, Mei H, Hu Y |
Signal Transduction and Targeted Therapy | 2023 |
Modulation of Radiation Doses and Chimeric Antigen Receptor T Cells: A Promising New Weapon in Solid Tumors—A Narrative Review
Pontoriero A, Critelli P, Chillari F, Ferrantelli G, Sciacca M, Brogna A, Parisi S, Pergolizzi S |
Journal of Personalized Medicine | 2023 |
Fully closed cell sorter for immune cell therapy manufacturing
Matsumoto M, Tashiro S, Ito T, Takahashi K, Hashimoto G, Kajihara J, Miyahara Y, Shiku H, Katsumoto Y |
2023 | |
Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions.
Lam N, Finney R, Yang S, Choi S, Wu X, Cutmore L, Andrade J, Huang L, Amatya C, Cam M, Kochenderfer JN |
2023 | |
Strategies for enhancing CAR T cell expansion and persistence in HIV infection
Rothemejer FH, Lauritsen NP, Søgaard OS, Tolstrup M |
Frontiers in immunology | 2023 |
Validation of a High-Sensitivity Assay for Detection of Chimeric Antigen Receptor T-Cell Vectors Using Low-Partition Digital PCR Technology.
Arcila ME, Patel U, Momeni-Boroujeni A, Yao J, Chan R, Chan J, Rijo I, Yu W, Chaves N, Patel H, Kakadiya S, Lachhander S, Senechal B, Riviere IC, Wang X, Sadelain M, Nafa K, Salazar P, Palomba L, Curran KJ, Park JH, Daniyan A, Borsu L |
The Journal of molecular diagnostics : JMD | 2023 |
Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7.
Bandara V, Foeng J, Gundsambuu B, Norton TS, Napoli S, McPeake DJ, Tyllis TS, Rohani-Rad E, Abbott C, Mills SJ, Tan LY, Thompson EJ, Willet VM, Nikitaras VJ, Zheng J, Comerford I, Johnson A, Coombs J, Oehler MK, Ricciardelli C, Cowin AJ, Bonder CS, Jensen M, Sadlon TJ, McColl SR, Barry SC |
Nature Communications | 2023 |
Bridging live-cell imaging and next-generation cancer treatment.
Alieva M, Wezenaar AKL, Wehrens EJ, Rios AC |
Nature reviews. Cancer | 2023 |
ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype
Moreno-Cortes E, Franco-Fuquen P, Garcia-Robledo JE, Forero J, Booth N, Castro JE |
Frontiers in Oncology | 2023 |
Development of a multiscale mechanistic modeling framework integrating differential cellular kinetics of CAR T‐cell subsets and immunophenotypes in cancer patients
Salem AM, Mugundu GM, Singh AP |
The Journal of Pathology | 2023 |
A major role for CD4+ T cells in driving cytokine release syndrome during CAR T cell therapy
Boulch M, Cazaux M, Cuffel A, Ruggiu M, Allain V, Corre B, Loe-Mie Y, Hosten B, Cisternino S, Auvity S, Thieblemont C, Caillat-Zucman S, Bousso P |
Cell reports. Medicine | 2023 |
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bücklein VL, Völkl S, Penack O, Albanyan O, Stock S, Müller F, Karschnia P, Petrera A, Reid K, Faramand R, Davila ML, Modi K, Dean EA, Bachmeier C, von Bergwelt-Baildon M, Locke FL, Bethge W, Bullinger L, Mackensen A, Barba P, Jain MD, Subklewe M |
Science Advances | 2023 |
Innate immune response restarts adaptive immune response in tumors
Li WS, Zhang QQ, Li Q, Liu SY, Yuan GQ, Pan YW |
Frontiers in immunology | 2023 |
Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions
Ji H, Hu C, Yang X, Liu Y, Ji G, Ge S, Wang X, Wang M |
Signal Transduction and Targeted Therapy | 2023 |
Human A2-CAR T Cells Reject HLA-A2+ Human Islets Transplanted into Mice Without Inducing Graft Versus Host Disease
Ellis CE, Mojibian M, Ida S, Fung VC, Skovsø S, McIver E, O\u2019Dwyer S, Webber TD, Braam MJ, Saber N, Sasaki S, Lynn FC, Kieffer TJ, Levings MK |
Transplantation | 2023 |
AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
Sakemura RL, Hefazi M, Cox MJ, Siegler EL, Sinha S, Hansen MJ, Stewart CM, Feigin JM, Roman CM, Schick KJ, Can I, Tapper EE, Horvei P, Adada MM, Bezerra ED, Fonkoua LA, Ruff MW, Forsman CL, Nevala WK, Boysen JC, Tschumper RC, Grand CL, Kuchimanchi KR, Mouritsen L, Foulks JM, Warner SL, Call TG, Parikh SA, Ding W, Kay NE, Kenderian SS |
Cancer immunology research | 2023 |
Cell Granularity Reflects Immune Cell Function and Enables Selection of Lymphocytes with Superior Attributes for Immunotherapy
Wu T, Tan JH, Sin W, Luah YH, Tan SY, Goh M, Birnbaum ME, Chen Q, Cheow LF |
Advanced Science | 2023 |
Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T Cell Therapy in Adults with high-risk Relapsed/Refractory ALL
Aldoss I, Khaled SK, Wang X, Palmer J, Wang Y, Wagner JR, Clark MC, Simpson J, Paul J, Vyas V, Chien SH, Stein A, Pullarkat V, Salhotra A, Al Malki MM, Aribi A, Sandhu K, Thomas SH, Budde LE, Marcucci G, Brown CE, Forman SJ |
Clinical cancer research | 2023 |
Exploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies
Zhang Y, Qin D, Shou AC, Liu Y, Wang Y, Zhou L |
Journal of Clinical Medicine | 2023 |
Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells
Wei Z, Xu J, Zhao C, Zhang M, Xu N, Kang L, Lou X, Yu L, Feng W |
Frontiers in immunology | 2023 |
Actin cytoskeleton remodeling at the cancer cell side of the immunological synapse: good, bad, or both?
Ockfen E, Filali L, Pereira Fernandes D, Hoffmann C, Thomas C |
Frontiers in immunology | 2023 |
Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy
Xu Q, Shi Y, Xue L, An F, Xu H, Liu X, Zhu X, Sun Z, Zhai Z, Wang X |
Cell transplantation | 2023 |
Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies
Yang C, Nguyen J, Yen Y |
Journal of biomedical science | 2023 |
Novel Approaches to Treatment of Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplantation
Liberatore C, Di Ianni M |
International journal of molecular sciences | 2023 |
Delivery of Plasmid DNA by Ionizable Lipid Nanoparticles to Induce CAR Expression in T Cells
Prazeres PH, Ferreira H, Costa PA, da Silva W, Alves MT, Padilla M, Thatte A, Santos AK, Lobo AO, Sabino A, Del Puerto HL, Mitchell MJ, Guimaraes PP |
International Journal of Nanomedicine | 2023 |
CAR T-Cells in Acute Lymphoblastic Leukemia: Current Status and Future Prospects
Almaeen AH, Abouelkheir M |
Biomedicines | 2023 |
A High-Throughput Microfluidic Cell Sorter Using a Three-Dimensional Coupled Hydrodynamic-Dielectrophoretic Pre-Focusing Module
Aghaamoo M, Cardenas-Benitez B, Lee AP |
Micromachines | 2023 |
Cellular and molecular waypoints along the path of T cell exhaustion
Lan X, Zebley CC, Youngblood B |
Science Immunology | 2023 |
Genome Editing in Engineered T Cells for Cancer Immunotherapy
Bonini C, Chapuis AG, Hudecek M, Guedan S, Magnani CF, Qasim W |
Human Gene Therapy | 2023 |
Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies.
Gao X, Liu J, Sun R, Zhang J, Cao X, Zhang Y, Zhao M |
Annals of Hematology | 2023 |
Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer
Tang L, Huang ZP, Mei H, Hu Y |
Military Medical Research | 2023 |
Developing Strategies to Improve the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia.
Guo S, Gao X, Sadhana M, Guo R, Liu J, Lu W, Zhao MF |
Current Treatment Options in Oncology | 2023 |
The Role of CD4 T Cell Help in CD8 T Cell Differentiation and Function During Chronic Infection and Cancer
Topchyan P, Lin S, Cui W |
Immune Network | 2023 |
CAR-T cell therapy for hematological malignancies: History, status and promise
Wang C, Wang J, Che S, Zhao H |
Heliyon | 2023 |
CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies
Louie RH, Cai C, Samir J, Singh M, Deveson IW, Ferguson JM, Amos TG, McGuire HM, Gowrishankar K, Adikari T, Balderas R, Bonomi M, Ruella M, Bishop D, Gottlieb D, Blyth E, Micklethwaite K, Luciani F |
Nature Communications | 2023 |
Harnessing CD3 diversity to optimize CAR T cells
Velasco Cárdenas RM, Brandl SM, Meléndez AV, Schlaak AE, Buschky A, Peters T, Beier F, Serrels B, Taromi S, Raute K, Hauri S, Gstaiger M, Lassmann S, Huppa JB, Boerries M, Andrieux G, Bengsch B, Schamel WW, Minguet S |
Nature Immunology | 2023 |
Model‐informed drug development of autologous CAR‐T cell therapy: Strategies to optimize CAR‐T cell exposure leveraging cell kinetic/dynamic modeling
Mc Laughlin AM, Milligan PA, Yee C, Bergstrand M |
The Journal of Pathology | 2023 |
Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies
Temple WC, Nix MA, Naik A, Izgutdina A, Huang BJ, Wicaksono G, Phojanakong P, Serrano JA, Young EP, Ramos E, Salangsang F, Steri V, Xirenayi S, Hermiston M, Logan AC, Stieglitz E, Wiita AP |
Journal for ImmunoTherapy of Cancer | 2023 |
Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia
Branella GM, Lee JY, Okalova J, Parwani KK, Alexander JS, Arthuzo RF, Fedanov A, Yu B, McCarty D, Brown HC, Chandrakasan S, Petrich BG, Doering CB, Spencer HT |
Frontiers in immunology | 2023 |
CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma
Ostojska M, Nowak E, Twardowska J, Lejman M, Zawitkowska J |
Journal of Personalized Medicine | 2023 |
CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
Saleh K, Pasquier F, Bigenwald C, De Botton S, Ribrag V, Castilla-Llorente C |
Journal of Clinical Medicine | 2023 |
Assessment and predictive ability of the absolute neutrophil count in peripheral blood for in vivo CAR T cells expansion and CRS
Zhang M, Long X, Xiao Y, Jin J, Chen C, Meng J, Liu W, Liu A, Chen L |
Journal for ImmunoTherapy of Cancer | 2023 |
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL.
Liang EC, Albittar A, Huang JJ, Hirayama AV, Kimble EL, Portuguese AJ, Chapuis A, Shadman M, Till BG, Cassaday RD, Milano F, Kiem HP, Riddell SR, Turtle CJ, Maloney DG, Gauthier J |
Blood Advances | 2023 |
Has the shortage of fludarabine altered the current paradigm of lymphodepletion in favor of bendamustine?
Filioglou D, Husnain M, Khurana S, Simpson RJ, Katsanis E |
Frontiers in immunology | 2023 |
DIALing-up the preclinical characterization of gene-modified adoptive cellular immunotherapies
Giardino Torchia ML, Moody G |
Frontiers in immunology | 2023 |
Toxicities of CAR T-cell therapy: a review of current literature
Asghar MS, Ismail Shah SM, Rani A, Kazmi S, Savul IS, Ukrani J, Khan F, Hasan CA, Rathore N, Syed M, Keswani S, Surkasha F, Mal D, Kumar D |
Annals of Medicine and Surgery | 2023 |
CAR-T treatment for cancer: prospects and challenges
Chen R, Chen L, Wang C, Zhu H, Gu L, Li Y, Xiong X, Chen G, Jian Z |
Frontiers in Oncology | 2023 |
A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023.
Li H, Huang Q, Zhang Y |
Human Vaccines & Immunotherapeutics | 2023 |
Cyclosporine A-resistant CAR-T cells mediate antitumour immunity in the presence of allogeneic cells.
Zhang Y, Fang H, Wang G, Yuan G, Dong R, Luo J, Lyu Y, Wang Y, Li P, Zhou C, Yin W, Xiao H, Sun J, Zeng X |
Nature Communications | 2023 |
Early prediction of cytokine release syndrome by measuring phosphate and magnesium levels following chimeric antigen receptor T cell therapy
Yoshida M, Matsuoka Y, Mitsuyuki S, Yonetani N, Kawai J, Kondo T, Ishikawa T |
2023 | |
Building safety into CAR-T therapy.
Peters DT, Savoldo B, Grover NS |
Human Vaccines & Immunotherapeutics | 2023 |
Recent advances in cellular immunotherapy for lymphoid malignancies.
Chung H, Cho H |
Blood Research | 2023 |
Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle
Lickefett B, Chu L, Ortiz-Maldonado V, Warmuth L, Barba P, Doglio M, Henderson D, Hudecek M, Kremer A, Markman J, Nauerth M, Negre H, Sanges C, Staber PB, Tanzi R, Delgado J, Busch DH, Kuball J, Luu M, Jäger U |
Frontiers in immunology | 2023 |
Engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptors.
Johnston AC, Alicea GM, Lee CC, Patel PV, Hanna EA, Vaz E, Forjaz A, Wan Z, Nair PR, Lim Y, Chen T, Du W, Kim D, Nichakawade TD, Rebecca VW, Bonifant CL, Fan R, Kiemen AL, Wu PH, Wirtz D |
bioRxiv : the preprint server for biology | 2023 |
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Cowan AJ, Pont MJ, Sather BD, Turtle CJ, Till BG, Libby EN 3rd, Coffey DG, Tuazon SA, Wood B, Gooley T, Wu VQ, Voutsinas J, Song X, Shadman M, Gauthier J, Chapuis AG, Milano F, Maloney DG, Riddell SR, Green DJ |
The Lancet Oncology | 2023 |
Current assessment and management of measurable residual disease in patients with acute lymphoblastic leukemia in the setting of CAR-T-cell therapy
Lin M, Zhao X, Chang Y, Zhao X |
Chinese Medical Journal | 2023 |
Manufacture of CD22 CAR T cells following positive versus negative selection results in distinct cytokine secretion profiles and γδ T cell output
Song HW, Benzaoui M, Dwivedi A, Underwood S, Shao L, Achar S, Posarac V, Remley VA, Prochazkova M, Cai Y, Jin P, Somerville RP, Stroncek DF, Altan-Bonnet G, Shah NN, Chien CD, Taylor N, Highfill SL |
2023 | |
CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS
Sakemura RL, Manriquez Roman C, Horvei P, Siegler EL, Girsch JH, Sirpilla OL, Stewart CM, Yun K, Can I, Ogbodo EJ, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Hefazi M, Ruff MW, Kimball BL, Mai LK, Huynh TN, Nevala WK, Ilieva K, Augsberger C, Patra-Kneuer M, Schanzer J, Endell J, Heitmüller C, Steidl S, Parikh SA, Ding W, Kay NE, Nowakowski GS, Kenderian SS |
Blood | 2023 |
Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma
Hirayama AV, Kimble EL, Wright JH, Fiorenza S, Gauthier J, Voutsinas JM, Wu Q, Yeung CC, Gazeau N, Pender BS, Kirchmeier DR, Torkelson A, Chutnik AN, Cassaday RD, Chapuis AG, Green DJ, Kiem HP, Milano F, Shadman M, Till BG, Riddell SR, Maloney DG, Turtle CJ |
Blood Advances | 2023 |
Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain
Mikkilineni L, Natrakul DA, Lam N, Manasanch EE, Mann J, Weissler KA, Wong N, Brudno JN, Goff SL, Yang JC, Ganaden M, Patel R, Zheng Z, Gartner JJ, Martin KR, Wang HW, Yuan CM, Lowe T, Maric I, Shao L, Jin P, Stroncek DF, Highfill SL, Rosenberg SA, Kochenderfer JN |
Molecular Therapy | 2023 |
Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies.
Angelos MG, Patel RP, Ruella M, Barta SK |
2023 | |
Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial
Brudno JN, Natrakul DA, Karrs J, Patel N, Maass-Moreno R, Ahlman MA, Mikkilineni L, Mann J, Stroncek DF, Highfill SL, Fromm GC, Patel R, Pittaluga S, Kochenderfer JN |
Blood Advances | 2023 |
Cooperative CAR targeting to selectively eliminate AML and minimize escape.
Haubner S, Mansilla-Soto J, Nataraj S, Kogel F, Chang Q, de Stanchina E, Lopez M, Ng MR, Fraser K, Subklewe M, Park JH, Wang X, Rivière I, Sadelain M |
Cancer Cell | 2023 |
Aptamer-Based Chromatographic Methods for Efficient and Economical Separation of Leukocyte Populations
Ling M, Cardle II, Song K, Yan AJ, Kacherovsky N, Jensen MC, Pun SH |
ACS Biomaterials Science & Engineering | 2023 |
INSPIRED Symposium Part 1: Clinical Variables Associated with Improved Outcomes for Children and Young Adults treated with Chimeric Antigen Receptor T cells for B cell Acute Lymphoblastic Leukemia.
Myers RM, Jacoby E, Pulsipher MA, Pasquini MC, Grupp SA, Shah NN, Laetsch TW, Curran KJ, Schultz LM |
2023 | |
All about blinatumomab: the bispecific T cell engager immunotherapy for B cell acute lymphoblastic leukemia
Mirfakhraie R, Dehaghi BK, Ghorbi MD, Ghaffari-Nazari H, Mohammadian M, Salimi M, Ardakani MT, Parkhideh S |
2023 | |
Promises and challenges of a decentralized CAR T-cell manufacturing model
Shah M, Krull A, Odonnell L, de Lima MJ, Bezerra E |
2023 | |
INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies-Established Findings and Future Priorities.
Ligon JA, Ramakrishna S, Ceppi F, Calkoen FGJ, Diorio C, Davis KL, Jacoby E, Gottschalk S, Schultz LM, Capitini CM |
Transplantation and cellular therapy | 2023 |
CAR T-cell manufacturing from naive/stem memory T-lymphocytes enhances antitumor responses while curtailing cytokine release syndrome
Silvia Arcangeli, Camilla Bove, Claudia Mezzanotte, Barbara Camisa, Laura Falcone, Francesco Manfredi, Eugenia Bezzecchi, Rita El Khoury, Rossana Norata, Francesca Sanvito, Maurilio Ponzoni, Beatrice Greco, Marta A Moresco, Matteo G. Carrabba, Fabio Ciceri, Chiara Bonini, Attilio Bondanza, Monica Casucci |
Journal of Clinical Investigation | 2022 |
Investigation of the Risk Factors to Predict Cytokine Release Syndrome in Relapsed or Refractory Acute B-lymphocytic Leukemia Patients Receiving IL-6 Knocking Down Anti-CD19 Chimeric Antigen Receptor T Cell Therapy
Wen-Jie Gong, Yan Qiu, Ming-Hao Li, Yan-Yan Li, Jing-Qiu Yu, Liqing Kang, Aining Sun, Depei Wu, Lei Yu, Sheng-Li Xue |
Frontiers in immunology | 2022 |
Single-cell analysis by mass cytometry reveals CD19 CAR T cell spatiotemporal plasticity in patients
L Goldberg, E Haas, V Vyas, R Urak, S Forman, X Wang |
OncoImmunology | 2022 |
Knowns and Unknowns about CAR-T Cell Dysfunction
A Titov, Y Kaminskiy, I Ganeeva, E Zmievskaya, A Valiullina, A Rakhmatullina, A Petukhov, R Miftakhova, A Rizvanov, E Bulatov |
Cancers | 2022 |
Highly aminated iron oxide nanoworms for simultaneous manufacturing and labeling of chimeric antigen receptor T cells
W Zhang, H Gaikwad, EV Groman, E Purev, D Simberg, G Wang |
Journal of Magnetism and Magnetic Materials | 2022 |
Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners
S Stock, A Kluever, S Endres, S Kobold |
Biomedicines | 2022 |
Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance
F Füchsl, A Krackhardt |
Cells | 2022 |
Engineered T cells and their therapeutic applications in autoimmune diseases
L Bao, X Bo, H Cao, C Qian, Z Wang, B Li |
Zoological Research | 2022 |
TCR-T Immunotherapy: The Challenges and Solutions
Y Liu, X Yan, F Zhang, X Zhang, F Tang, Z Han, Y Li |
Frontiers in Oncology | 2022 |
PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function
M Suematsu, S Yagyu, N Nagao, S Kubota, Y Shimizu, M Tanaka, Y Nakazawa, T Imamura |
Frontiers in immunology | 2022 |
A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021
L Miao, J Zhang, Z Zhang, S Wang, F Tang, M Teng, Y Li |
Frontiers in immunology | 2022 |
Development of CAR T Cell Therapy in Children—A Comprehensive Overview
M Boettcher, A Joechner, Z Li, S Yang, P Schlegel |
Journal of Clinical Medicine | 2022 |
Overcome tumor relapse in CAR T cell therapy
C Huo, J Yang, Y Gu, D Wang, X Zhang, Y Li |
Clinical & Translational Oncology | 2022 |
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy
Y Zhang, S Li, Y Wang, Y Lu, Y Xu, Q Rao, H Wang, H Xing, Z Tian, K Tang, L Lv, M Wang, J Wang |
Experimental Hematology and Oncology | 2022 |
iNKT: A new avenue for CAR-based cancer immunotherapy
Y Liu, G Wang, D Chai, Y Dang, J Zheng, H Li |
Translational oncology | 2022 |
A T-cell independent universal cellular therapy strategy through antigen depletion
D Li, W Wang, S Xie, M Ge, R Wang, Q Xu, Y Sun, J Zhu, H Liu |
Theranostics | 2022 |
Reprogramming the tumor microenvironment by genome editing for precision cancer therapy
K Liu, J Cui, Y Zhan, Q Ouyang, Q Lu, D Yang, X Li, J Yin |
Molecular Cancer | 2022 |
Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy
M Khelil, Y Godet, S Abdeljaoued, C Borg, O Adotévi, R Loyon |
Cancers | 2022 |
Harnessing the chemokine system to home CAR-T cells into solid tumors
J Foeng, I Comerford, S McColl |
Cell reports. Medicine | 2022 |
The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patients
M Li, S Xue, X Tang, J Xu, S Chen, Y Han, H Qiu, M Miao, N Xu, J Tan, L Kang, Z Yu, X Lou, Y Xu, J Chen, Z Yan, W Feng, D Wu, L Yu |
Scientific Reports | 2022 |
Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?
J Buechner, I Caruana, A Künkele, S Rives, K Vettenranta, P Bader, C Peters, A Baruchel, F Calkoen |
Frontiers in Pediatrics | 2022 |
Novel immunotherapies in multiple myeloma
K Ohmine, R Uchibori |
International Journal of Hematology | 2022 |
Humanized CD30-Targeted Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity Against Hodgkin’s Lymphoma Cells
J Guo, S He, Y Zhu, W Yu, D Yang, X Zhao |
Frontiers in Cell and Developmental Biology | 2022 |
Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models
H Lee, I Kim, U Kim, S Choi, T Kim, D Lee, Y Lee, J Lee, J Jo, Y Lee, H Lee, S Kim, J Ahn |
Neoplasia (New York, N.Y.) | 2022 |
Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model
Y Wang, A Buck, M Grimaud, A Culhane, S Kodangattil, C Razimbaud, D Bonal, Q Nguyen, Z Zhu, K Wei, M O'Donnell, Y Huang, S Signoretti, T Choueiri, G Freeman, Q Zhu, W Marasco |
Molecular Therapy — Oncolytics | 2022 |
Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody
J Ye, Y Jia, I Tuhin, J Tan, M Monty, N Xu, L Kang, M Li, X Lou, M Zhou, X Fang, J Shao, H Zhu, Z Yan, L Yu |
Molecular Therapy — Oncolytics | 2022 |
HLA-independent T cell receptors for targeting tumors with low antigen density
J Mansilla-Soto, J Eyquem, S Haubner, M Hamieh, J Feucht, N Paillon, A Zucchetti, Z Li, M Sjöstrand, P Lindenbergh, M Saetersmoen, A Dobrin, M Maurin, A Iyer, A Angus, M Miele, Z Zhao, T Giavridis, S van der Stegen, F Tamzalit, I Rivière, M Huse, R Hendrickson, C Hivroz, M Sadelain |
Nature Medicine | 2022 |
Effectiveness and Safety of Anti-CD19 Chimeric Antigen Receptor-T Cell Immunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis
Z Ying, Y Song, J Zhu |
Frontiers in pharmacology | 2022 |
CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells
N Hebbar, R Epperly, A Vaidya, U Thanekar, S Moore, M Umeda, J Ma, S Patil, D Langfitt, S Huang, C Cheng, J Klco, S Gottschalk, M Velasquez |
Nature Communications | 2022 |
Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias
K Panuciak, M Margas, K Makowska, M Lejman |
Cells | 2022 |
Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
Rahman MM, Behl T, Islam MR, Alam MN, Islam MM, Albarrati A, Albratty M, Meraya AM, Bungau SG |
Molecules (Basel, Switzerland) | 2022 |
Optimization of Culture Conditions for the Generation of Canine CD20-CAR-T Cells for Adoptive Immunotherapy.
Sakai O, Yamamoto H, Igase M, Mizuno T |
In vivo (Athens, Greece) | 2022 |
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion.
Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, Sauter CS, Shah NN, Abou-El-Enein M |
Nature reviews. Clinical oncology | 2022 |
The Past, Present, and Future of Non-Viral CAR T Cells
Moretti A, Ponzo M, Nicolette CA, Tcherepanova IY, Biondi A, Magnani CF |
Frontiers in immunology | 2022 |
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy.
Juluri KR, Wu QV, Voutsinas J, Hou J, Hirayama AV, Mullane E, Miles N, Maloney DG, Turtle CJ, Bar M, Gauthier J |
Blood Advances | 2022 |
Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains.
Wutti-In Y, Sujjitjoon J, Sawasdee N, Panya A, Kongkla K, Yuti P, Yongpitakwattana P, Thepmalee C, Junking M, Chieochansin T, Poungvarin N, Yamabhai M, Yenchitsomanus PT |
Frontiers in Oncology | 2022 |
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia.
Dekker L, Calkoen FG, Jiang Y, Blok H, Veldkamp SR, De Koning C, Spoon M, Admiraal R, Hoogerbrugge P, Vormoor B, Vormoor HJ, Visscher H, Bierings M, Van Der Vlugt M, Van Tinteren H, Nijstad AL, Huitema ADR, Van Der Elst KCM, Pieters R, Lindemans CA, Nierkens S |
Blood Advances | 2022 |
Treating CAR-T relapses: check not checkmate.
Spiegel JY, Komanduri KV |
Blood | 2022 |
Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine.
Huyghe N, Benidovskaya E, Stevens P, Van den Eynde M |
Cancers | 2022 |
Impact of Manufacturing Procedures on CAR T Cell Functionality
Watanabe N, Mo F, McKenna MK |
Frontiers in immunology | 2022 |
Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies
Atilla PA, Atilla E |
Translational oncology | 2022 |
Targeting of the alphav beta3 integrin complex by CAR-T cells leads to rapid regression of diffuse intrinsic pontine glioma and glioblastoma.
Cobb DA, de Rossi J, Liu L, An E, Lee DW |
Journal for ImmunoTherapy of Cancer | 2022 |
Cytopenia after CAR-T Cell Therapy-A Brief Review of a Complex Problem.
Sharma N, Reagan PM, Liesveld JL |
Cancers | 2022 |
T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.
Dai Z, Mu W, Zhao Y, Cheng J, Lin H, Ouyang K, Jia X, Liu J, Wei Q, Wang M, Liu C, Tan T, Zhou J |
Signal Transduction and Targeted Therapy | 2022 |
A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma.
Ying Z, He T, Jin S, Wang X, Zheng W, Lin N, Tu M, Xie Y, Ping L, Liu W, Deng L, Ding Y, Hu X, Bu B, Lu X, Song Y, Zhu J |
2022 | |
Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects.
Qian S, Villarejo-Campos P, Guijo I, Hernández-Villafranca S, García-Olmo D, González-Soares S, Guadalajara H, Jiménez-Galanes S, Qian C |
Frontiers in immunology | 2022 |
Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on “Off-the-Shelf” T Cell Therapy Using iPSC Technology and Gene Editing
Furukawa Y, Hamano Y, Shirane S, Kinoshita S, Azusawa Y, Ando J, Nakauchi H, Ando M |
Cells | 2022 |
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
Dimitri A, Herbst F, Fraietta JA |
Molecular Cancer | 2022 |
Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer
Lou K, Feng S, Zhang G, Zou J, Zou X |
Frontiers in Oncology | 2022 |
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, Lundh S, Pruteanu-Malinici L, Nobles CL, Maji S, Frey NV, Gill SI, Tian L, Kulikovskaya I, Gupta M, Ambrose DE, Davis MM, Fraietta JA, Brogdon JL, Young RM, Chew A, Levine BL, Siegel DL, Alanio C, Wherry EJ, Bushman FD, Lacey SF, Tan K, June CH |
Nature | 2022 |
Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation
Khan AN, Chowdhury A, Karulkar A, Jaiswal AK, Banik A, Asija S, Purwar R |
Frontiers in immunology | 2022 |
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Zhang X, Zhu L, Zhang H, Chen S, Xiao Y |
Frontiers in immunology | 2022 |
Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention.
Zhang B, Li X, Yin T, Qin D, Chen Y, Ma Q, Shu P, Wang Y |
Journal of Oncology | 2022 |
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
An L, Lin Y, Deng B, Yin Z, Zhao D, Ling Z, Wu T, Zhao Y, Chang AH, Tong C, Liu S |
BMC Cancer | 2022 |
Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
Cao XY, Li JJ, Lu PH, Liu KY |
International Journal of Hematology | 2022 |
Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy
Gu J, Liu S, Cui W, Dai H, Cui Q, Yin J, Li Z, Kang L, Qiu H, Han Y, Miao M, Chen S, Xue S, Wang Y, Jin Z, Zhu X, Yu L, Wu D, Tang X |
Frontiers in immunology | 2022 |
IL-6/IFN-γ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro
Zhang H, Lv X, Kong Q, Tan Y |
Human Vaccines & Immunotherapeutics | 2022 |
Cytotoxic Efficiency of Human CD8+ T Cell Memory Subtypes
Knörck A, Schäfer G, Alansary D, Richter J, Thurner L, Hoth M, Schwarz EC |
Frontiers in immunology | 2022 |
The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease
Hont AB, Powell AB, Sohai DK, Valdez IK, Stanojevic M, Geiger AE, Chaudhary K, Dowlati E, Bollard CM, Cruz CR |
Molecular Therapy | 2022 |
Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL
Bai Z, Woodhouse S, Zhao Z, Arya R, Govek K, Kim D, Lundh S, Baysoy A, Sun H, Deng Y, Xiao Y, Barrett DM, Myers RM, Grupp SA, June CH, Fan R, Camara PG, Melenhorst JJ |
Science Advances | 2022 |
CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies
Marhelava K, Krawczyk M, Firczuk M, Fidyt K |
Cells | 2022 |
Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus
Rive CM, Yung E, Dreolini L, Brown SD, May CG, Woodsworth DJ, Holt RA |
2022 | |
Toward Rapid, Widely Available Autologous CAR-T Cell Therapy – Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital
Hort S, Herbst L, Bäckel N, Erkens F, Niessing B, Frye M, König N, Papantoniou I, Hudecek M, Jacobs JJ, Schmitt RH |
Frontiers in Medicine | 2022 |
Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study.
Sheykhhasan M, Manoochehri H, Dama P |
Cancer Gene Therapy | 2022 |
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy
Fabrizio VA, Boelens JJ, Mauguen A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Mackall CL, Laetsch TW, Schultz LM, Curran KJ |
Blood Advances | 2022 |
CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy
Elmas E, Saljoughian N, de Souza Fernandes Pereira M, Tullius BP, Sorathia K, Nakkula RJ, Lee DA, Naeimi Kararoudi M |
Frontiers in Oncology | 2022 |
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, De Angelis B, Choudhary R, Espie D, Galy A, Holland C, Ivics Z, Kantari-Mimoun C, Kersten MJ, Köhl U, Kuhn C, Laugel B, Locatelli F, Marchiq I, Markman J, Moresco MA, Morris E, Negre H, Quintarelli C, Rade M, Reiche K, Renner M, Ruggiero E, Sanges C, Stauss H, Themeli M, Van den Brulle J, Hudecek M, Casucci M |
Journal for ImmunoTherapy of Cancer | 2022 |
Enabling Allogeneic T Cell-Based Therapies: Scalable Stirred-Tank Bioreactor Mediated Manufacturing
Gatla H, Uth N, Levinson Y, Navaei A, Sargent A, Ramaswamy S, Friedrich Ben-Nun I |
2022 | |
Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era
Atallah-Yunes SA, Robertson MJ, Davé UP, Ghione P, Perna F |
Frontiers in immunology | 2022 |
Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives
Lv M, Liu Y, Liu W, Xing Y, Zhang S |
Frontiers in immunology | 2022 |
Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.
Lahman MC, Schmitt TM, Paulson KG, Vigneron N, Buenrostro D, Wagener FD, Voillet V, Martin L, Gottardo R, Bielas J, McElrath JM, Stirewalt DL, Pogosova-Agadjanyan EL, Yeung CC, Pierce RH, Egan DN, Bar M, Hendrie PC, Kinsella S, Vakil A, Butler J, Chaffee M, Linton J, McAfee MS, Hunter DS, Bleakley M, Rongvaux A, Van den Eynde BJ, Chapuis AG, Greenberg PD |
Science Translational Medicine | 2022 |
Tumour immunotherapy: lessons from predator-prey theory.
Hamilton PT, Anholt BR, Nelson BH |
Nature reviews. Immunology | 2022 |
Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies
Xie B, Li Z, Zhou J, Wang W |
Cancers | 2022 |
CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure
Caballero AC, Escribà-Garcia L, Alvarez-Fernández C, Briones J |
Frontiers in immunology | 2022 |
CAR-T Cell Performance: How to Improve Their Persistence?
López-Cantillo G, Urueña C, Camacho BA, Ramírez-Segura C |
Frontiers in immunology | 2022 |
Optimized NGFR-derived hinges for rapid and efficient enrichment and detection of CAR T cells in vitro and in vivo
Bister A, Ibach T, Haist C, Gerhorst G, Smorra D, Soldierer M, Roellecke K, Wagenmann M, Scheckenbach K, Gattermann N, Wiek C, Hanenberg H |
2022 | |
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome
Ishihara M, Kitano S, Kageyama S, Miyahara Y, Yamamoto N, Kato H, Mishima H, Hattori H, Funakoshi T, Kojima T, Sasada T, Sato E, Okamoto S, Tomura D, Nukaya I, Chono H, Mineno J, Kairi MF, Diem Hoang Nguyen P, Simoni Y, Nardin A, Newell E, Fehlings M, Ikeda H, Watanabe T, Shiku H |
Journal for ImmunoTherapy of Cancer | 2022 |
Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study
Yang J, He J, Zhang X, Li J, Wang Z, Zhang Y, Qiu L, Wu Q, Sun Z, Ye X, Yin W, Cao W, Shen L, Sersch M, Lu P |
Blood Cancer Journal | 2022 |
Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms
Michels A, Ho N, Buchholz CJ |
Molecular Therapy | 2022 |
T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells
Battram AM, Oliver-Caldés A, Suárez-Lledó M, Lozano M, Bosch i Crespo M, Martínez-Cibrián N, Cid J, Moreno DF, Rodríguez-Lobato LG, Urbano-Ispizua A, Fernández de Larrea C |
2022 | |
Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions
Sudarsanam H, Buhmann R, Henschler R |
Frontiers in Bioengineering and Biotechnology | 2022 |
Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells
Li L, Li Q, Yan ZX, Sheng LS, Fu D, Xu P, Wang L, Zhao WL |
Scientific Reports | 2022 |
Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects.
Ceppi F, Wilson AL, Annesley C, Kimmerly GR, Summers C, Brand A, Seidel K, Wu QV, Beebe A, Brown C, Mgebroff S, Lindgren C, Rawlings-Rhea SD, Huang W, Pulsipher MA, Wayne AS, Park JR, Jensen MC, Gardner RA |
Cancer immunology research | 2022 |
Mapping CAR T-Cell Design Space Using Agent-Based Models.
Prybutok AN, Yu JS, Leonard JN, Bagheri N |
Frontiers in Molecular Biosciences | 2022 |
CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments.
Jogalekar MP, Rajendran RL, Khan F, Dmello C, Gangadaran P, Ahn BC |
Frontiers in immunology | 2022 |
In vivo generation of CAR T cells in the presence of human myeloid cells
Ho N, Agarwal S, Milani M, Cantore A, Buchholz CJ, Thalheimer FB |
2022 | |
Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions
Alnefaie A, Albogami S, Asiri Y, Ahmad T, Alotaibi SS, Al-Sanea MM, Althobaiti H |
Frontiers in Bioengineering and Biotechnology | 2022 |
Biological and Molecular Factors Predicting Response to Adoptive Cell Therapies in Cancer
Ferrer G, Álvarez-Errico D, Esteller M |
JNCI Journal of the National Cancer Institute | 2022 |
Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma
Yamasaki-Morita M, Arai Y, Ishihara T, Onishi T, Shimo H, Nakanishi K, Nishiyama Y, Jo T, Hiramatsu H, Mitsuyoshi T, Mizumoto C, Kanda J, Nishikori M, Kitawaki T, Nogami K, Takaori-Kondo A, Nagao M, Adachi S |
Blood Advances | 2022 |
The efficacy and safety of chimeric antigen receptor T cells in digestive system cancers: a systematic review and meta-analysis
Zhao Z, Zhang J, Bian J, Lu X |
Annals of translational medicine | 2022 |
The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis
Marrapodi MM, Mascolo A, di Mauro G, Mondillo G, Pota E, Rossi F |
Frontiers in Pediatrics | 2022 |
Clinical Trials for Chimeric Antigen Receptor T-Cell Therapy: Lessons Learned and Future Directions
Schroeder BA, Jess J, Sankaran H, Shah NN |
Current Opinion in Hematology | 2022 |
Efficient derivation of chimeric-antigen receptor-modified TSCM cells
Kranz E, Kuhlmann CJ, Chan J, Kim PY, Chen IS, Kamata M |
Frontiers in immunology | 2022 |
A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma.
He P, Liu H, Zimdahl B, Wang J, Luo M, Chang Q, Tian F, Ni F, Yu D, Liu H, Chen L, Wang H, Zhang M, Grupp SA, Liu C |
Journal of Cancer Research and Clinical Oncology | 2022 |
Development of minimal physiologically-based pharmacokinetic-pharmacodynamic models for characterizing cellular kinetics of CAR T cells following local deliveries in mice.
Tsai CH, Singh AP, Xia CQ, Wang H |
Journal of Pharmacokinetics and Pharmacodynamics | 2022 |
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications.
Sun R, Kim AH |
Cancer metastasis reviews | 2022 |
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S, Benmebarek MR, Kluever AK, Darowski D, Jost C, Stubenrauch KG, Benz J, Freimoser-Grundschober A, Moessner E, Umana P, Subklewe M, Endres S, Klein C, Kobold S |
Journal for ImmunoTherapy of Cancer | 2022 |
Chimeric antigen receptor T cell: A cancer immunotherapy
Singh S, Khasbage S, Kaur RJ, Sidhu JK, Bhandari B |
Indian journal of pharmacology | 2022 |
人源化CD19 CAR-T细胞治疗儿童及青少年复发难治急性淋巴细胞白血病患者的疗效及安全性
|
2022 | |
Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies
Xie D, Jin X, Sun R, Zhang M, Wang J, Xiong X, Zhang X, Zhao M |
Technology in cancer research & treatment | 2022 |
DLL4 and VCAM1 enhance the emergence of T cell–competent hematopoietic progenitors from human pluripotent stem cells
Michaels YS, Edgar JM, Major MC, Castle EL, Zimmerman C, Yin T, Hagner A, Lau C, Hsu HH, Ibañez-Rios MI, Durland LJ, Knapp DJ, Zandstra PW |
Science Advances | 2022 |
Stem-like T cells and niches: Implications in human health and disease
Yi L, Yang L |
Frontiers in immunology | 2022 |
CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies
To V, Evtimov VJ, Jenkin G, Pupovac A, Trounson AO, Boyd RL |
Frontiers in immunology | 2022 |
Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment.
Füchsl F, Krackhardt AM |
Cancers | 2022 |
Current Progress of CAR-NK Therapy in Cancer Treatment.
Pang Z, Wang Z, Li F, Feng C, Mu X |
Cancers | 2022 |
Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.
Xiao X, Wang Y, Zou Z, Yang Y, Wang X, Xin X, Tu S, Li Y |
Frontiers in immunology | 2022 |
Automated, scaled, transposon-based production of CAR T cells
Lock D, Monjezi R, Brandes C, Bates S, Lennartz S, Teppert K, Gehrke L, Karasakalidou-Seidt R, Lukic T, Schmeer M, Schleef M, Werchau N, Eyrich M, Assenmacher M, Kaiser A, Prommersberger S, Schaser T, Hudecek M |
Journal for ImmunoTherapy of Cancer | 2022 |
CAR-T cell potency: from structural elements to vector backbone components.
Mazinani M, Rahbarizadeh F |
Biomarker Research | 2022 |
Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy
Yang TT, Meng Y, Kong DL, Wei GQ, Zhang MM, Wu WJ, Shi JM, Luo Y, Zhao YM, Yu J, Jing RR, Zhao MY, Zhao HL, Huang H, Hu YX |
Frontiers in immunology | 2022 |
Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype.
Kang S, Wang L, Xu L, Wang R, Kang Q, Gao X, Yu L |
Oncogene | 2022 |
Applying a clinical lens to animal models of CAR-T cell therapies
Duncan BB, Dunbar CE, Ishii K |
2022 | |
Generation and Functional Characterization of PLAP CAR-T Cells against Cervical Cancer Cells
Yekehfallah V, Pahlavanneshan S, Sayadmanesh A, Momtahan Z, Ma B, Basiri M |
Biomolecules | 2022 |
Co-Stimulatory Receptor Signaling in CAR-T Cells
Honikel MM, Olejniczak SH |
Biomolecules | 2022 |
Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T‐cellular therapy development
Kast J, Nozohouri S, Zhou D, Yago MR, Chen P, Ahamadi M, Dutta S, Upreti VV |
Clinical and Translational Science | 2022 |
The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia
Ragoonanan D, Sheikh IN, Gupta S, Khazal SJ, Tewari P, Petropoulos D, Li S, Mahadeo KM |
Biomedicines | 2022 |
Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies
Liu Q, Liu Z, Wan R, Huang W |
Cancers | 2022 |
Rethinking cancer targeting strategies in the era of smart cell therapeutics.
Allen GM, Lim WA |
Nature reviews. Cancer | 2022 |
The challenge of selecting tumor antigens for chimeric antigen receptor T-cell therapy in ovarian cancer.
Ding H, Zhang J, Zhang F, Xu Y, Yu Y, Liang W, Li Q |
Medical Oncology | 2022 |
Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology.
Qi T, McGrath K, Ranganathan R, Dotti G, Cao Y |
Advanced Drug Delivery Reviews | 2022 |
Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B cell lymphoma
Kedmi M, Shouval R, Fried S, Bomze D, Fein J, Cohen Z, Danilesko I, Shem-Tov N, Yerushalmi R, Jacoby E, Besser M, Shimoni A, Nagler A, Avigdor A |
2022 | |
Humanized CD19-directed CAR-T Cell Therapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia With CNSL or Neurological Comorbidity
Zhang N, Shao J, Li H, Zhu J, Xia M, Chen K, Jiang H |
Journal of immunotherapy (Hagerstown, Md. : 1997) | 2022 |
The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy
Wang Y, Song Z, Geng Y, Gao L, Xu L, Tang G, Ni X, Chen L, Chen J, Wang T, Fu W, Feng D, Yu X, Wang L, Yang J |
Frontiers in Oncology | 2022 |
Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma.
Maldonado-Pérez N, Tristán-Manzano M, Justicia-Lirio P, Martínez-Planes E, Muñoz P, Pavlovic K, Cortijo-Gutiérrez M, Blanco-Benítez C, Castella M, Juan M, Wenes M, Romero P, Molina-Estévez FJ, Marañón C, Herrera C, Benabdellah K, Martin F |
Frontiers in immunology | 2022 |
Challenges of chimeric antigen receptor-T/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies.
Wang H, Pan W |
Molecular and Cellular Biochemistry | 2022 |
Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours.
Mao R, Hussein MS, He Y |
Expert Reviews in Molecular Medicine | 2022 |
Adapter-Mediated Transduction with Lentiviral Vectors: A Novel Tool for Cell-Type-Specific Gene Transfer.
Cordes N, Winter N, Kolbe C, Kotter B, Mittelstaet J, Assenmacher M, Cathomen T, Kaiser A, Schaser T |
Viruses | 2022 |
Immunotherapy approaches for hematological cancers.
Lanier OL, Pérez-Herrero E, Andrea APD', Bahrami K, Lee E, Ward DM, Ayala-Suárez N, Rodríguez-Méndez SM, Peppas NA |
iScience | 2022 |
Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy.
Strati P, Jallouk AP, Sun R, Choi J, Das K, Cherng HJ, Ahmed S, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Steiner RE, Huff CD, Yu Y, Mistry H, Pulsifer B, Noorani M, Saini N, Shpall EJ, Kebriaei P, Flowers CR, Westin JR, Hildebrandt MAT, Neelapu SS |
Leukemia | 2022 |
Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy.
Kong D, Yang T, Geng J, Jing R, Zhang Q, Wei G, Huang H, Hu Y |
Journal of Zhejiang University. Science. B | 2022 |
Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products.
Shao L, Shi R, Zhao Y, Liu H, Lu A, Ma J, Cai Y, Fuksenko T, Pelayo A, Shah NN, Kochenderfer JN, Norberg SM, Hinrichs C, Highfill SL, Somerville RP, Panch SR, Jin P, Stroncek DF |
Journal of Translational Medicine | 2022 |
Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL
Talleur AC, Qudeimat A, Métais JY, Langfitt D, Mamcarz E, Crawford JC, Huang S, Cheng C, Hurley C, Madden R, Sharma A, Suliman A, Srinivasan A, Velasquez MP, Obeng EA, Willis C, Akel S, Karol SE, Inaba H, Bragg A, Zheng W, Zhou SM, Schell S, Tuggle-Brown M, Cullins D, Patil SL, Li Y, Thomas PG, Zebley C, Youngblood B, Pui CH, Lockey T, Geiger TL, Meagher MM, Triplett BM, Gottschalk S |
Blood Advances | 2022 |
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR
Shalabi H, Qin H, Su A, Yates B, Wolters PL, Steinberg SM, Ligon JA, Silbert S, DéDé K, Benzaoui M, Goldberg S, Achar S, Schneider D, Shahani SA, Little L, Foley T, Molina JC, Panch S, Mackall CL, Lee DW, Chien CD, Pouzolles M, Ahlman M, Yuan CM, Wang HW, Wang Y, Inglefield J, Toledo-Tamula MA, Martin S, Highfill SL, Altan-Bonnet G, Stroncek D, Fry TJ, Taylor N, Shah NN |
Blood | 2022 |
CD58 loss in tumor cells confers functional impairment of CAR T cells
Yan X, Chen D, Ma X, Wang Y, Guo Y, Wei J, Tong C, Zhu Q, Lu Y, Yu Y, Wu Z, Han W |
Blood Advances | 2022 |
Immunotherapy for the treatment of multiple myeloma
Boussi LS, Avigan ZM, Rosenblatt J |
Frontiers in immunology | 2022 |
EEG-based grading of immune effector cell-associated neurotoxicity syndrome
Jones DK, Eckhardt CA, Sun H, Tesh RA, Malik P, Quadri S, Firme MS, van Sleuwen M, Jain A, Fan Z, Jing J, Ge W, Nascimento FA, Sheikh IS, Jacobson C, Frigault M, Kimchi EY, Cash SS, Lee JW, Dietrich J, Westover MB |
Scientific Reports | 2022 |
Strategies to enhance CAR-T persistence.
Liu Y, An L, Huang R, Xiong J, Yang H, Wang X, Zhang X |
Biomarker Research | 2022 |
Thrombosis and lymphocyte subsets of COVID-19 omicron BA.2 variant patients with cancer
Yin J, Cong X, Wang N, Song W, Guan Y, Zhang Y, Li Z, Liu Z |
Frontiers in Oncology | 2022 |
Pan-Cancer Analysis Identifies Tumor Cell Surface Targets for CAR-T Cell Therapies and Antibody Drug Conjugates
Li X, Zhou J, Zhang W, You W, Wang J, Zhou L, Liu L, Chen WW, Li H |
Cancers | 2022 |
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients
Saygin C, Cannova J, Stock W, Muffly L |
Haematologica | 2022 |
Multiple CAR-T cell therapy for acute B-cell lymphoblastic leukemia after hematopoietic stem cell transplantation: A case report
Deng L, Xiaolin Y, Wu Q, Song X, Li W, Hou Y, Liu Y, Wang J, Tian J, Zuo X, Zhou F |
Frontiers in immunology | 2022 |
Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse
Liu L, Ma C, Zhang Z, Witkowski MT, Aifantis I, Ghassemi S, Chen W |
Journal for ImmunoTherapy of Cancer | 2022 |
Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?
Plocque A, Mitri C, Lefèvre C, Tabary O, Touqui L, Philippart F |
Drugs | 2022 |
Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
Asmamaw Dejenie T, Tiruneh G\/Medhin M, Dessie Terefe G, Tadele Admasu F, Wale Tesega W, Chekol Abebe E |
Human Vaccines & Immunotherapeutics | 2022 |
Harnessing the Potential of Chimeric Antigen Receptor T-Cell Therapy for the Treatment of T-Cell Malignancies: A Dare or Double Dare?
Assi R, Salman H |
Cells | 2022 |
Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance
Qin Y, Xu G |
Frontiers in immunology | 2022 |
Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
Huang L, Li J, Yang J, Zhang X, Zhang M, He J, Zhang G, Li W, Wang H, Li J, Lu P |
Cells | 2022 |
Dose-response correlation for CAR-T cells: a systematic review of clinical studies.
Rotte A, Frigault MJ, Ansari A, Gliner B, Heery C, Shah B |
Journal for ImmunoTherapy of Cancer | 2022 |
Mechanisms of immune effector cell‐associated neurotoxicity syndrome after CAR‐T treatment
Gu T, Hu K, Si X, Hu Y, Huang H |
2022 | |
[Three cases of hemodiafiltration for the treatment of CAR-T related grade 3 - 4 cytokine release syndrome after ineffective treatment with IL-6 receptor inhibitors].
Chen SY, Chen WH, Wan XC, Du X, Luo CR, Li XQ, Zhang XH |
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi | 2022 |
Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes.
Smole A |
Radiology and Oncology | 2022 |
Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma
Monfrini C, Stella F, Aragona V, Magni M, Ljevar S, Vella C, Fardella E, Chiappella A, Nanetti F, Pennisi M, Dodero A, Guidetti A, Corradini P, Carniti C |
Clinical cancer research | 2022 |
Transcriptomic analysis of the innate immune response to in vitro transfection of plasmid DNA
Warga E, Anderson J, Tucker M, Harris E, Elmer J |
2022 | |
Chimeric antigen receptor T-cell therapy for multiple myeloma
Wang Z, Chen C, Wang L, Jia Y, Qin Y |
Frontiers in immunology | 2022 |
Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis
Li L, Wang L, Liu Q, Wu Z, Zhang Y, Xia R |
Frontiers in Oncology | 2022 |
NOTCH1 signaling during CD4+ T-cell activation alters transcription factor networks and enhances antigen responsiveness
Wilkens AB, Fulton EC, Pont MJ, Cole GO, Leung I, Stull SM, Hart MR, Bernstein ID, Furlan SN, Riddell SR |
Blood | 2022 |
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
Gauthier J, Gazeau N, Hirayama AV, Hill JA, Wu V, Cearley A, Perkins P, Kirk A, Shadman M, Chow VA, Gopal AK, Hodges Dwinal A, Williamson S, Myers J, Chen A, Nagle S, Hayes-Lattin B, Schachter L, Maloney DG, Turtle CJ, Sorror ML, Maziarz RT |
Blood | 2022 |
Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy
Berger SC, Fehse B, Akyüz N, Geffken M, Wolschke C, Janson D, Gagelmann N, Luther M, Wichmann D, Frenzel C, Thayssen G, Alegiani A, Badbaran A, Zeschke S, Dierlamm J, Kröger N, Ayuk FA |
Haematologica | 2022 |
Dual antigen–targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia
Cichocki F, Goodridge JP, Bjordahl R, Mahmood S, Davis ZB, Gaidarova S, Abujarour R, Groff B, Witty A, Wang H, Tuininga K, Kodal B, Felices M, Bonello G, Huffman J, Dailey T, Lee TT, Walcheck B, Valamehr B, Miller JS |
Blood | 2022 |
Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer
Hagel KR, Arafeh R, Gang S, Arnoff TE, Larson RC, Doench JG, Mathewson ND, Wucherpfennig KW, Maus MV, Hahn WC |
Cancer research | 2022 |
Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies
Cichocki F, van der Stegen SJ, Miller JS |
Blood | 2022 |
Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
Dupouy S, Marchiq I, Derippe T, Almena-Carrasco M, Jozwik A, Fouliard S, Adimy Y, Geronimi J, Graham C, Jain N, Maus MV, Mohty M, Boissel N, Teshima T, Kato K, Benjamin R, Balandraud S |
2022 | |
How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL
Myers RM, Shah NN, Pulsipher MA |
Blood | 2022 |
Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia
Kirkey DC, Loeb AM, Castro S, McKay CN, Perkins L, Pardo L, Leonti AR, Tang TT, Loken MR, Brodersen LE, Loeb KR, Scheinberg DA, Le Q, Meshinchi S |
Blood Advances | 2022 |
A new story for an old challenge: Would flow cytometry beat molecular biology in monitoring chimeric antigen receptor T cell pharmacokinetics?
Lambert C, Ntrivalas E, Sack U |
Cytometry Part A | 2022 |
Phase I CAR-T Clinical Trials Review
Bulsara S, Wu M, Wang T |
Anticancer research | 2022 |
Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
Abbasi S, Totmaj MA, Abbasi M, Hajazimian S, Goleij P, Behroozi J, Shademan B, Isazadeh A, Baradaran B |
Cancer Medicine | 2022 |
Post-mortem neuropathologic examination of a 6-case series of CAR T-cell treated patients.
Vidal-Robau N, Caballero G, Archilla I, Ladino A, Fernández S, Ortiz-Maldonado V, Rovira M, Gómez-Hernando M, Delgado J, Suárez-Lledó M, Fernández de Larrea C, Balagué O, Frigola G, Muñoz A, Ortiz E, Ribalta T, Martinez MJ, Angeles-Marcos M, Español-Rego M, González A, Benitez-Ribas D, Martinez-Hernandez E, Castro P, Aldecoa I |
Free neuropathology | 2022 |
Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function
Leung I, Templeton ML, Lo Y, Rajan A, Stull SM, Garrison SM, Salter AI, Smythe KS, Correnti CE, Srivastava S, Yeung CC, Riddell SR |
Blood Advances | 2022 |
Genome-edited allogeneic donor “universal” chimeric antigen receptor T cells
Qasim W |
Blood | 2022 |
Should All CAR-T Therapy for Acute Lymphoblastic Leukemia Be Consolidated with Allogeneic Stem Cell Transplant?
Marinos A, Heslop HE |
Best practice & research. Clinical haematology | 2022 |
Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant
Gottlieb DJ, Sutrave G, Jiang W, Avdic S, Street JA, Simms R, Clancy LE, Antonenas V, Gloss BS, Bateman C, Bishop DC, Micklethwaite KP, Blyth E |
American Journal of Hematology | 2022 |
Safety switch optimization enhances antibody-mediated elimination of CAR T cells
Shabaneh TB, Moffett HF, Stull SM, Derezes T, Tait LJ, Park S, Riddell SR, Lajoie MJ |
2022 | |
Therapeutic cancer vaccination targeting antigens and adjuvants to lymphoid tissues using genetically modified T cells
Joshua R. Veatch, Naina Singhi, Shivani Srivastava, Julia L Szeto, Brenda Jesernig, Sylvia M. Stull, Matthew Fitzgibbon, Megha Sarvothama, Sushma Yechan-Gunja, Scott E James, Stanley R Riddell |
Journal of Clinical Investigation | 2021 |
Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia
MJ Cox, F Lucien, R Sakemura, JC Boysen, Y Kim, P Horvei, CM Roman, MJ Hansen, EE Tapper, EL Siegler, C Forsman, SB Crotts, KJ Schick, M Hefazi, MW Ruff, I Can, M Adada, E Bezerra, LA Fonkoua, WK Nevala, E Braggio, W Ding, SA Parikh, NE Kay, SS Kenderian |
Molecular Therapy | 2021 |
Immune inactivation of anti-simian immunodeficiency virus chimeric antigen receptor T cells in rhesus macaques
F Haeseleer, Y Fukazawa, H Park, B Varco-Merth, BJ Rust, JV Smedley, K Eichholz, CW Peterson, R Mason, HP Kiem, M Roederer, LJ Picker, AA Okoye, L Corey |
Molecular Therapy — Methods & Clinical Development | 2021 |
Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival
J Julamanee, S Terakura, K Umemura, Y Adachi, K Miyao, S Okuno, E Takagi, T Sakai, D Koyama, T Goto, R Hanajiri, M Hudecek, P Steinberger, J Leitner, T Nishida, M Murata, H Kiyoi |
Molecular Therapy | 2021 |
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
Z Wang, N Li, K Feng, M Chen, Y Zhang, Y Liu, Q Yang, J Nie, N Tang, X Zhang, C Cheng, L Shen, J He, X Ye, W Cao, H Wang, W Han |
Cellular and Molecular Immunology | 2021 |
Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma
S Harada, M Ando, J Ando, M Ishii, T Yamaguchi, S Yamazaki, T Toyota, K Ohara, M Ohtaka, M Nakanishi, C Shin, Y Ota, K Nakashima, K Ohshima, C Imai, Y Nakazawa, H Nakauchi, N Komatsu |
Molecular Therapy | 2021 |
Metabolic barriers to cancer immunotherapy
K DePeaux, GM Delgoffe |
Nature Reviews Immunology | 2021 |
Improving CAR T-Cell Persistence
V Pietrobon, LA Todd, A Goswami, O Stefanson, Z Yang, F Marincola |
International journal of molecular sciences | 2021 |
Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia
AK Jaiswal, H Truong, TM Tran, TL Lin, D Casero, MO Alberti, DS Rao |
Scientific Reports | 2021 |
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
S Chandrasekaran, CR Funk, T Kleber, CM Paulos, M Shanmugam, EK Waller |
Frontiers in immunology | 2021 |
Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL
B Deng, J Pan, Z Liu, S Liu, Y Chen, X Qu, Y Zhang, Y Lin, Y Zhang, X Yu, Z Zhang, X Niu, R Luan, M Ma, X Li, T Liu, , H Niu, AH Chang, C Tong |
Molecular Therapy — Methods & Clinical Development | 2021 |
Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials
S Smirnov, A Petukhov, K Levchuk, S Kulemzin, A Staliarova, K Lepik, O Shuvalov, A Zaritskey, A Daks, O Fedorova |
Frontiers in immunology | 2021 |
Super-Treg: Toward a New Era of Adoptive Treg Therapy Enabled by Genetic Modifications
L Amini, J Greig, M Schmueck-Henneresse, HD Volk, S Bézie, P Reinke, C Guillonneau, DL Wagner, I Anegon |
Frontiers in immunology | 2021 |
Biology and Treatment of Leukemia and Bone Marrow Neoplasms
V Pullarkat, G Marcucci |
2021 | |
A Mathematical Description of the Bone Marrow Dynamics during CAR T-Cell Therapy in B-Cell Childhood Acute Lymphoblastic Leukemia
Á Martínez-Rubio, S Chulián, CB Goñi, MR Orellana, AP Martínez, A Navarro-Zapata, C Ferreras, VM Pérez-García, M Rosa |
International journal of molecular sciences | 2021 |
Interleukin‐37 improves T‐cell‐mediated immunity and chimeric antigen receptor T‐cell therapy in aged backgrounds
JA Hamilton, MY Lee, R Hunter, RS Ank, JY Story, G Talekar, T Sisroe, DB Ballak, A Fedanov, CC Porter, EZ Eisenmesser, CA Dinarello, SS Raikar, J DeGregori, CJ Henry |
Aging Cell | 2021 |
Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job
M Schwerdtfeger, MR Benmebarek, S Endres, M Subklewe, V Desiderio, S Kobold |
Current Hematologic Malignancy Reports | 2021 |
How Can We Engineer CAR T Cells to Overcome Resistance?
M Glover, S Avraamides, J Maher |
Biologics : targets & therapy | 2021 |
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
KM Cappell, JN Kochenderfer |
Nature Reviews Clinical Oncology | 2021 |
Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma
NW van de Donk, M Themeli, SZ Usmani |
2021 | |
Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy
S Lamure, FV Laethem, DD Verbizier, C Lozano, E Gehlkopf, JJ Tudesq, C Serrand, M Benzaoui, T Kanouni, A Quintard, JD Vos, E Tchernonog, L Platon, X Ayrignac, P Ceballos, A Sirvent, M François, H Guedon, P Quittet, C Mongellaz, A Conte, C Herbaux, C Bret, N Taylor, V Dardalhon, G Cartron |
Cancers | 2021 |
BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma
L Xia, J Liu, Z Zheng, Y Chen, J Ding, Y Hu, G Hu, N Xia, W Liu |
Molecular Therapy | 2021 |
The Current and Future Role of Radiation Therapy in the Era of CAR T-cell Salvage
C DeSelm |
British Journal of Radiology | 2021 |
Pharmacologic Control of CAR T Cells
B Caulier, JM Enserink, S Wälchli |
International journal of molecular sciences | 2021 |
Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction
R Hong, Y Hu, H Huang |
Frontiers in immunology | 2021 |
Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function
AI Salter, A Rajan, JJ Kennedy, RG Ivey, SA Shelby, I Leung, ML Templeton, V Muhunthan, V Voillet, D Sommermeyer, JR Whiteaker, R Gottardo, SL Veatch, AG Paulovich, SR Riddell |
Science signaling | 2021 |
CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges
M Narkhede, A Mehta, SM Ansell, G Goyal |
Annals of translational medicine | 2021 |
Born to survive: how cancer cells resist CAR T cell therapy
J Lemoine, M Ruella, R Houot |
Journal of Hematology & Oncology | 2021 |
Engineering-enhanced CAR T cells for improved cancer therapy
MC Milone, J Xu, SJ Chen, MK Collins, J Zhou, DJ Powell, JJ Melenhorst |
2021 | |
CAR T-Cell Production Using Nonviral Approaches
V Lukjanov, I Koutná, P Šimara, LA Ponce-Soto |
Journal of Immunology Research | 2021 |
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
JY Spiegel, S Patel, L Muffly, NM Hossain, J Oak, JH Baird, MJ Frank, P Shiraz, B Sahaf, J Craig, M Iglesias, S Younes, Y Natkunam, MG Ozawa, E Yang, J Tamaresis, H Chinnasamy, Z Ehlinger, W Reynolds, R Lynn, MC Rotiroti, N Gkitsas, S Arai, L Johnston, R Lowsky, RG Majzner, E Meyer, RS Negrin, AR Rezvani, S Sidana, J Shizuru, WK Weng, C Mullins, A Jacob, I Kirsch, M Bazzano, J Zhou, S Mackay, SJ Bornheimer, L Schultz, S Ramakrishna, KL Davis, KA Kong, NN Shah, H Qin, T Fry, S Feldman, CL Mackall, DB Miklos |
Nature Medicine | 2021 |
Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapy
LO Afolabi, MO Afolabi, MM Sani, WO Okunowo, D Yan, L Chen, Y Zhang, X Wan |
IBMS BoneKEy | 2021 |
Current Immunotherapies for Glioblastoma Multiforme
B Huang, X Li, Y Li, J Zhang, Z Zong, H Zhang |
Frontiers in immunology | 2021 |
Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors
V Pietrobon, A Cesano, F Marincola, JN Kather |
Frontiers in immunology | 2021 |
The role of small molecules in cell and gene therapy
LL Brayshaw, C Martinez-Fleites, T Athanasopoulos, T Southgate, L Jespers, C Herring |
2021 | |
Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments
X Xu, S Huang, X Xiao, Q Sun, X Liang, S Chen, Z Zhao, Z Huo, S Tu, Y Li |
Frontiers in immunology | 2021 |
Cas9 RNP transfection by vapor nanobubble photoporation for ex vivo cell engineering
L Raes, M Pille, A Harizaj, G Goetgeluk, JV Hoeck, S Stremersch, JC Fraire, T Brans, OG de Jong, R Maas-Bakker, E Mastrobattista, P Vader, SC Smedt, B Vandekerckhove, K Raemdonck, K Braeckmans |
Molecular Therapy — Nucleic Acids | 2021 |
Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients
L Biasco, N Izotova, C Rivat, S Ghorashian, R Richardson, A Guvenel, R Hough, R Wynn, B Popova, A Lopes, M Pule, AJ Thrasher, PJ Amrolia |
2021 | |
An overview of multiplexed analyses of CAR T-cell therapies: insights and potential
BP DePriest, N Vieira, A Bidgoli, S Paczesny |
Expert Review of Proteomics | 2021 |
Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model
A Mueller-Schoell, N Puebla-Osorio, R Michelet, MR Green, A Künkele, W Huisinga, P Strati, B Chasen, SS Neelapu, C Yee, C Kloft |
Cancers | 2021 |
Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward
PS Kozani, PS Kozani, F Rahbarizadeh |
Frontiers in immunology | 2021 |
Targeting NK Cells to Enhance Melanoma Response to Immunotherapies
H Lee, IP Silva, U Palendira, RA Scolyer, GV Long, JS Wilmott |
Cancers | 2021 |
The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy
ML Schubert, R Rohrbach, M Schmitt, CK Stein-Thoeringer |
Frontiers in immunology | 2021 |
Making Potent CAR T Cells Using Genetic Engineering and Synergistic Agents
CH Park |
Cancers | 2021 |
Immunogenicity of CAR T cells in cancer therapy
DL Wagner, E Fritsche, MA Pulsipher, N Ahmed, M Hamieh, M Hegde, M Ruella, B Savoldo, NN Shah, CJ Turtle, AS Wayne, M Abou-el-Enein |
Nature Reviews Clinical Oncology | 2021 |
CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
P Karschnia, J Blobner, N Teske, F Schöberl, E Fitzinger, M Dreyling, JC Tonn, N Thon, M Subklewe, L von Baumgarten |
Cancers | 2021 |
The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma
J Sandoval-Sus, JC Chavez |
Therapeutic Advances in Hematology | 2021 |
Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia
X Zhang, J Yang, J Li, W Li, D Song, X Lu, F Wu, J Li, D Chen, X Li, Z Xu, S Liu, Z Li, K Ying, P Lu |
Cancer Immunology, Immunotherapy | 2021 |
The antigen‐binding moiety in the driver's seat of CARs
H Hanssens, F Meeus, KD Veirman, K Breckpot, N Devoogdt |
Medicinal Research Reviews | 2021 |
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
M Abou-el-Enein, M Elsallab, SA Feldman, AD Fesnak, HE Heslop, P Marks, BG Till, G Bauer, B Savoldo |
2021 | |
Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment
M Cosenza, S Sacchi, S Pozzi |
International journal of molecular sciences | 2021 |
Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis
S Kaczanowska, DW Beury, V Gopalan, AK Tycko, H Qin, ME Clements, J Drake, C Nwanze, M Murgai, Z Rae, W Ju, KA Alexander, J Kline, CF Contreras, KM Wessel, S Patel, S Hannenhalli, MC Kelly, RN Kaplan |
Cell | 2021 |
Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy
L Lindo, LH Wilkinson, KA Hay |
Frontiers in immunology | 2021 |
Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy
R Rezaei, HE Ghaleh, M Farzanehpour, R Dorostkar, R Ranjbar, M Bolandian, MM Nodooshan, AG Alvanegh |
Cancer Gene Therapy | 2021 |
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
X Xiao, S Huang, S Chen, Y Wang, Q Sun, X Xu, Y Li |
Journal of Experimental & Clinical Cancer Research | 2021 |
Hypoxia and the phenomenon of immune exclusion
V Pietrobon, FM Marincola |
Journal of Translational Medicine | 2021 |
Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer
R He, Y Lao, W Yu, X Zhang, M Jiang, C Zhu |
Frontiers in Oncology | 2021 |
Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer
A Kumar, R Watkins, AE Vilgelm |
Frontiers in immunology | 2021 |
In vivo CART cell imaging: Paving the way for success in CART cell therapy
R Sakemura, I Can, EL Siegler, SS Kenderian |
Molecular Therapy — Oncolytics | 2021 |
Enhancing Therapeutic Efficacy of Double Negative T Cells against Acute Myeloid Leukemia Using Idelalisib
H Kang, JB Lee, I Khatri, Y Na, C DSouza, A Arruda, MD Minden, L Zhang |
Cancers | 2021 |
Targeting Glioblastoma: The Current State of Different Therapeutic Approaches
I Khan, S Mahfooz, E Elbasan, B Karacam, M Oztanir, M Hatiboglu |
Current neuropharmacology | 2021 |
Bcl-2 Enhances Chimeric Antigen Receptor T Cell Persistence by Reducing Activation-Induced Apoptosis
H Wang, P Han, X Qi, F Li, M Li, L Fan, H Zhang, X Zhang, X Yang |
Cancers | 2021 |
Adoptive Immunotherapy beyond CAR T-Cells
A Titov, E Zmievskaya, I Ganeeva, A Valiullina, A Petukhov, A Rakhmatullina, R Miftakhova, M Fainshtein, A Rizvanov, E Bulatov |
Cancers | 2021 |
Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia
M Gurney, M ODwyer |
Cancers | 2021 |
Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs
E Moghanloo, H Mollanoori, M Talebi, S Pashangzadeh, F Faraji, F Hadjilooei, H Mahmoodzadeh |
Translational oncology | 2021 |
A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy
MH Meeuwsen, AK Wouters, L Jahn, RS Hagedoorn, MG Kester, DF Remst, LT Morton, DM van der Steen, C Kweekel, AH de Ru, M Griffioen, PA van Veelen, JH Falkenburg, MH Heemskerk |
Molecular Therapy | 2021 |
In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL
PS Kozani, PS Kozani, RS O'Connor |
Molecular cancer therapeutics | 2021 |
Insights on Droplet Digital PCR–Based Cellular Kinetics and Biodistribution Assay Support for CAR-T Cell Therapy
H Sugimoto, S Chen, JP Minembe, J Chouitar, X He, H Wang, X Fang, MG Qian |
The AAPS Journal | 2021 |
Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia
VA Fabrizio, KJ Curran |
Best practice & research. Clinical haematology | 2021 |
The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains
Z Dai, W Mu, Y Zhao, X Jia, J Liu, Q Wei, T Tan, J Zhou |
Molecular Therapy | 2021 |
Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials
Y Que, M Xu, Y Xu, VD Almeida, L Zhu, Z Wang, Y Wang, X Liu, L Jiang, D Wang, C Li, J Zhou |
Frontiers in immunology | 2021 |
Efficacy and safety of humanized CD19 CAR‑T as a salvage therapy for recurrent CNSL of B‑ALL following murine CD19 CAR‑T cell therapy
X Li, MJ Liu, N Mou, ZX Yang, J Wang, J Mu, HB Zhu, Q Deng |
Oncology Letters | 2021 |
Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies
Z Guo, S Tu, S Yu, L Wu, W Pan, N Chang, X Zhou, C Song, Y Li, Y He |
Cancer Science | 2021 |
CAR-T cells: Early successes in blood cancer and challenges in solid tumors
H Dana, GM Chalbatani, SA Jalali, HR Mirzaei, SA Grupp, ER Suarez, C Rapôso, TJ Webster |
Acta pharmaceutica Sinica. B | 2021 |
Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia
W Liao, ME Kohler, T Fry, P Ernst |
Experimental Hematology | 2021 |
Proceedings From the First International Workshop at Sidra Medicine: “Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development”, 15th–16th February 2019, Doha, Qatar
B Guerrouahen, M Elnaggar, A Al-Mohannadi, D Kizhakayil, C Bonini, R Benjamin, R Brentjens, CJ Buchholz, G Casorati, S Ferrone, FL Locke, F Martin, A Schambach, C Turtle, P Veys, HJ van der Vliet, C Maccalli |
Frontiers in immunology | 2021 |
Current Status of CAR T Cell Therapy for Leukemias
K Harris, JL LaBelle, MR Bishop |
Current Treatment Options in Oncology | 2021 |
Cellular networks controlling T cell persistence in adoptive cell therapy
JD Chan, J Lai, CY Slaney, A Kallies, PA Beavis, PK Darcy |
Nature Reviews Immunology | 2021 |
A Systematic Review of the Efforts and Hindrances of Modeling and Simulation of CAR T-cell Therapy
U Nukala, MR Messan, ON Yogurtcu, X Wang, H Yang |
The AAPS Journal | 2021 |
Bench‐to‐bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic‐pharmacodynamic model: A case study with anti‐BCMA CAR‐T
AP Singh, W Chen, X Zheng, H Mody, TJ Carpenter, A Zong, DL Heald |
CPT Pharmacometrics Syst. Pharmacol. | 2021 |
Physiological Imaging Methods for Evaluating Response to Immunotherapies in Glioblastomas
S Chawla, V Shehu, PK Gupta, K Nath, H Poptani |
International journal of molecular sciences | 2021 |
Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis
W Lei, M Xie, Q Jiang, N Xu, P Li, A Liang, KH Young, W Qian |
Cancers | 2021 |
Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response
SY Wang, TV Moore, AV Dalheim, GM Scurti, MI Nishimura |
Scientific Reports | 2021 |
Opening of the Blood–Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models
A Sabbagh, K Beccaria, X Ling, A Marisetty, M Ott, H Caruso, E Barton, LY Kong, D Fang, K Latha, DY Zhang, J Wei, J DeGroot, MA Curran, G Rao, J Hu, C Desseaux, G Bouchoux, M Canney, A Carpentier, AB Heimberger |
Clinical cancer research | 2021 |
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies
J Gauthier, ED Bezerra, AV Hirayama, S Fiorenza, A Sheih, CK Chou, EL Kimble, BS Pender, RM Hawkins, A Vakil, TD Phi, RN Steinmetz, AW Jamieson, M Bar, RD Cassaday, AG Chapuis, AJ Cowan, DJ Green, HP Kiem, F Milano, M Shadman, BG Till, SR Riddell, DG Maloney, CJ Turtle |
Blood | 2021 |
Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma
X Li, Y Feng, F Shang, Z Yu, T Wang, J Zhang, Z Song, P Wang, B Shi, J Wang |
Frontiers in Oncology | 2021 |
Reactions Related to CAR-T Cell Therapy
L Miao, Z Zhang, Z Ren, Y Li |
Frontiers in immunology | 2021 |
Beyond the storm — subacute toxicities and late effects in children receiving CAR T cells
H Shalabi, J Gust, A Taraseviciute, PL Wolters, AB Leahy, C Sandi, TW Laetsch, L Wiener, RA Gardner, V Nussenblatt, JA Hill, KJ Curran, TS Olson, C Annesley, HW Wang, J Khan, MC Pasquini, CN Duncan, SA Grupp, MA Pulsipher, NN Shah |
Nature Reviews Clinical Oncology | 2021 |
CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial
M Shao, Q Yu, X Teng, X Guo, G Wei, H Xu, J Cui, AH Chang, Y Hu, H Huang |
Bone Marrow Transplantation | 2021 |
CAR T-cell therapy in multiple myeloma: more room for improvement
PJ Teoh, WJ Chng |
Blood Cancer Journal | 2021 |
The Anticancer Potential of T Cell Receptor-Engineered T Cells
M Ecsedi, MS McAfee, AG Chapuis |
Trends in Cancer | 2021 |
Single-cell transcriptome analysis of CAR T-cell products reveals subpopulations, stimulation, and exhaustion signatures
X Wang, C Peticone, E Kotsopoulou, B Göttgens, FJ Calero-Nieto |
OncoImmunology | 2021 |
Cytolytic Activity of CAR T Cells and Maintenance of Their CD4+ Subset Is Critical for Optimal Antitumor Activity in Preclinical Solid Tumor Models
M Csaplár, J Szöllősi, S Gottschalk, G Vereb, Á Szöőr |
Cancers | 2021 |
Genome edited B cells: a new frontier in immune cell therapies
GL Rogers, PM Cannon |
Molecular Therapy | 2021 |
Single-cell Analysis Technologies for Immuno-oncology Research: From Mechanistic Delineation to Biomarker Discovery
Z Bai, G Su, R Fan |
Genomics, proteomics & bioinformatics / Beijing Genomics Institute | 2021 |
Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy
K Wudhikarn, JR Flynn, I Rivière, M Gönen, X Wang, B Senechal, KJ Curran, M Roshal, PG Maslak, MB Geyer, EF Halton, C Diamonte, ML Davila, M Sadelain, RJ Brentjens, JH Park |
Blood | 2021 |
Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis
L Hu, A Charwudzi, Q Li, W Zhu, Q Tao, S Xiong, Z Zhai |
Annals of Hematology | 2021 |
Mutated GM‐CSF‐based CAR‐T cells targeting CD116/CD131 complexes exhibit enhanced anti‐tumor effects against acute myeloid leukaemia
A Hasegawa, S Saito, S Narimatsu, S Nakano, M Nagai, H Ohnota, Y Inada, H Morokawa, I Nakashima, D Morita, Y Ide, K Matsuda, H Tashiro, S Yagyu, M Tanaka, Y Nakazawa |
IBMS BoneKEy | 2021 |
A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Y Zhang, J Li, X Lou, X Chen, Z Yu, L Kang, J Chen, J Zhou, X Zong, Z Yang, M Li, N Xu, S Jia, H Geng, G Chen, H Dai, X Tang, L Yu, D Wu, C Li |
Frontiers in Oncology | 2021 |
Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse
S Faude, J Wei, K Muralidharan, X Xu, G Wertheim, M Paessler, VG Bhoj, SA Grupp, SL Maude, SR Rheingold, V Pillai |
Blood Advances | 2021 |
The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy
GJ Kimmel, FL Locke, PM Altrock |
Proceedings of the Royal Society B: Biological Sciences | 2021 |
State-of-Art of Cellular Therapy for Acute Leukemia
JB Lee, D Vasic, H Kang, KK Fang, L Zhang |
International journal of molecular sciences | 2021 |
Human T cells engineered with a leukemia lipid-specific TCR enables donor-unrestricted recognition of CD1c-expressing leukemia
M Consonni, C Garavaglia, A Grilli, C de Lalla, A Mancino, L Mori, GD Libero, D Montagna, M Casucci, M Serafini, C Bonini, D Häussinger, F Ciceri, M Bernardi, S Mastaglio, S Bicciato, P Dellabona, G Casorati |
Nature Communications | 2021 |
Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains
S Choi, MA Pegues, N Lam, C Geldres, D Vanasse, JN Kochenderfer |
Human Gene Therapy | 2021 |
The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel
K Wudhikarn, R Bansal, A Khurana, MA Hathcock, NN Bennani, J Paludo, JC Villasboas, Y Wang, PB Johnston, SM Ansell, Y Lin |
Blood Cancer Journal | 2021 |
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis
NA Vitanza, AJ Johnson, AL Wilson, C Brown, JK Yokoyama, A Künkele, CA Chang, S Rawlings-Rhea, W Huang, K Seidel, CM Albert, N Pinto, J Gust, LS Finn, JG Ojemann, J Wright, RJ Orentas, M Baldwin, RA Gardner, MC Jensen, JR Park |
Nature Medicine | 2021 |
Comparison of Three CD3-Specific Separation Methods Leading to Labeled and Label-Free T Cells
R Weiss, W Gerdes, R Berthold, U Sack, U Koehl, S Hauschildt, A Grahnert |
Cells | 2021 |
CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities
JW Fischer, N Bhattarai |
Frontiers in immunology | 2021 |
Adding Help to an HLA-A*24:02 Tumor-Reactive γδTCR Increases Tumor Control
I Johanna, P Hernández-López, S Heijhuurs, W Scheper, L Bongiovanni, A de Bruin, DX Beringer, R Oostvogels, T Straetemans, Z Sebestyen, J Kuball |
Frontiers in immunology | 2021 |
CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
Y Sun, Y Su, Y Wang, N Liu, Y Li, J Chen, Z Qiao, J Niu, J Hu, B Zhang, H Ning, L Hu |
Frontiers in immunology | 2021 |
CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
YB Xue, X Lai, RL Li, CL Ge, BZ Zeng, Z Li, QF Fu, LF Zhao, SW Dong, JY Yang, JY Guo, QY Meng, QH Tan, ZH Li, HY Ding, YL Zhang, SH Liu, AH Chang, H Yao, RC Luo |
Frontiers in Oncology | 2021 |
NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity
RM Richards, F Zhao, KA Freitas, KR Parker, P Xu, A Fan, E Sotillo, M Daugaard, HZ Oo, J Liu, WJ Hong, PH Sorensen, HY Chang, AT Satpathy, RG Majzner, R Majeti, CL Mackall |
2021 | |
HSC and iPS cell‐derived CAR‐NK cells as reliable cell‐based therapy solutions
J Arias, J Yu, M Varshney, J Inzunza, I Nalvarte |
Stem Cells Translational Medicine | 2021 |
A Novel Peptide-MHC Targeted Chimeric Antigen Receptor T Cell Forms a T Cell-like Immune Synapse
SS Wang, K Luong, FM Gracey, S Jabar, B McColl, RS Cross, MR Jenkins |
Biomedicines | 2021 |
[Mechanism and prevention strategies of neurotoxicity in CAR-T treatment of B cell tumors]
Q Zhang, Y Xiao |
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi | 2021 |
What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Q Wang, B Xie, S Liu, Y Shi, Y Tao, D Xiao, W Wang |
Frontiers in immunology | 2021 |
TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy
Y Nai, L Du, M Shen, T Li, J Huang, X Han, F Luo, W Wang, D Pang, A Jin |
Frontiers in Molecular Biosciences | 2021 |
Relapsed ALL: CAR T vs transplant vs novel therapies
N Frey |
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program | 2021 |
[Humanized BCMA CAR-T cell salvage therapy in two refractory multiple myeloma patients who progressed after their murine BCMA CAR-T cell therapy]
R Cui, P Li, Q Li, J Mu, Y L Jiang, Y Y Jiang, Q Deng |
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi | 2021 |
Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome—A Wandering Road to Remission
Y Wang, L Wang, Y Zeng, R Hong, C Zu, ET Yin, H Zhao, G Wei, L Yang, A Jin, Y Hu, H Huang |
Frontiers in Oncology | 2021 |
T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
PH Mehta, S Fiorenza, RM Koldej, A Jaworowski, DS Ritchie, KM Quinn |
Frontiers in immunology | 2021 |
A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia.
Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione C |
International journal of molecular sciences | 2021 |
Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia.
Perica K, Flynn J, Curran KJ, Rivere I, Wang X, Senechal B, Halton E, Diamonte C, Pineda J, Bernal Y, Gonen M, Sadelain M, Brentjens RJ, Park JH |
Leukemia | 2021 |
Immune Effector Cell Associated Neurotoxicity (ICANS) in Pediatric and Young Adult Patients Following Chimeric Antigen Receptor (CAR) T-Cell Therapy: Can We Optimize Early Diagnosis?
Brown BD, Tambaro FP, Kohorst M, Chi L, Mahadeo KM, Tewari P, Petropoulos D, Slopis JM, Sadighi Z, Khazal S |
Frontiers in Oncology | 2021 |
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.
Shah NN, Lee DW, Yates B, Yuan CM, Shalabi H, Martin S, Wolters PL, Steinberg SM, Baker EH, Delbrook CP, Stetler-Stevenson M, Fry TJ, Stroncek DF, Mackall CL |
Journal of Clinical Oncology | 2021 |
CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB, Newman H, Li Y, Liu H, Myers R, DiNofia A, Dolan JG, Callahan C, Baniewicz D, Devine K, Wray L, Aplenc R, June CH, Grupp SA, Rheingold SR, Maude SL |
The Lancet Haematology | 2021 |
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease.
Lu W, Wei Y, Cao Y, Xiao X, Li Q, Lyu H, Jiang Y, Zhang H, Li X, Jiang Y, Meng J, Yuan T, Zhu H, He X, Jin X, Sun R, Sui T, Liu K, Zhao M |
Cancer Immunology, Immunotherapy | 2021 |
Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas.
Salvaris R, Ong J, Gregory GP |
Journal of Personalized Medicine | 2021 |
Natural Receptor- and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing
Branella GM, Spencer HT |
Cells | 2021 |
Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity.
Foster MC, Savoldo B, Lau W, Rubinos C, Grover N, Armistead P, Coghill J, Hagan RS, Morrison K, Buchanan FB, Cheng C, Laing S, Ivanova A, West J, Foster A, Serody J, Dotti G |
Blood | 2021 |
[Preparation of a novel tri-specific T cell engager targeting CD19 antigen and its anti-leukemia effect exploration].
Chen ML, Peng N, Liu XY, Zhang T, Xu YX, Tian Z, Xing HY, Tang KJ, Rao Q, Wang JX, Wang M |
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi | 2021 |
Real-World Outcome in the pre-CAR-T Era of Myeloma Patients Qualifying for CAR-T Cell Therapy
Brechbühl S, Bacher U, Jeker B, Pabst T |
Mediterranean journal of hematology and infectious diseases | 2021 |
Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia
Abuasab T, Rowe J, Tvito A |
Biologics : targets & therapy | 2021 |
Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma
Thudium Mueller K, Grupp SA, Maude SL, Levine JE, Pulsipher MA, Boyer MW, August KJ, Myers GD, Tam CS, Jaeger U, Foley SR, Borchmann P, Schuster SJ, Waller EK, Awasthi R, Potthoff B, Warren A, Waldron ER, McBlane F, Chassot-Agostinho A, Laetsch TW |
Blood Advances | 2021 |
Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing.
Noaks E, Peticone C, Kotsopoulou E, Bracewell DG |
2021 | |
Consolidative Hematopoietic Stem Cell Transplantation After CD19 CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis.
Xu X, Chen S, Zhao Z, Xiao X, Huang S, Huo Z, Li Y, Tu S |
Frontiers in Oncology | 2021 |
POINT: CAR T cells better than BiTEs
Molina JC, Shah NN |
Blood Advances | 2021 |
Direct control of CAR T cells through small molecule-regulated antibodies
Park S, Pascua E, Lindquist KC, Kimberlin C, Deng X, Mak YS, Melton Z, Johnson TO, Lin R, Boldajipour B, Abraham RT, Pons J, Sasu BJ, Van Blarcom TJ, Chaparro-Riggers J |
Nature Communications | 2021 |
Successful Treatment of Refractory and Relapsed CNS Acute Lymphoblastic Leukemia With CD-19 CAR-T Immunotherapy: A Case Report
Htun KT, Gong Q, Ma L, Wang P, Tan Y, Wu G, Chen J |
Frontiers in Oncology | 2021 |
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia
Seber A, de CastroJunior CG, Kerbauy LN, Hirayama AV, Bonfim C, Fernandes JF, Souza M, Schafell R, Nabhan S, Loggetto SR, Simões BP, Rocha V, de Lima M, Guerino-Cunha RL, Bittencourt H |
2021 | |
Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies
Han L, Zhou J, Li L, Zhou K, Zhao L, Zhu X, Yin Q, Li Y, You H, Zhang J, Song Y, Gao Q |
Cancer biology & medicine | 2021 |
Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial.
Kadauke S, Myers RM, Li Y, Aplenc R, Baniewicz D, Barrett DM, Barz Leahy A, Callahan C, Dolan JG, Fitzgerald JC, Gladney W, Lacey SF, Liu H, Maude SL, McGuire R, Motley LS, Teachey DT, Wertheim GB, Wray L, DiNofia AM, Grupp SA |
Journal of Clinical Oncology | 2021 |
Current Management and New Developments in the Treatment of ALL.
Darrah J, Sun W |
Cancer treatment and research | 2021 |
Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse
Ding L, Wang Y, Hong R, Zhao H, Zhou L, Wei G, Wu W, Xu H, Zhang Y, Luo Y, Shi J, Chang AH, Hu Y, Huang H |
Frontiers in Oncology | 2021 |
A novel CD34-derived hinge for rapid and efficient detection and enrichment of CAR T cells
Bister A, Ibach T, Haist C, Smorra D, Roellecke K, Wagenmann M, Scheckenbach K, Gattermann N, Wiek C, Hanenberg H |
2021 | |
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Roddie C, Dias J, O'Reilly MA, Abbasian M, Cadinanos-Garai A, Vispute K, Bosshard-Carter L, Mitsikakou M, Mehra V, Roddy H, Hartley JA, Spanswick V, Lowe H, Popova B, Clifton-Hadley L, Wheeler G, Olejnik J, Bloor A, Irvine D, Wood L, Marzolini MA, Domning S, Farzaneh F, Lowdell MW, Linch DC, Pule MA, Peggs KS |
Journal of Clinical Oncology | 2021 |
EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations
Beuchat I, Danish HH, Rubin DB, Jacobson C, Robertson M, Vaitkevicius H, Lee JW |
Neuro-Oncology | 2021 |
Imagining the cell therapist: Future CAR T cell monitoring and intervention strategies to improve patient outcomes
Jain MD, Spiegel JY |
2021 | |
Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
Shahid S, Ramaswamy K, Flynn J, Mauguen A, Perica K, Park JH, Forlenza CJ, Shukla NN, Steinherz PG, Margossian SP, Boelens JJ, Kernan NA, Curran KJ |
2021 | |
Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.
Jetani H, Navarro-Bailón A, Maucher M, Frenz S, Verbruggen C, Yeguas A, Vidriales MB, González M, Rial Saborido J, Kraus S, Mestermann K, Thomas S, Bonig H, Luu M, Monjezi R, Mougiakakos D, Sauer M, Einsele H, Hudecek M |
Blood | 2021 |
Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
Le Q, Castro S, Tang T, Loeb AM, Hylkema T, McKay CN, Perkins L, Srivastava S, Call L, Smith J, Leonti A, Ries R, Pardo L, Loken MR, Correnti C, Fiorenza S, Turtle CJ, Riddell S, Tarlock K, Meshinchi S |
Clinical cancer research | 2021 |
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence
Katsarou A, Sjöstrand M, Naik J, Mansilla-Soto J, Kefala D, Kladis G, Nianias A, Ruiter R, Poels R, Sarkar I, Patankar YR, Merino E, Reijmers RM, Frerichs KA, Yuan H, de Bruijn J, Stroopinsky D, Avigan D, van de Donk NW, Zweegman S, Mutis T, Sadelain M, Groen RW, Themeli M |
Science Translational Medicine | 2021 |
Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, Fasano CC, Rheingold SR, DiNofia A, Wray L, Aplenc R, Baniewicz D, Liu H, Shaw PA, Pequignot E, Getz KD, Brogdon JL, Fesnak AD, Siegel DL, Davis MM, Bartoszek C, Lacey SF, Hexner EO, Chew A, Wertheim GB, Levine BL, June CH, Grupp SA, Maude SL |
Journal of Clinical Oncology | 2021 |
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, O'Dwyer KM, Holmes H, Arellano ML, Ghobadi A, Pagel JM, Lin Y, Cassaday RD, Park JH, Abedi M, Castro JE, DeAngelo DJ, Malone AK, Mawad R, Schiller GJ, Rossi JM, Bot A, Shen T, Goyal L, Jain RK, Vezan R, Wierda WG |
Blood | 2021 |
A Subset of Cytotoxic Effector Memory T cells Enhances CAR T cell Efficacy in a Model of Pancreatic Ductal Adenocarcinoma
Konduri V, Joseph SK, Byrd TT, Nawas Z, Vazquez-Perez J, Hofferek CJ, Halpert MM, Liu D, Liang Z, Baig Y, Salsman VS, Oyewole-Said D, Tsimelzon A, Burns BA, Chen C, Levitt JM, Yao Q, Ahmed NM, Hegde M, Decker WK |
Science Translational Medicine | 2021 |
KTE-X19 for relapsed/refractory adult B-cell acute lymphoblastic leukemia: phase 2 results from the single-arm, multicenter ZUMA-3 study
Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O\u2019Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Feng C, Dong J, Shen T, Milletti F, Rossi JM, Vezan R, Masouleh BK, Houot R |
Lancet (London, England) | 2021 |
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities
Chiara F. Magnani, Giuseppe Gaipa, Federico Lussana, Daniela Belotti, Giuseppe Gritti, Sara Napolitano, Giada Matera, Benedetta Cabiati, Chiara Buracchi, Gianmaria Borleri, Grazia Fazio, Silvia Zaninelli, Sarah Tettamanti, Stefania Cesana, Valentina Colombo, Michele Quaroni, Giovanni Cazzaniga, Attilio Rovelli, Ettore Biagi, Stefania Galimberti, Andrea Calabria, Fabrizio Benedicenti, Eugenio Montini, Silvia Ferrari, Martino Introna, Adriana Balduzzi, Maria Grazia Valsecchi, Giuseppe Dastoli, Alessandro Rambaldi, Andrea Biondi |
Journal of Clinical Investigation | 2020 |
Immunotherapy of lymphomas
Stephen Ansell, Yi Lin |
Journal of Clinical Investigation | 2020 |
State of the art in CAR T-cell therapy for CD19+ B-cell malignancies
Matthew J. Frigault, Marcela V. Maus |
Journal of Clinical Investigation | 2020 |
Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia
LY Chen, LQ Kang, HX Zhou, HQ Gao, XF Zhu, N Xu, L Yu, DP Wu, SL Xue, AN Sun |
Translational oncology | 2020 |
EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo
L Xia, Z Zheng, J Liu, Y Chen, J Ding, N Xia, W Luo, W Liu |
IBMS BoneKEy | 2020 |
Engineering T cells for immunotherapy of primary human hepatocellular carcinoma
LD Galva, L Cai, Y Shao, Y He |
Journal of genetics and genomics = Yi chuan xue bao | 2020 |
Engineering Solutions for Mitigation of Chimeric Antigen Receptor T-Cell Dysfunction
A Gavriil, M Barisa, E Halliwell, J Anderson |
Cancers | 2020 |
Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia
V Barsan, S Ramakrishna, KL Davis |
Current Oncology Reports | 2020 |
Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?
SR Goldsmith, A Ghobadi, JF DiPersio |
Frontiers in Oncology | 2020 |
Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
E García-Guerrero, B Sierro-Martínez, JA Pérez-Simón |
Frontiers in immunology | 2020 |
Persistent STAT5 activation reprograms the epigenetic landscape in CD4 + T cells to drive polyfunctionality and antitumor immunity
ZC Ding, H Shi, NS Aboelella, K Fesenkova, EJ Park, Z Liu, L Pei, J Li, RA McIndoe, H Xu, GA Piazza, BR Blazar, DH Munn, G Zhou |
Science Immunology | 2020 |
TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals
F Manfredi, BC Cianciotti, A Potenza, E Tassi, M Noviello, A Biondi, F Ciceri, C Bonini, E Ruggiero |
Frontiers in immunology | 2020 |
The Emerging Landscape of Immune Cell Therapies
E Weber, M Maus, C Mackall |
Cell | 2020 |
How to Combine the Two Landmark Treatment Methods—Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
M Zhang, H Huang |
Frontiers in immunology | 2020 |
Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer
D Sur, A Havasi, C Cainap, G Samasca, C Burz, O Balacescu, I Lupan, D Deleanu, A Irimie |
Journal of Clinical Medicine | 2020 |
Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward
L Jafarzadeh, E Masoumi, K Fallah-Mehrjardi, HR Mirzaei, J Hadjati |
Frontiers in immunology | 2020 |
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice
M Cerrano, M Ruella, MA Perales, C Vitale, DG Faraci, L Giaccone, M Coscia, M Maloy, M Sanchez-Escamilla, H Elsabah, A Fadul, E Maffini, G Pittari, B Bruno |
Frontiers in immunology | 2020 |
In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes
S Agarwal, JD Hanauer, AM Frank, V Riechert, FB Thalheimer, CJ Buchholz |
Molecular Therapy | 2020 |
The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies
A Zhylko, M Winiarska, A Graczyk-Jarzynka |
Cancers | 2020 |
Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment
N Watanabe, MK McKenna, AR Shaw, M Suzuki |
Molecular Therapy | 2020 |
Engineering better chimeric antigen receptor T cells
H Zhang, P Zhao, H Huang |
Experimental Hematology and Oncology | 2020 |
The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy
D Liu, S Badeti, G Dotti, JJ, H Wang, J Dermody, P Soteropoulos, D Streck, RB Birge, C Liu |
Cell Communication and Signaling | 2020 |
Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery
TJ Gardner, CM Bourne, MM Dacek, K Kurtz, M Malviya, L Peraro, PC Silberman, KC Vogt, MJ Unti, R Brentjens, D Scheinberg |
Cancers | 2020 |
Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment
A Titov, A Valiullina, E Zmievskaya, E Zaikova, A Petukhov, R Miftakhova, E Bulatov, A Rizvanov |
Cancers | 2020 |
Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies
WY Lin, HH Wang, YW Chen, CF Lin, HC Fan, YY Lee |
International journal of molecular sciences | 2020 |
Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?
H Jiang, Y Hu, H Mei |
Biomarker Research | 2020 |
Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML)
UH Acharya, RB Walter |
Cancers | 2020 |
The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19
P Braendstrup, BL Levine, M Ruella |
Cytotherapy | 2020 |
[Mechanisms and countermeasures in relapse of relapsed/refractory non-Hodgkin lymphoma after treatment of CD19 chimeric antigen receptor T cells]
S Y Wang, J Cao, K L Xu |
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi | 2020 |
A narrative review of critical factors for better efficacy of CD19 chimeric antigen receptor T cell therapy in the treatment of B cell malignancies
J Liu, L Wang, H Yang, M Xing, S Liu, Z Yu, L Ma |
Translational cancer research | 2020 |
Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly
SD Munter, AV Parys, L Bral, J Ingels, G Goetgeluk, S Bonte, M Pille, L Billiet, K Weening, A Verhee, JV der Heyden, T Taghon, G Leclercq, T Kerre, J Tavernier, B Vandekerckhove |
International journal of molecular sciences | 2020 |
Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer
AJ Petty, B Heyman, Y Yang |
Cancers | 2020 |
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
E Zah, E Nam, V Bhuvan, U Tran, BY Ji, SB Gosliner, X Wang, CE Brown, YY Chen |
Nature Communications | 2020 |
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
K Fousek, J Watanabe, SK Joseph, A George, X An, TT Byrd, JS Morris, A Luong, MA Martínez-Paniagua, K Sanber, SA Navai, AZ Gad, VS Salsman, PR Mathew, HN Kim, DL Wagner, L Brunetti, A Jang, ML Baker, N Varadarajan, M Hegde, YM Kim, N Heisterkamp, H Abdel-Azim, N Ahmed |
Leukemia | 2020 |
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
H Dai, Z Wu, H Jia, C Tong, Y Guo, D Ti, X Han, Y Liu, W Zhang, C Wang, Y Zhang, M Chen, Q Yang, Y Wang, W Han |
Journal of Hematology & Oncology | 2020 |
Evaluation of piggyBac ‐mediated anti‐CD19 CAR‐T cells after ex vivo expansion with aAPCs or magnetic beads
LR Yang, L Li, MY Meng, WJ Wang, SL Yang, YY Zhao, RQ Wang, H Gao, WW Tang, Y Yang, LL Yang, LW Liao, ZL Hou |
Journal of Cellular and Molecular Medicine | 2020 |
Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies
EL Siegler, SS Kenderian |
Frontiers in immunology | 2020 |
Chimeric Antigen Receptor T Cell Therapy Comes to Clinical Practice
DA Wall, J Krueger |
Current Oncology | 2020 |
CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
AW Martens, SR Janssen, IA Derks, HC Adams, L Izhak, R van Kampen, SH Tonino, E Eldering, GJ van der Windt, AP Kater |
Journal for ImmunoTherapy of Cancer | 2020 |
Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
R Mhaidly, E Verhoeyen |
Cancers | 2020 |
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
R Gu, F Liu, D Zou, Y Xu, Y Lu, B Liu, W Liu, X Chen, K Liu, Y Guo, X Gong, R Lv, X Chen, C Zhou, M Zhong, H Wang, H Wei, Y Mi, L Qiu, L Lv, M Wang, Y Wang, X Zhu, J Wang |
Journal of Hematology & Oncology | 2020 |
T-cells with a single tumor antigen-specific T-cell receptor can be generated in vitro from clinically relevant stem cell sources
S Bonte, SD Munter, G Goetgeluk, J Ingels, M Pille, L Billiet, T Taghon, G Leclercq, B Vandekerckhove, T Kerre |
OncoImmunology | 2020 |
Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells
D Wijewarnasuriya, C Bebernitz, AV Lopez, S Rafiq, RJ Brentjens |
Cancer immunology research | 2020 |
Harnessing neoantigen specific CD4 T cells for cancer immunotherapy
SE Brightman, MS Naradikian, AM Miller, SP Schoenberger |
Journal of leukocyte biology | 2020 |
To Remember or to Forget: The Role of Good and Bad Memories in Adoptive T Cell Therapy for Tumors
A Mondino, T Manzo |
Frontiers in immunology | 2020 |
Reactive Myelopoiesis and the Onset of Myeloid-Mediated Immune Suppression: Implications for Adoptive Cell Therapy
P Innamarato, S Pilon-Thomas |
Cellular Immunology | 2020 |
Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer
S Lundh, IY Jung, A Dimitri, A Vora, JJ Melenhorst, JK Jadlowsky, JA Fraietta |
Clinical and Experimental Medicine | 2020 |
CARs: Beyond T Cells and T Cell-Derived Signaling Domains
NM Sievers, J Dörrie, N Schaft |
International journal of molecular sciences | 2020 |
The Role of Circulating Tumor Cells in the Metastatic Cascade: Biology, Technical Challenges, and Clinical Relevance
H Dianat-Moghadam, M Azizi, Z Eslami-S, LE Cortés-Hernández, M Heidarifard, M Nouri, C Alix-Panabières |
Cancers | 2020 |
Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer
AH Ko, AC Jordan, E Tooker, SF Lacey, RB Chang, Y Li, AP Venook, M Tempero, L Damon, L Fong, MH OHara, BL Levine, JJ Melenhorst, G Plesa, CH June, GL Beatty |
Molecular Therapy | 2020 |
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy
A Sheih, V Voillet, LA Hanafi, HA DeBerg, M Yajima, R Hawkins, V Gersuk, SR Riddell, DG Maloney, ME Wohlfahrt, D Pande, MR Enstrom, HP Kiem, JE Adair, R Gottardo, PS Linsley, CJ Turtle |
Nature Communications | 2020 |
The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing
JM Riberdy, S Zhou, F Zheng, YI Kim, J Moore, A Vaidya, RE Throm, A Sykes, N Sahr, CL Bonifant, B Ryu, S Gottschalk, MP Velasquez |
Molecular Therapy — Methods & Clinical Development | 2020 |
GP130 Cytokines in Breast Cancer and Bone
T Omokehinde, RW Johnson |
Cancers | 2020 |
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
R Upadhyay, JA Boiarsky, G Pantsulaia, J Svensson-Arvelund, MJ Lin, A Wroblewska, S Bhalla, N Scholler, A Bot, JM Rossi, N Sadek, S Parekh, A Lagana, A Baccarini, M Merad, BD Brown, JD Brody |
Cancer Discovery | 2020 |
Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells
RY Alhabbab |
Frontiers in Genetics | 2020 |
Mechanisms of resistance to CAR T cell therapies
N Singh, E Orlando, J Xu, J Xu, Z Binder, MK Collins, DM ORourke, JJ Melenhorst |
Seminars in Cancer Biology | 2020 |
Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia
T Jain, MR Litzow |
Therapeutic Advances in Hematology | 2020 |
The Role of Immune Checkpoints after Cellular Therapy
F Schmitz, D Wolf, TA Holderried |
International journal of molecular sciences | 2020 |
Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies
KR Parker, D Migliorini, E Perkey, KE Yost, A Bhaduri, P Bagga, M Haris, NE Wilson, F Liu, K Gabunia, J Scholler, TJ Montine, VG Bhoj, R Reddy, S Mohan, I Maillard, AR Kriegstein, CH June, HY Chang, AD Posey, AT Satpathy |
Cell | 2020 |
A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity
JA Hammill, JM Kwiecien, A Dvorkin-Gheva, VW Lau, C Baker, Y Wu, K Bezverbnaya, C Aarts, CW Heslen, GF Denisova, H Derocher, K Milne, BH Nelson, JL Bramson |
Molecular Therapy — Oncolytics | 2020 |
4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling
BI Philipson, RS OConnor, MJ May, CH June, SM Albelda, MC Milone |
Science signaling | 2020 |
Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment
T Shi, X Song, Y Wang, F Liu, J Wei |
Frontiers in immunology | 2020 |
Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia:
X Zhang, JJ Li, PH Lu |
Chinese Medical Journal | 2020 |
HIV-Resistant and HIV-Specific CAR-Modified CD4+ T Cells Mitigate HIV Disease Progression and Confer CD4+ T Cell Help In Vivo
CR Maldini, K Gayout, RS Leibman, DL Dopkin, JP Mills, X Shan, JA Glover, JL Riley |
Molecular Therapy | 2020 |
Potential strategies against resistance to CAR T-cell therapy in haematological malignancies
Q Cai, M Zhang, Z Li |
Therapeutic advances in medical oncology | 2020 |
The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities
AS Davey, ME Call, MJ Call |
Cancers | 2020 |
The Application of CAR-T Cells in Haematological Malignancies
K Skorka, K Ostapinska, A Malesa, K Giannopoulos |
Archivum Immunologiae et Therapiae Experimentalis | 2020 |
Efficacy and safety of chimeric antigen receptor-T cells in the treatment of B cell lymphoma: a systematic review and meta-analysis
XH Zheng, , QQ Dong, F Chen, SB Yang, WB Li |
Chinese Medical Journal | 2020 |
Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
T Badar, NN Shah |
Current Treatment Options in Oncology | 2020 |
A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes
D Schäfer, J Henze, R Pfeifer, A Schleicher, J Brauner, N Mockel-Tenbrinck, C Barth, D Gudert, WA Rawashdeh, IC Johnston, O Hardt |
Frontiers in immunology | 2020 |
Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia
MH Boroojerdi, F Rahbarizadeh, PS Kozani, E Kamali, PS Kozani |
Medical Oncology | 2020 |
Cytokines in CAR T Cell–Associated Neurotoxicity
J Gust, R Ponce, WC Liles, GA Garden, CJ Turtle |
Frontiers in immunology | 2020 |
Peripheral inflammation and blood–brain barrier disruption: effects and mechanisms
X Huang, B Hussain, J Chang |
CNS Neuroscience & Therapeutics | 2020 |
CAR T cell therapy: newer approaches to counter resistance and cost
RK Yadav, A Ali, S Kumar, A Sharma, B Baghchi, P Singh, S Das, C Singh, S Sharma |
Heliyon | 2020 |
Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy
GP Dunn, TF Cloughesy, MV Maus, RM Prins, DA Reardon, AM Sonabend |
Neuro-Oncology | 2020 |
Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
Y Nie, W Lu, D Chen, H Tu, Z Guo, X Zhou, M Li, S Tu, Y Li |
Biomarker Research | 2020 |
T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020
V Jawa, F Terry, J Gokemeijer, S Mitra-Kaushik, BJ Roberts, S Tourdot, AS Groot |
Frontiers in immunology | 2020 |
Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
MA Morgan, H Büning, M Sauer, A Schambach |
Frontiers in immunology | 2020 |
Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib:
JS Qin, TG Johnstone, A Baturevych, RJ Hause, SP Ragan, CR Clouser, JC Jones, R Ponce, CM Krejsa, RA Salmon, MO Ports |
Journal of immunotherapy (Hagerstown, Md. : 1997) | 2020 |
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
J Gauthier, AV Hirayama, J Purushe, KA Hay, J Lymp, DH Li, CC Yeung, A Sheih, BS Pender, RM Hawkins, A Vakil, TD Phi, RN Steinmetz, M Shadman, SR Riddell, DG Maloney, CJ Turtle |
Blood | 2020 |
CAR T and CAR NK cells in multiple myeloma: Expanding the targets
UA Shah, S Mailankody |
Best practice & research. Clinical haematology | 2020 |
CAR T-cell immunotherapy of B-cell malignancy: the story so far
L Halim, J Maher |
2020 | |
Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?
CF Magnani, S Tettamanti, G Alberti, I Pisani, A Biondi, M Serafini, G Gaipa |
Cells | 2020 |
Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges
S Jasinski, FA Reyes, GC Yametti, J Pierro, E Raetz, WL Carroll |
Pediatric Drugs | 2020 |
Immune Literacy: Reading, Writing, and Editing Adaptive Immunity
L Csepregi, RA Ehling, B Wagner, ST Reddy |
iScience | 2020 |
4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells
Q Dai, P Han, X Qi, F Li, M Li, L Fan, H Zhang, X Zhang, X Yang |
Frontiers in immunology | 2020 |
Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer
M Jung, Y Yang, JE McCloskey, M Zaman, Y Vedvyas, X Zhang, D Stefanova, KD Gray, IM Min, R Zarnegar, YY Choi, JH Cheong, SH Noh, SY Rha, HC Chung, MM Jin |
Molecular Therapy — Oncolytics | 2020 |
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
MV Maus, S Alexander, MR Bishop, JN Brudno, C Callahan, ML Davila, C Diamonte, J Dietrich, JC Fitzgerald, MJ Frigault, TJ Fry, JL Holter-Chakrabarty, KV Komanduri, DW Lee, FL Locke, SL Maude, PL McCarthy, E Mead, SS Neelapu, TG Neilan, BD Santomasso, EJ Shpall, DT Teachey, CJ Turtle, T Whitehead, SA Grupp |
Journal for ImmunoTherapy of Cancer | 2020 |
convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting
KE Landgraf, SR Williams, D Steiger, D Gebhart, S Lok, DW Martin, KT Roybal, KC Kim |
2020 | |
Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia
S Loff, J Dietrich, JE Meyer, J Riewaldt, J Spehr, M von Bonin, C Gründer, M Swayampakula, K Franke, A Feldmann, M Bachmann, G Ehninger, A Ehninger, M Cartellieri |
Molecular Therapy — Oncolytics | 2020 |
Biomarkers in individualized management of chimeric antigen receptor T cell therapy
M Du, P Hari, Y Hu, H Mei |
Biomarker Research | 2020 |
A comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy
C Cai, D Tang, Y Han, E Shen, OA Ahmed, C Guo, H Shen, S Zeng |
Aging | 2020 |
Case Report: Humanized Selective CD19CAR-T Treatment Induces MRD-Negative Remission in a Pediatric B-ALL Patient With Primary Resistance to Murine-Based CD19CAR-T Therapy
K Wang, Y Zhao, X Wang, B Wang, M Qin, G Zhu, H Wu, Z Liu, X Zheng, H Zheng, Z Chen |
Frontiers in immunology | 2020 |
Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia?
E Abadir, RE Gasiorowski, PA Silveira, S Larsen, GJ Clark |
Journal of Clinical Medicine | 2020 |
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
A Cordeiro, ED Bezerra, AV Hirayama, JA Hill, QV Wu, J Voutsinas, ML Sorror, CJ Turtle, DG Maloney, M Bar |
Biology of Blood and Marrow Transplantation | 2020 |
CAR T Cell Generation by piggyBac Transposition from Linear Doggybone DNA Vectors Requires Transposon DNA-Flanking Regions
DC Bishop, L Caproni, K Gowrishankar, M Legiewicz, K Karbowniczek, J Tite, DJ Gottlieb, KP Micklethwaite |
Molecular Therapy — Methods & Clinical Development | 2020 |
Identification of human CD4 + T cell populations with distinct antitumor activity
MH Nelson, HM Knochelmann, SR Bailey, LW Huff, JS Bowers, K Majchrzak-Kuligowska, MM Wyatt, MP Rubinstein, S Mehrotra, MI Nishimura, KE Armeson, PG Giresi, MJ Zilliox, HE Broxmeyer, CM Paulos |
Science Advances | 2020 |
Triggers, Timescales, and Treatments for Cytokine-Mediated Tissue Damage
D McBride, M Kerr, N Dorn, D Ogbonna, E Santos, N Shah |
2020 | |
Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia
F An, H Wang, Z Liu, F Wu, J Zhang, Q Tao, Y Li, Y Shen, Y Ruan, Q Zhang, Y Pan, W Zhu, H Qin, Y Wang, Y Fu, Z Feng, Z Zhai |
Nature Communications | 2020 |
Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma
X Zhou, H Einsele, S Danhof |
Journal of Clinical Medicine | 2020 |
Real-Time Killing Assays to Assess the Potency of a New Anti-Simian Immunodeficiency Virus Chimeric Antigen Receptor T Cell
F Haeseleer, K Eichholz, SU Tareen, N Iwamoto, M Roederer, F Kirchhoff, H Park, AA Okoye, L Corey |
AIDS Research and Human Retroviruses | 2020 |
Better Epitope Discovery, Precision Immune Engineering, and Accelerated Vaccine Design Using Immunoinformatics Tools
AS Groot, L Moise, F Terry, AH Gutierrez, P Hindocha, G Richard, DF Hoft, TM Ross, AR Noe, Y Takahashi, V Kotraiah, SE Silk, CM Nielsen, AM Minassian, R Ashfield, M Ardito, SJ Draper, WD Martin |
Frontiers in immunology | 2020 |
A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced On-Target, Off-Tumor Activation
RB Roberto, R Castellanos-Rueda, S Frey, D Egli, R Vazquez-Lombardi, E Kapetanovic, J Kucharczyk, ST Reddy |
Molecular Therapy | 2020 |
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL
R Awasthi, L Pacaud, E Waldron, CS Tam, U Jäger, P Borchmann, S Jaglowski, SR Foley, K van Besien, ND Wagner-Johnston, MJ Kersten, SJ Schuster, G Salles, RT Maziarz, Ö Anak, C del Corral, J Chu, I Gershgorin, I Pruteanu-Malinici, A Chakraborty, KT Mueller, EK Waller |
Blood Advances | 2020 |
Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions
U Greenbaum, KM Mahadeo, P Kebriaei, EJ Shpall, NY Saini |
Frontiers in Oncology | 2020 |
Secondary donor-derived humanized CD19-modified CAR-T cells induce remission in relapsed/refractory mixed phenotype acute leukemia after allogeneic hematopoietic stem cell transplantation: a case report
MY Li, ZH Lin, MM Hu, LQ Kang, X Wu, Q Chen, X Kong, J Zhang, HY Qiu, DP Wu |
Biomarker Research | 2020 |
Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma
EM Hsieh, RH Rouce |
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program | 2020 |
Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL
VS Sheth, J Gauthier |
Bone Marrow Transplantation | 2020 |
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
J Wei, Y Liu, C Wang, Y Zhang, C Tong, G Dai, W Wang, JE Rasko, JJ Melenhorst, W Qian, A Liang, W Han |
Signal Transduction and Targeted Therapy | 2020 |
Chimeric antigen receptor–T cells with cytokine neutralizing capacity
AH Tan, N Vinanica, D Campana |
Blood Advances | 2020 |
Toxicity Induced by a Bispecific T Cell–Redirecting Protein Is Mediated by Both T Cells and Myeloid Cells in Immunocompetent Mice
C Godbersen-Palmer, TA Coupet, Z Grada, SC Zhang, CL Sentman |
Journal of immunology (Baltimore, Md. : 1950) | 2020 |
Low Level Donor Chimerism of CD19 CAR-T Cells Returned to Complete Donor Chimerism in Patients with Relapse After Allo-Hematopoietic Stem Cell Transplant Q Li, J Mu, J Yuan, Z Yang, J Wang, Q Deng |
OncoTargets and therapy | 2020 |
Using apelin-based synthetic Notch receptors to detect angiogenesis and treat solid tumors
Z Wang, F Wang, J Zhong, T Zhu, Y Zheng, T Zhao, Q Xie, F Ma, R Li, Q Tang, F Xu, X Tian, J Zhu |
Nature Communications | 2020 |
PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo
Q Liao, Y Mao, H He, X Ding, X Zhang, J Xu |
Biomarker Research | 2020 |
Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
W Sang, M Shi, J Yang, J Cao, L Xu, D Yan, M Yao, H Liu, W Li, B Zhang, K Sun, X Song, C Sun, J Jiao, Y Qin, T Sang, Y Ma, M Wu, X Gao, H Cheng, Z Yan, D Li, H Sun, F Zhu, Y Wang, L Zeng, Z Li, J Zheng, K Xu |
Cancer Medicine | 2020 |
Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report
Z Liang, H Zhang, M Shao, Q Cui, Z Wu, L Xiao, H Huang, Y Hu |
Medicine | 2020 |
Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma
L Perez-Amill, G Suñe, A Antoñana-Vildosola, M Castella, A Najjar, J Bonet, N Fernández-Fuentes, S Inogés, A López, C Bueno, M Juan, Á Urbano-Ispizua, B Martín-Antonio |
Haematologica | 2020 |
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
JA Park, NK Cheung |
Journal of Hematology & Oncology | 2020 |
Advances in Developing CAR T-Cell Therapy for HIV Cure
J Qi, C Ding, X Jiang, Y Gao |
Frontiers in immunology | 2020 |
Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus
M Mineo, SM Lyons, M Zdioruk, N von Spreckelsen, R Ferrer-Luna, H Ito, QA Alayo, P Kharel, AG Larsen, WY Fan, S Auduong, K Grauwet, C Passaro, JK Khalsa, K Shah, DA Reardon, KL Ligon, R Beroukhim, H Nakashima, P Ivanov, PJ Anderson, SE Lawler, EA Chiocca |
Molecular Cell | 2020 |
Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma
T Bilich, A Nelde, J Bauer, S Walz, M Roerden, HR Salih, K Weisel, B Besemer, A Marcu, M Lübke, J Schuhmacher, MC Neidert, HG Rammensee, S Stevanović, JS Walz |
Blood Cancer Journal | 2020 |
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
FL Locke, JM Rossi, SS Neelapu, CA Jacobson, DB Miklos, A Ghobadi, OO Oluwole, PM Reagan, LJ Lekakis, Y Lin, M Sherman, M Better, WY Go, JS Wiezorek, A Xue, A Bot |
Blood Advances | 2020 |
Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials
X Xiang, Q He, Y Ou, W Wang, Y Wu |
Frontiers in pharmacology | 2020 |
Tuning the Antigen Density Requirement for CAR T-cell Activity
RG Majzner, SP Rietberg, E Sotillo, R Dong, VT Vachharajani, L Labanieh, JH Myklebust, M Kadapakkam, EW Weber, AM Tousley, RM Richards, S Heitzeneder, SM Nguyen, V Wiebking, J Theruvath, RC Lynn, P Xu, AR Dunn, RD Vale, CL Mackall |
Cancer Discovery | 2020 |
Chimeric antigen receptor T‐cell therapies: Optimising the dose
N Dasyam, P George, R Weinkove |
British Journal of Clinical Pharmacology | 2020 |
Improving CAR T cell therapy by optimizing critical quality attributes
OL Reddy, DF Stroncek, SR Panch |
Seminars in Hematology | 2020 |
Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia
X Zhao, J Yang, X Zhang, XA Lu, M Xiong, J Zhang, X Zhou, F Qi, T He, Y Ding, X Hu, FD Smet, P Lu, X Huang |
Molecular Therapy — Oncolytics | 2020 |
Immuntherapien zur Behandlung der chronischen Hepatitis-B-Virusinfektion – eine Übersicht unter besonderer Berücksichtigung von CAR-T-Zellen
Z Ivics, M Amberger, T Zahn, E Hildt |
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz | 2020 |
Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes
L Schultz |
Frontiers in immunology | 2020 |
Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia
RM Myers, J Dolan, DT Teachey |
Expert Review of Clinical Immunology | 2020 |
Cluster of differentiation 19 chimeric antigen receptor T‑cell therapy in pediatric acute lymphoblastic leukemia (Review)
Z Fu, J Zhou, R Chen, Y Jin, T Ni, L Qian, C Xiao |
Oncology Letters | 2020 |
CART Cell Toxicities: New Insight into Mechanisms and Management:
A Zahid, EL Siegler, SS Kenderian |
2020 | |
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.
Shah NN, Highfill SL, Shalabi H, Yates B, Jin J, Wolters PL, Ombrello A, Steinberg SM, Martin S, Delbrook C, Hoffman L, Little L, Ponduri A, Qin H, Qureshi H, Dulau-Florea A, Salem D, Wang HW, Yuan C, Stetler-Stevenson M, Panch S, Tran M, Mackall CL, Stroncek DF, Fry TJ |
Journal of Clinical Oncology | 2020 |
[Chimeric antigen receptors T cells for treatment of B-cell acute lymphoblastic leukemia previously infected with hepatitis B virus: two cases report and literatures review].
Han L, Zhou J, Zhu XH, Fu YW, Li LL, Gao QL, Song YP |
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi | 2020 |
Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies.
Zhu F, Wei G, Zhang M, Zhao H, Wu W, Yang L, Hu Y, Huang H |
Cell transplantation | 2020 |
Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy.
Hu SI, Ko MC, Dai YH, Lin HA, Chen LC, Huang KY, Pang TL, Kuo CY, Lin HC |
Annals of translational medicine | 2020 |
Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells.
Gu B, Shi BY, Zhang X, Zhou SY, Chu JH, Wu XJ, Fu CC, Qiu HY, Han Y, Chen SN, Yu L, Ma X, Wu DP |
Bone Marrow Transplantation | 2020 |
How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.
Hill JA, Seo SK |
Blood | 2020 |
Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma.
Gupta S, Seethapathy H, Strohbehn IA, Frigault MJ, O'Donnell EK, Jacobson CA, Motwani SS, Parikh SM, Curhan GC, Reynolds KL, Leaf DE, Sise ME |
American journal of kidney diseases : the official journal of the National Kidney Foundation | 2020 |
A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy.
Giordano-Attianese G, Gainza P, Gray-Gaillard E, Cribioli E, Shui S, Kim S, Kwak MJ, Vollers S, Corria Osorio AJ, Reichenbach P, Bonet J, Oh BH, Irving M, Coukos G, Correia BE |
Nature Biotechnology | 2020 |
A VHH-Based Anti-MUC1 Chimeric Antigen Receptor for Specific Retargeting of Human Primary T Cells to MUC1-Positive Cancer Cells.
Rajabzadeh A, Rahbarizadeh F, Ahmadvand D, Kabir Salmani M, Hamidieh AA |
2020 | |
Inefficient CAR-proximal signaling blunts antigen sensitivity.
Gudipati V, Rydzek J, Doel-Perez I, Gonçalves VDR, Scharf L, Königsberger S, Lobner E, Kunert R, Einsele H, Stockinger H, Hudecek M, Huppa JB |
Nature Immunology | 2020 |
[Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Jiang YL, Li Q, Pu YD, Jiang YY, Yuan T, Deng Q, Li YM, Han MZ, Zhai WH |
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi | 2020 |
Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults.
Vora SB, Waghmare A, Englund JA, Qu P, Gardner RA, Hill JA |
Open Forum Infectious Diseases | 2020 |
Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features.
Zhang X, Lu XA, Yang J, Zhang G, Li J, Song L, Su Y, Shi Y, Zhang M, He J, Song D, Lv F, Li W, Wu Y, Wang H, Liu H, Zhou X, He T, Lu P |
Blood Advances | 2020 |
Recognizing and Grading CAR T-Cell Toxicities: An Advanced Practitioner Perspective.
Sievers S, Watson G, Johncy S, Adkins S |
Frontiers in Oncology | 2020 |
A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses.
Arbelaez CA, Estrada J, Gessner MA, Glaus C, Morales AB, Mohn D, Phee H, Lipford JR, Johnston JA |
npj Vaccines | 2020 |
Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant
Liu P, Liu M, Lyu C, Lu W, Cui R, Wang J, Li Q, Mou N, Deng Q, Yang D |
Frontiers in Oncology | 2020 |
Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia
Conde-Royo D, Juárez-Salcedo LM, Dalia S |
Drugs in Context | 2020 |
CAR-T细胞桥接异基因造血干细胞移植治疗复发/难治急性B淋巴细胞白血病的临床分析
|
2020 | |
Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab.
Ribera JM, Genescà E, Ribera J |
Therapeutic Advances in Hematology | 2020 |
Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes.
Kang L, Tang X, Zhang J, Li M, Xu N, Qi W, Tan J, Lou X, Yu Z, Sun J, Wang Z, Dai H, Chen J, Lin G, Wu D, Yu L |
Experimental Hematology and Oncology | 2020 |
Non-genetic mechanisms of therapeutic resistance in cancer.
Marine JC, Dawson SJ, Dawson MA |
Nature reviews. Cancer | 2020 |
CAR T cells vs allogeneic HSCT for poor-risk ALL.
Diorio C, Maude SL |
Hematology | 2020 |
Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China.
Ying Z, Yang H, Guo Y, Li W, Zou D, Zhou D, Wang Z, Zhang M, Wu J, Liu H, Zhang P, Yang S, Zhou Z, Zheng H, Song Y, Zhu J |
Cancer Medicine | 2020 |
Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date
Si S, Teachey DT |
Therapeutics and Clinical Risk Management | 2020 |
Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy
Rubin DB, Al Jarrah A, Li K, LaRose S, Monk AD, Ali AB, Spendley LN, Nikiforow S, Jacobson C, Vaitkevicius H |
JAMA neurology | 2020 |
Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma
Wang T, Gao L, Wang Y, Zhu W, Xu L, Wang Y, Yue W, Tang G, Chen L, Chen J, Zhang W, Yu X, Feng D, Yang J |
Immunotherapy | 2020 |
Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models.
Qin D, Li D, Zhang B, Chen Y, Liao X, Li X, Alexander PB, Wang Y, Li QJ |
OncoImmunology | 2020 |
Humanized anti‐CD19 chimeric antigen receptor‐T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection
Cui R, Lyu C, Li Q, Jiang Y, Mou N, Yang Z, Liu X, Deng Q, Li L |
Hematological Oncology | 2020 |
Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia.
Wang J, Mou N, Yang Z, Li Q, Jiang Y, Meng J, Liu X, Deng Q |
British Journal of Haematology | 2020 |
Different sites of extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor T cell therapy.
Zhou L, Li P, Ye S, Tang X, Wang J, Liu J, Liang A |
Frontiers of Medicine | 2020 |
Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.
Batra SA, Rathi P, Guo L, Courtney AN, Fleurence J, Balzeau J, Shaik RS, Nguyen TP, Wu MF, Bulsara S, Mamonkin M, Metelitsa LS, Heczey A |
Cancer immunology research | 2020 |
Navigating the Fas Lane to Improved Cellular Therapy of Cancer
Madhav Dhodapkar |
Journal of Clinical Investigation | 2019 |
Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in T regulatory cells
Nicholas AJ Dawson, Caroline Lamarche, Romy Hoeppli, Peter Bergqvist, Vivian Fung, Emma McIver, Qing Huang, Jana Gillies, Madeleine Speck, Paul Orban, Jonathan Bush, Majid Mojibian, Megan Levings |
JCI Insight | 2019 |
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T-cells for relapsed/refractory CLL
Mark B Geyer, Isabelle Rivière, Brigitte Sénéchal, Xiuyan Wang, Yongzeng Wang, Terence Purdon, Meier Hsu, Sean M Devlin, Lia Palomba, Elizabeth Halton, Yvette Bernal, Michel Sadelain, Jae Park, Renier J. Brentjens |
JCI Insight | 2019 |
ROR1-CAR T-cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models
Lars Wallstabe, Claudia Göttlich, Lena Nelke, Johanna Kühnemundt, Thomas Schwarz, Thomas Nerreter, Hermann Einsele, Heike Walles, Gudrun Dandekar, Sarah Nietzer, Michael Hudecek |
JCI Insight | 2019 |
Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.
Dyantha I. van der Lee, Rogier M. Reijmers, M. Wilhelmina Honders, Renate S. Hagedoorn, Rob de Jong, Michel D.G. Kester, Dirk M. van der Steen, Arnoud H. de Ru, Christiaan Kweekel, Helena M Bijen, Inge Jedema, Hendrik Veelken, Peter A. van Veelen, Mirjam H.M. Heemskerk, J.H.Frederik Falkenburg, Marieke Griffioen |
Journal of Clinical Investigation | 2019 |
CD19 CAR T cell product and disease attributes predict leukemia remission durability
Olivia C. Finney, Hannah M Brakke, Stephanie Rawlings-Rhea, Roxana Hicks, Danielle Doolittle, Marisa Lopez, Robert B. Futrell, Rimas J. Orentas, Daniel Li, Rebecca A Gardner, Michael C Jensen |
Journal of Clinical Investigation | 2019 |
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
Adam D Cohen, Alfred L. Garfall, Edward Stadtmauer, Jan Melenhorst, Simon F Lacey, Eric Lancaster, Dan T. Vogl, Brendan Weiss, Karen Dengel, Anne Marie Nelson, Gabriela Plesa, Fang Chen, Megan M Davis, Wei-Ting Hwang, Regina Young, Jennifer L. Brogdon, Randi Isaacs, Iulian Pruteanu-Malinici, Don L Siegel, Bruce L Levine, Carl H. June, Michael C. Milone |
Journal of Clinical Investigation | 2019 |
T-Cell Receptor–Based Immunotherapy for Hematologic Malignancies:
MA Biernacki, M Brault, M Bleakley |
The Cancer Journal | 2019 |
Emerging Cellular Therapies for Cancer
S Guedan, M Ruella, CH June |
Annual Review of Immunology | 2019 |
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
SS Chandran, CA Klebanoff |
Immunological Reviews | 2019 |
Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy
S Stock, M Schmitt, L Sellner |
International journal of molecular sciences | 2019 |
CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products
JC Chavez, C Bachmeier, MA Kharfan-Dabaja |
Therapeutic Advances in Hematology | 2019 |
Single-cell Analysis of CAR-T Cell Activation Reveals A Mixed TH1/TH2 Response Independent of Differentiation
I Xhangolli, B Dura, GH Lee, D Kim, Y Xiao, R Fan |
Genomics, proteomics & bioinformatics / Beijing Genomics Institute | 2019 |
The making and function of CAR cells
M Zabel, PA Tauber, WF Pickl |
Immunology Letters | 2019 |
Mechanisms of resistance to CAR T cell therapy
NN Shah, TJ Fry |
Nature Reviews Clinical Oncology | 2019 |
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
S Stoiber, BL Cadilha, MR Benmebarek, S Lesch, S Endres, S Kobold |
Cells | 2019 |
CAR-T Cells: Future Perspectives
S Charrot, S Hallam |
2019 | |
CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV
GB Kim, K Hege, JL Riley |
Frontiers in immunology | 2019 |
Genetically engineered T cells for cancer immunotherapy
D Li, X Li, WL Zhou, Y Huang, X Liang, L Jiang, X Yang, J Sun, Z Li, WD Han, W Wang |
Signal Transduction and Targeted Therapy | 2019 |
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
S Rafiq, CS Hackett, RJ Brentjens |
Nature Reviews Clinical Oncology | 2019 |
[PD-1 expression, mRNA level and cytotoxicity changes in CD19CAR-T cells]
Y D Pu, J Wang, Q Deng, H B Zhu, Y Y Jiang, J X Meng, Y M Li |
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi | 2019 |
Engineering and Design of Chimeric Antigen Receptors
S Guedan, H Calderon, AD Posey, MV Maus |
Molecular Therapy — Methods & Clinical Development | 2019 |
CAR T cells for brain tumors: Lessons learned and road ahead
D Akhavan, D Alizadeh, D Wang, MR Weist, JK Shepphird, CE Brown |
Immunological Reviews | 2019 |
Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies
MK Song, BB Park, JE Uhm |
International journal of molecular sciences | 2019 |
Gene editing for immune cell therapies
SR Bailey, MV Maus |
Nature Biotechnology | 2019 |
Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors
A Balakrishnan, A Rajan, AI Salter, PL Kosasih, Q Wu, J Voutsinas, MC Jensen, A Plückthun, SR Riddell |
Clinical cancer research | 2019 |
Clinical lessons learned from the first leg of the CAR T cell journey
R Majzner, C Mackall |
Nature Medicine | 2019 |
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma
X Xu, W Huang, A Heczey, D Liu, L Guo, M Wood, J Jin, AN Courtney, B Liu, EJ Pierro, J Hicks, GA Barragan, H Ngai, Y Chen, B Savoldo, G Dotti, LS Metelitsa |
Clinical cancer research | 2019 |
Cytotoxic Activity and Memory T Cell Subset Distribution of in vitro-Stimulated CD8+ T Cells Specific for HER2/neu Epitopes
M Kuznetsova, J Lopatnikova, J Shevchenko, A Silkov, A Maksyutov, S Sennikov |
Frontiers in immunology | 2019 |
Neuroendocrine Regulation of Tumor-Associated Immune Cells
CB Colon-Echevarria, R Lamboy-Caraballo, AN Aquino-Acevedo, GN Armaiz-Pena |
Frontiers in Oncology | 2019 |
Switching on the green light for chimeric antigen receptor T-cell therapy
S Mardiana, J Lai, IG House, PA Beavis, PK Darcy |
IBMS BoneKEy | 2019 |
Overcoming Challenges in Process Development of Cellular Therapies
SL Highfill, DF Stroncek |
Current Hematologic Malignancy Reports | 2019 |
Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function
MO Hurtado, J Wolbert, J Fisher, B Flutter, S Stafford, J Barton, N Jain, G Barone, Y Majani, J Anderson, PA Beavis |
PloS one | 2019 |
Chimeric Antigen Receptor T-Cells: The Future is Now
W Mchayleh, P Bedi, R Sehgal, M Solh |
Journal of Clinical Medicine | 2019 |
CAR T Cells: A Snapshot on the Growing Options to Design a CAR
A Holzinger, H Abken |
2019 | |
Large-scale expansion and characterization of CD3+ T-cells in the Quantum® Cell Expansion System
C Coeshott, B Vang, M Jones, B Nankervis |
Journal of Translational Medicine | 2019 |
Human Platelet Lysate Media Supplement Supports Lentiviral Transduction and Expansion of Human T Lymphocytes While Maintaining Memory Phenotype
E Canestrari, HR Steidinger, B McSwain, SJ Charlebois, CT Dann |
Journal of Immunology Research | 2019 |
Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches
ML Duong, MR Collinson-Pautz, E Morschl, A Lu, SP Szymanski, M Zhang, ME Brandt, WC Chang, KL Sharp, SM Toler, KM Slawin, AE Foster, DM Spencer, JH Bayle |
Molecular Therapy — Oncolytics | 2019 |
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
S Hofmann, ML Schubert, L Wang, B He, B Neuber, P Dreger, C Müller-Tidow, M Schmitt |
Journal of Clinical Medicine | 2019 |
CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies
JP Mochel, SC Ekker, CM Johannes, AE Jergens, K Allenspach, A Bourgois-Mochel, M Knouse, S Benzekry, W Wierson, AK LeBlanc, SS Kenderian |
The AAPS Journal | 2019 |
Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters
YG Lee, H Chu, Y Lu, CP Leamon, M Srinivasarao, KS Putt, PS Low |
Nature Communications | 2019 |
Target selection for CAR-T therapy
J Wei, X Han, J Bo, W Han |
Journal of Hematology & Oncology | 2019 |
Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer
Y Shang, F Zhou |
Frontiers in Oncology | 2019 |
Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
X Xu, Q Sun, X Liang, Z Chen, X Zhang, X Zhou, M Li, H Tu, Y Liu, S Tu, Y Li |
Frontiers in immunology | 2019 |
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
AB Nixon, KA Schalper, I Jacobs, S Potluri, IM Wang, C Fleener |
Journal for ImmunoTherapy of Cancer | 2019 |
Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
T Ma, J Shi, H Liu |
Annals of Hematology | 2019 |
Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
J Cheng, L Zhao, Y Zhang, Y Qin, Y Guan, T Zhang, C Liu, J Zhou |
Frontiers in Oncology | 2019 |
Robust Selections of Various Hematopoietic Cell Fractions on the CliniMACS Plus Instrument
SR Panch, OL Reddy, K Li, T Bikkani, A Rao, S Yarlagadda, S Highfill, D Fowler, RW Childs, M Battiwalla, J Barrett, A Larochelle, C Mackall, N Shah, DF Stroncek |
2019 | |
Chimeric Antigen Receptor T-cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety—A Systematic Review with Meta-Analysis
WL Yu, ZC Hua |
Cancers | 2019 |
Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B‐cell malignancies
SA Tuazon, A Li, T Gooley, TW Eunson, DG Maloney, CJ Turtle, ML Linenberger, LS ConnellySmith |
Transfusion | 2019 |
Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy
S Chen, L Li, F Zhang, Y Wang, Y Hu, L Zhao |
Journal of Immunology Research | 2019 |
Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment
I Aldoss, SK Khaled, E Budde, AS Stein |
Current Oncology Reports | 2019 |
Pharmacologic control of CAR-T cell function using dasatinib
EW Weber, RC Lynn, E Sotillo, J Lattin, P Xu, CL Mackall |
Blood Advances | 2019 |
Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy S Cohen, P Fishman |
Drug design, development and therapy | 2019 |
Evaluation of a Fully Human, Hepatitis B Virus-Specific Chimeric Antigen Receptor in an Immunocompetent Mouse Model
MM Festag, J Festag, SP Fräßle, T Asen, J Sacherl, S Schreiber, MA Mück-Häusl, DH Busch, K Wisskirchen, U Protzer |
Molecular Therapy | 2019 |
Chimeric Antigen Receptors for T-Cell Malignancies
LD Scherer, MK Brenner, M Mamonkin |
Frontiers in Oncology | 2019 |
Antigen Targets for the Development of Immunotherapies in Leukemia
J Bauer, A Nelde, T Bilich, J Walz |
International journal of molecular sciences | 2019 |
Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies
YJ Lu, H Chu, LW Wheeler, M Nelson, E Westrick, JF Matthaei, II Cardle, A Johnson, J Gustafson, N Parker, M Vetzel, LC Xu, EZ Wang, MC Jensen, PJ Klein, PS Low, CP Leamon |
Frontiers in Oncology | 2019 |
CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response
NF Kuhn, TJ Purdon, DG van Leeuwen, AV Lopez, KJ Curran, AF Daniyan, RJ Brentjens |
Cancer Cell | 2019 |
Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy LL Riegler, GP Jones, DW Lee |
Therapeutics and Clinical Risk Management | 2019 |
In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy
JG Borrega, P Gödel, MA Rüger, ÖA Onur, A Shimabukuro-Vornhagen, M Kochanek, B Böll |
2019 | |
Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma
MP Brown, LM Ebert, T Gargett |
IBMS BoneKEy | 2019 |
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
N Raje, J Berdeja, Y Lin, D Siegel, S Jagannath, D Madduri, M Liedtke, J Rosenblatt, MV Maus, A Turka, LP Lam, RA Morgan, K Friedman, M Massaro, J Wang, G Russotti, Z Yang, T Campbell, K Hege, F Petrocca, MT Quigley, N Munshi, JN Kochenderfer |
New England Journal of Medicine | 2019 |
Emerging therapies for non-small cell lung cancer
C Zhang, NB Leighl, YL Wu, WZ Zhong |
Journal of Hematology & Oncology | 2019 |
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
M Hamieh, A Dobrin, A Cabriolu, SJ van der Stegen, T Giavridis, J Mansilla-Soto, J Eyquem, Z Zhao, BM Whitlock, MM Miele, Z Li, KM Cunanan, M Huse, RC Hendrickson, X Wang, I Rivière, M Sadelain |
Nature | 2019 |
Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors
S Zheng, M Asnani, A Thomas-Tikhonenko |
The Cancer Journal | 2019 |
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells
AV Hirayama, J Gauthier, KA Hay, JM Voutsinas, Q Wu, T Gooley, D Li, S Cherian, X Chen, BS Pender, RM Hawkins, A Vakil, RN Steinmetz, UH Acharya, RD Cassaday, AG Chapuis, TM Dhawale, PC Hendrie, HP Kiem, RC Lynch, J Ramos, M Shadman, BG Till, SR Riddell, DG Maloney, CJ Turtle |
Blood | 2019 |
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
AJ Kansagra, NV Frey, M Bar, TW Laetsch, PA Carpenter, BN Savani, HE Heslop, CM Bollard, KV Komanduri, DA Gastineau, C Chabannon, MA Perales, M Hudecek, M Aljurf, L Andritsos, JA Barrett, V Bachanova, C Bonini, A Ghobadi, SI Gill, JA Hill, S Kenderian, P Kebriaei, A Nagler, D Maloney, HD Liu, NN Shah, MA Kharfan-Dabaja, EJ Shpall, GJ Mufti, L Johnston, E Jacoby, A Bazarbachi, JF DiPersio, SZ Pavletic, DL Porter, SA Grupp, M Sadelain, MR Litzow, M Mohty, SK Hashmi |
Bone Marrow Transplantation | 2019 |
Analysis of the function of MAGE-A in esophageal carcinoma by bioinformatics:
X Chen, S Cai, L Wang, X Zhang, W Li, X Cao |
Medicine | 2019 |
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy
KA Hay, J Gauthier, AV Hirayama, JM Voutsinas, Q Wu, D Li, TA Gooley, S Cherian, X Chen, BS Pender, RM Hawkins, A Vakil, RN Steinmetz, G Schoch, AG Chapuis, BG Till, HP Kiem, JD Ramos, M Shadman, RD Cassaday, UH Acharya, SR Riddell, DG Maloney, CJ Turtle |
Blood | 2019 |
A safe and potent anti-CD19 CAR T cell therapy
Z Ying, XF Huang, X Xiang, Y Liu, , Y Song, X Guo, H Liu, N Ding, T Zhang, P Duan, Y Lin, W Zheng, X Wang, N Lin, M Tu, Y Xie, C Zhang, W Liu, L Deng, S Gao, L Ping, X Wang, N Zhou, J Zhang, Y Wang, S Lin, M Mamuti, X Yu, L Fang, S Wang, H Song, G Wang, L Jones, J Zhu, SY Chen |
Nature Medicine | 2019 |
Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma S Li, L Xue, M Wang, P Qiang, H Xu, X Zhang, W Kang, F You, H Xu, Y Wang, X Liu, L Yang, X Wang |
OncoTargets and therapy | 2019 |
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
T Nerreter, S Letschert, R Götz, S Doose, S Danhof, H Einsele, M Sauer, M Hudecek |
Nature Communications | 2019 |
Imaging CAR T cell therapy with PSMA-targeted positron emission tomography
I Minn, DJ Huss, HH Ahn, TM Chinn, A Park, J Jones, M Brummet, SP Rowe, P Sysa-Shah, Y Du, HI Levitsky, MG Pomper |
Science Advances | 2019 |
Adverse Events of Oncologic Immunotherapy and Their Management
FD Barber |
Asia-Pacific Journal of Oncology Nursing | 2019 |
Clinical Approach to the Patient in Critical State Following Immunotherapy and/or Stem Cell Transplantation: Guideline for the On-Call Physician
Constantinescu, Bodolea, Pasca, Teodorescu, Dima, Rus, Tat, AC, Tanase, Tomuleasa, Einsele |
Journal of Clinical Medicine | 2019 |
Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?
KD Cummins, S Gill |
Haematologica | 2019 |
Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
H Jia, Z Wang, Y Wang, Y Liu, H Dai, C Tong, Y Guo, B Guo, D Ti, X Han, Q Yang, Z Wu, W Han |
Journal of Hematology & Oncology | 2019 |
Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics
SR Panch, SK Srivastava, N Elavia, A McManus, S Liu, P Jin, SL Highfill, X Li, P Dagur, JN Kochenderfer, TJ Fry, CL Mackall, D Lee, NN Shah, DF Stroncek |
Molecular Therapy | 2019 |
Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells F Yang, J Zhang, X Zhang, M Tian, J Wang, L Kang, H Qiu, D Wu |
OncoTargets and therapy | 2019 |
Preservation of cell-based immunotherapies for clinical trials
R Li, R Johnson, G Yu, DA Mckenna, A Hubel |
Cytotherapy | 2019 |
Human CD4 + T Cells Specific for Merkel Cell Polyomavirus Localize to Merkel Cell Carcinomas and Target a Required Oncogenic Domain
NV Longino, J Yang, JG Iyer, D Ibrani, IT Chow, KJ Laing, VL Campbell, KG Paulson, RM Kulikauskas, CD Church, EA James, P Nghiem, WW Kwok, DM Koelle |
Cancer immunology research | 2019 |
Traceless aptamer-mediated isolation of CD8+ T cells for chimeric antigen receptor T-cell therapy
N Kacherovsky, II Cardle, EL Cheng, JL Yu, ML Baldwin, SJ Salipante, MC Jensen, SH Pun |
Nature Biomedical Engineering | 2019 |
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy
AV Hirayama, J Gauthier, KA Hay, JM Voutsinas, Q Wu, BS Pender, RM Hawkins, A Vakil, RN Steinmetz, SR Riddell, DG Maloney, CJ Turtle |
Blood | 2019 |
CAR-T – and a side order of IgG, to go? – Immunoglobulin replacement in patients receiving CAR-T cell therapy
JA Hill, S Giralt, TR Torgerson, HM Lazarus |
Blood Reviews | 2019 |
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
I Ramachandran, DE Lowther, R Dryer-Minnerly, R Wang, S Fayngerts, D Nunez, G Betts, N Bath, AJ Tipping, L Melchiori, JM Navenot, J Glod, CL Mackall, SP DAngelo, DM Araujo, WA Chow, GD Demetri, M Druta, BA Tine, SA Grupp, AR Razak, B Wilky, M Iyengar, T Trivedi, EV Winkle, K Chagin, R Amado, GK Binder, S Basu |
Journal for ImmunoTherapy of Cancer | 2019 |
Engineered T Cell Therapy for Cancer in the Clinic
L Zhao, YJ Cao |
Frontiers in immunology | 2019 |
Recent updates on CAR T clinical trials for multiple myeloma
Q Lin, J Zhao, Y Song, D Liu |
Molecular Cancer | 2019 |
Chimeric Antigen Receptor T-Cell Therapy Clinical Results in Pediatric and Young Adult B-ALL:
AM DiNofia, SL Maude |
2019 | |
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma
A Schmidts, M Ormhøj, BD Choi, AO Taylor, AA Bouffard, I Scarfò, RC Larson, MJ Frigault, K Gallagher, AP Castano, LS Riley, ML Cabral, AC Boroughs, RM Cárdenas, W Schamel, J Zhou, S Mackay, YT Tai, KC Anderson, MV Maus |
Blood Advances | 2019 |
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy
M Shadman, J Gauthier, KA Hay, JM Voutsinas, F Milano, A Li, AV Hirayama, ML Sorror, S Cherian, X Chen, RD Cassaday, BG Till, AK Gopal, BM Sandmaier, DG Maloney, CJ Turtle |
Blood Advances | 2019 |
Immune-Based Therapies in Acute Leukemia
MT Witkowski, A Lasry, WL Carroll, I Aifantis |
Trends in Cancer | 2019 |
Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy
JA Hill, EM Krantz, KA Hay, S Dasgupta, T Stevens-Ayers, RA Ignacio, M Bar, J Maalouf, S Cherian, X Chen, G Pepper, SR Riddell, DG Maloney, MJ Boeckh, CJ Turtle |
Blood Advances | 2019 |
Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment
J Rice, S Nagle, J Randall, HE Hinson |
Current Treatment Options in Neurology | 2019 |
Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy
CH Karches, MR Benmebarek, ML Schmidbauer, M Kurzay, R Klaus, M Geiger, F Rataj, BL Cadilha, S Lesch, C Heise, R Murr, J vom Berg, M Jastroch, D Lamp, J Ding, P Duewell, G Niederfellner, C Sustmann, S Endres, C Klein, S Kobold |
Clinical cancer research | 2019 |
Mechanisms of and approaches to overcoming resistance to immunotherapy
L Schultz, R Gardner |
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program | 2019 |
A highly soluble Sleeping Beauty transposase improves control of gene insertion
I Querques, A Mades, C Zuliani, C Miskey, M Alb, E Grueso, M Machwirth, T Rausch, H Einsele, Z Ivics, M Hudecek, O Barabas |
Nature Biotechnology | 2019 |
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy
RA Gardner, F Ceppi, J Rivers, C Annesley, C Summers, A Taraseviciute, J Gust, KJ Leger, K Tarlock, TM Cooper, OC Finney, H Brakke, DH Li, JR Park, MC Jensen |
Blood | 2019 |
Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model
AP Singh, X Zheng, X Lin-Schmidt, W Chen, TJ Carpenter, A Zong, W Wang, DL Heald |
mAbs | 2019 |
CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia
HL Pacenta, TW Laetsch, S John |
Pediatric Drugs | 2019 |
Evidence of long‐lasting anti‐CD19 activity of engrafted CD19 chimeric antigen receptor–modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia
F Ma, JY Ho, H Du, F Xuan, X Wu, Q Wang, L Wang, Y Liu, M Ba, Y Wang, J Luo, J Li |
Hematological Oncology | 2019 |
Current status and hurdles for CAR-T cell immune therapy
R Zhao, Y Cui, S Li, L Qin, P Li |
2019 | |
Next Generation of Cancer Treatments: Chimeric Antigen Receptor T-Cell Therapy and Its Related Toxicities
G Echeverry, GW Fischer, E Mead |
Anesthesia & Analgesia | 2019 |
Molecular Design, Optimization, and Genomic Integration of Chimeric B Cell Receptors in Murine B Cells
T Pesch, L Bonati, W Kelton, C Parola, RA Ehling, L Csepregi, D Kitamura, ST Reddy |
Frontiers in immunology | 2019 |
Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells
L Herrera, S Santos, MA Vesga, J Anguita, I Martin-Ruiz, T Carrascosa, M Juan, C Eguizabal |
Scientific Reports | 2019 |
Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy
AJ Kansagra, NV Frey, M Bar, TW Laetsch, PA Carpenter, BN Savani, HE Heslop, CM Bollard, KV Komanduri, DA Gastineau, C Chabannon, MA Perales, M Hudecek, M Aljurf, L Andritsos, JA Barrett, V Bachanova, C Bonini, A Ghobadi, SI Gill, J Hill, S Kenderian, P Kebriaei, A Nagler, D Maloney, HD Liu, NN Shah, MA Kharfan-Dabaja, EJ Shpall, GJ Mufti, L Johnston, E Jacoby, A Bazarbachi, JF DiPersio, SZ Pavletic, DL Porter, SA Grupp, M Sadelain, MR Litzow, M Mohty, SK Hashmi |
Biology of Blood and Marrow Transplantation | 2019 |
Beat pediatric ALL MRD: CD28 CAR T and transplant.
Ruella M, Locke FL |
Blood | 2019 |
Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG+ AML
Yao S, Jianlin C, Yarong L, Botao L, Qinghan W, Hongliang F, Lu Z, Hongmei N, Pin W, Hu C, Liangding H, Bin Z |
Frontiers in Oncology | 2019 |
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
Curran KJ, Margossian SP, Kernan NA, Silverman LB, Williams DA, Shukla N, Kobos R, Forlenza CJ, Steinherz P, Prockop S, Boulad F, Spitzer B, Cancio MI, Boelens JJ, Kung AL, Szenes V, Park JH, Sauter CS, Heller G, Wang X, Senechal B, O\u2019Reilly RJ, Riviere I, Sadelain M, Brentjens RJ |
Blood | 2019 |
CAR-T在造血干细胞移植中的作用
|
2019 | |
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells.
Lapteva N, Gilbert M, Diaconu I, Rollins LA, Al-Sabbagh M, Naik S, Krance RA, Tripic T, Hiregange M, Raghavan D, Dakhova O, Rouce RH, Liu H, Omer B, Savoldo B, Dotti G, Cruz CR, Sharpe K, Gates M, Orozco A, Durett A, Pacheco E, Gee AP, Ramos CA, Heslop HE, Brenner MK, Rooney CM |
Clinical cancer research | 2019 |
Management of cytokine release syndrome related to CAR-T cell therapy.
Chen H, Wang F, Zhang P, Zhang Y, Chen Y, Fan X, Cao X, Liu J, Yang Y, Wang B, Lei B, Gu L, Bai J, Wei L, Zhang R, Zhuang Q, Zhang W, Zhao W, He A |
Frontiers of Medicine | 2019 |
Hemophagocytic Lymphohistiocytosis and Other Culture Negative Sepsis-Like Syndromes in the ICU
Denstaedt SJ, Singer BH |
2019 | |
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL |
Journal of Clinical Oncology | 2019 |
Driving the CAR to the Bone Marrow Transplant Program.
Dave H, Jerkins L, Hanley PJ, Bollard CM, Jacobsohn D |
Current Hematologic Malignancy Reports | 2019 |
Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies.
Jacoby E |
2019 | |
Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia.
Maffini E, Saraceni F, Lanza F |
2019 | |
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
Sonia Guedan, Avery D. Posey, Jr., Carolyn Shaw, Anna Wing, Tong Da, Prachi Patel, Shannon McGettigan, Victoria Casado-Medrano, Omkar U. Kawalekar, Mireia Uribe-Herranz, J. Joseph Melenhorst, Simon Lacey, Decheng Song, John Scholler, Brian Keith, Regina Young, Carl June |
JCI Insight | 2018 |
Glioblastoma-Targeted CD4+ CAR-T cells outperform CD8+ cells for Sustained Effector Function and Superior Antitumor Activity
Dongrui Wang, Brenda Aguilar, Renate Starr, Darya Alizadeh, Alfonso Brito, Aniee Sarkissian, Julie Ostberg, Stephen J. Forman, Christine Brown |
JCI Insight | 2018 |
4-1BB enhancement of CAR T function requires NF-κB and TRAFs
Gongbo Li, Justin C Boucher, Bishwas Shrestha, Hiroshi Kotani, Kyungho Park, Yongliang Zhang, Xuefeng Wang, Lawrence Guan, Nolan J Beatty, Daniel Abate-Daga, Marco L Davila |
JCI Insight | 2018 |
CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies
HM Knochelmann, AS Smith, CJ Dwyer, MM Wyatt, S Mehrotra, CM Paulos |
Frontiers in immunology | 2018 |
Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
C Tomuleasa, S Fuji, C Berce, A Onaciu, S Chira, B Petrushev, WT Micu, V Moisoiu, C Osan, C Constantinescu, S Pasca, A Jurj, L Pop, I Berindan-Neagoe, D Dima, S Kitano |
Frontiers in immunology | 2018 |
Beyond Cell Death: New Functions for TNF Family Cytokines in Autoimmunity and Tumor Immunotherapy
F Yi, N Frazzette, AC Cruz, CA Klebanoff, RM Siegel |
Trends in Molecular Medicine | 2018 |
Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors
LL Yan, BN Liu |
OncoTargets and therapy | 2018 |
Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients
JM Hoffmann, ML Schubert, L Wang, A Hückelhoven, L Sellner, S Stock, A Schmitt, C Kleist, U Gern, A Loskog, P Wuchter, S Hofmann, AD Ho, C Müller-Tidow, P Dreger, M Schmitt |
Frontiers in immunology | 2018 |
Posttransplant chimeric antigen receptor therapy
M Smith, J Zakrzewski, S James, M Sadelain |
Blood | 2018 |
CAR T cell therapy for B-cell lymphomas
JC Chavez, FL Locke |
Best practice & research. Clinical haematology | 2018 |
Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells
AS Cheung, DK Zhang, ST Koshy, DJ Mooney |
Nature Biotechnology | 2018 |
CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors
AC Filley, M Henriquez, M Dey |
Frontiers in Oncology | 2018 |
TGF-β-responsive CAR-T cells promote anti-tumor immune function
AJ Hou, ZN Chang, MH Lorenzini, E Zah, YY Chen |
Bioengineering & Translational Medicine | 2018 |
CAR T cells for infection, autoimmunity and allotransplantation
CR Maldini, GI Ellis, JL Riley |
Nature Reviews Immunology | 2018 |
Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
JH Cho, JJ Collins, WW Wong |
Cell | 2018 |
Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia
F Blaeschke, D Stenger, T Kaeuferle, S Willier, R Lotfi, AD Kaiser, M Assenmacher, M Döring, J Feucht, T Feuchtinger |
Cancer Immunology, Immunotherapy | 2018 |
Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies—the German Cancer Consortium approach
AM Krackhardt, B Anliker, M Hildebrandt, M Bachmann, SB Eichmüller, DM Nettelbeck, M Renner, L Uharek, G Willimsky, M Schmitt, WS Wels, M Schüssler-Lenz |
Cancer Immunology, Immunotherapy | 2018 |
Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
S Sun, H Hao, G Yang, Y Zhang, Y Fu |
Journal of Immunology Research | 2018 |
The Pharmacology of T Cell Therapies
MC Milone, VG Bhoj |
Molecular Therapy — Methods & Clinical Development | 2018 |
Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function
AI Salter, RG Ivey, JJ Kennedy, V Voillet, A Rajan, EJ Alderman, UJ Voytovich, C Lin, D Sommermeyer, L Liu, JR Whiteaker, R Gottardo, AG Paulovich, SR Riddell |
Science signaling | 2018 |
Dawn of chimeric antigen receptor T cell therapy in non-Hodgkin Lymphoma
K Perica, ML Palomba, RJ Brentjens |
2018 | |
Teaching an old dog new tricks: next-generation CAR T cells
N Tokarew, J Ogonek, S Endres, M von Bergwelt-Baildon, S Kobold |
British Journal of Cancer | 2018 |
Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells
R Elahi, E Khosh, S Tahmasebi, A Esmaeilzadeh |
Frontiers in immunology | 2018 |
Nanobody Based Dual Specific CARs
SD Munter, J Ingels, G Goetgeluk, S Bonte, M Pille, K Weening, T Kerre, H Abken, B Vandekerckhove |
International journal of molecular sciences | 2018 |
Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme
V Jindal |
Molecular Neurobiology | 2018 |
Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma
CE Brown, B Aguilar, R Starr, X Yang, WC Chang, L Weng, B Chang, A Sarkissian, A Brito, JF Sanchez, JR Ostberg, M DApuzzo, B Badie, ME Barish, SJ Forman |
Molecular Therapy | 2018 |
The development of CAR design for tumor CAR-T cell therapy
D Xu, G Jin, D Chai, X Zhou, W Gu, Y Chong, J Song, J Zheng |
Oncotarget | 2018 |
CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
S Guedan, R Alemany |
Frontiers in immunology | 2018 |
Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
J Xu, Q Wang, H Xu, C Gu, L Jiang, J Wang, D Wang, B Xu, X Mao, J Wang, Z Wang, Y Xiao, Y Zhang, C Li, J Zhou |
Journal of Hematology & Oncology | 2018 |
Current development of chimeric antigen receptor T-cell therapy
J Wang, Y Hu, H Huang |
Stem Cell Investigation | 2018 |
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
AI Salter, MJ Pont, SR Riddell |
Blood | 2018 |
In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia
Z Cheng, R Wei, Q Ma, L Shi, F He, Z Shi, T Jin, R Xie, B Wei, J Chen, H Fang, X Han, JA Rohrs, P Bryson, Y Liu, QJ Li, B Zhu, P Wang |
Molecular Therapy | 2018 |
Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis:
LS Kean |
Blood | 2018 |
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
KM Mahadeo, SJ Khazal, H Abdel-Azim, JC Fitzgerald, A Taraseviciute, CM Bollard, P Tewari, C Duncan, C Traube, D McCall, ME Steiner, IM Cheifetz, LE Lehmann, R Mejia, JM Slopis, R Bajwa, P Kebriaei, PL Martin, J Moffet, J McArthur, D Petropoulos, JO Curry, S Featherston, J Foglesong, B Shoberu, A Gulbis, ME Mireles, L Hafemeister, C Nguyen, N Kapoor, K Rezvani, SS Neelapu, EJ Shpall |
Nature Reviews Clinical Oncology | 2018 |
Modulation of immune responses in lentiviral vector-mediated gene transfer
A Annoni, S Gregori, L Naldini, A Cantore |
Cellular Immunology | 2018 |
mRNA as novel technology for passive immunotherapy
T Schlake, A Thess, M Thran, I Jordan |
Cellular and Molecular Life Sciences | 2018 |
Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy
MB Geyer, I Rivière, B Sénéchal, X Wang, Y Wang, TJ Purdon, M Hsu, SM Devlin, E Halton, N Lamanna, J Rademaker, M Sadelain, RJ Brentjens, JH Park |
Molecular Therapy | 2018 |
CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile:
I Magalhaes, I Kalland, JN Kochenderfer, A Österborg, M Uhlin, J Mattsson |
Journal of immunotherapy (Hagerstown, Md. : 1997) | 2018 |
Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions:
SY Lee, P Olsen, DH Lee, AL Kenoyer, LE Budde, S OSteen, DJ Green, S Heimfeld, MC Jensen, SR Riddell, OW Press, BG Till |
Journal of immunotherapy (Hagerstown, Md. : 1997) | 2018 |
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
JA Fraietta, SF Lacey, EJ Orlando, I Pruteanu-Malinici, M Gohil, S Lundh, AC Boesteanu, Y Wang, RS OConnor, WT Hwang, E Pequignot, DE Ambrose, C Zhang, N Wilcox, F Bedoya, C Dorfmeier, F Chen, L Tian, H Parakandi, M Gupta, RM Young, FB Johnson, I Kulikovskaya, L Liu, J Xu, SH Kassim, MM Davis, BL Levine, NV Frey, DL Siegel, AC Huang, EJ Wherry, H Bitter, JL Brogdon, DL Porter, CH June, JJ Melenhorst |
Nature Medicine | 2018 |
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1c259T cells in Synovial Sarcoma
SP D'Angelo, L Melchiori, MS Merchant, DB Bernstein, J Glod, RN Kaplan, SA Grupp, WD Tap, K Chagin, GK Binder, S Basu, DE Lowther, R Wang, N Bath, A Tipping, G Betts, I Ramachandran, JM Navenot, H Zhang, DK Wells, EV Winkle, G Kari, T Trivedi, T Holdich, LN Pandite, R Amado, CL Mackall |
Cancer Discovery | 2018 |
Design considerations for early-phase clinical trials of immune-oncology agents
NA Wages, C Chiuzan, KS Panageas |
Journal for ImmunoTherapy of Cancer | 2018 |
CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation
P Bajgain, S Tawinwung, L DElia, S Sukumaran, N Watanabe, V Hoyos, P Lulla, MK Brenner, AM Leen, JF Vera |
Journal for ImmunoTherapy of Cancer | 2018 |
Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy
S Srivastava, SR Riddell |
Journal of immunology (Baltimore, Md. : 1950) | 2018 |
Cell‐Templated Silica Microparticles with Supported Lipid Bilayers as Artificial Antigen‐Presenting Cells for T Cell Activation
BR Olden, CR Perez, AL Wilson, II Cardle, YS Lin, B Kaehr, JA Gustafson, MC Jensen, SH Pun |
Advanced Healthcare Materials | 2018 |
CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
S Vairy, JL Garcia, P Teira, H Bittencourt |
Drug design, development and therapy | 2018 |
Animal Models for Preclinical Development of Allogeneic Hematopoietic Cell Transplantation
SS Graves, MH Parker, R Storb |
ILAR journal / National Research Council, Institute of Laboratory Animal Resources | 2018 |
Chimeric Antigen Receptor Therapy
CH June, M Sadelain |
New England Journal of Medicine | 2018 |
T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology
ME Sharpe |
Toxicologic pathology | 2018 |
Clinical use of lentiviral vectors
MC Milone, U ODoherty |
Leukemia | 2018 |
CAR T Cell Therapy for Neuroblastoma
RM Richards, E Sotillo, RG Majzner |
Frontiers in immunology | 2018 |
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
JA Fraietta, CL Nobles, MA Sammons, S Lundh, SA Carty, TJ Reich, AP Cogdill, JJ Morrissette, JE DeNizio, S Reddy, Y Hwang, M Gohil, I Kulikovskaya, F Nazimuddin, M Gupta, F Chen, JK Everett, KA Alexander, E Lin-Shiao, MH Gee, X Liu, RM Young, D Ambrose, Y Wang, J Xu, MS Jordan, KT Marcucci, BL Levine, KC Garcia, Y Zhao, M Kalos, DL Porter, RM Kohli, SF Lacey, SL Berger, FD Bushman, CH June, JJ Melenhorst |
Nature | 2018 |
Enhancing the potency and specificity of engineered T cells for cancer treatment
S Sukumaran, N Watanabe, P Bajgain, K Raja, S Mohammed, WE Fisher, MK Brenner, AM Leen, JF Vera |
Cancer Discovery | 2018 |
Cytokine release syndrome
A Shimabukuro-Vornhagen, P Gödel, M Subklewe, HJ Stemmler, HA Schlößer, M Schlaak, M Kochanek, B Böll, MS von Bergwelt-Baildon |
Journal for ImmunoTherapy of Cancer | 2018 |
Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene
M Casucci, L Falcone, B Camisa, M Norelli, S Porcellini, A Stornaiuolo, F Ciceri, C Traversari, C Bordignon, C Bonini, A Bondanza |
Frontiers in immunology | 2018 |
The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
Z Zhao, Y Chen, NM Francisco, Y Zhang, M Wu |
Acta pharmaceutica Sinica. B | 2018 |
Genetically enhanced T lymphocytes and the intensive care unit
T Tat, H Li, CS Constantinescu, A Onaciu, S Chira, C Osan, S Pasca, B Petrushev, V Moisoiu, WT Micu, C Berce, S Tranca, D Dima, I Berindan-Neagoe, J Shen, C Tomuleasa, L Qian |
Oncotarget | 2018 |
Chimeric antigen receptor modified T-cells for cancer treatment
X Han, Y Wang, WD Han |
Chronic Diseases and Translational Medicine | 2018 |
Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
Y Zou, W Xu, J Li |
Journal of Hematology & Oncology | 2018 |
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
JN Brudno, JN Kochenderfer |
Blood Reviews | 2018 |
Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities
BR Dholaria, CA Bachmeier, F Locke |
BioDrugs | 2018 |
Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers
C Rossig, S Kailayangiri, S Jamitzky, B Altvater |
Frontiers in Oncology | 2018 |
Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma
CM Bollard, T Tripic, CR Cruz, G Dotti, S Gottschalk, V Torrano, O Dakhova, G Carrum, CA Ramos, H Liu, MF Wu, AN Marcogliese, C Barese, Y Zu, DY Lee, O OConnor, AP Gee, MK Brenner, HE Heslop, CM Rooney |
Journal of Clinical Oncology | 2018 |
Delayed Terminal Ileal Perforation in a Relapsed/refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy
Y Hu, J Wang, C Pu, K Zhao, Q Cui, G Wei, W Wu, L Xiao, Y Xiao, J Wang, Z Wu, H Huang |
Cancer Research and Treatment | 2018 |
Cytokine Release Syndrome Grade is a Predictive Marker for Infections in Relapsed or Refractory B-cell All Patients Treated with CAR T Cells
JH Park, FA Romero, Y Taur, M Sadelain, RJ Brentjens, TM Hohl, SK Seo |
Clinical Infectious Diseases | 2018 |
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
JH Park, I Rivière, M Gonen, X Wang, B Sénéchal, KJ Curran, C Sauter, Y Wang, B Santomasso, E Mead, M Roshal, P Maslak, M Davila, RJ Brentjens, M Sadelain |
New England Journal of Medicine | 2018 |
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
SL Maude, TW Laetsch, J Buechner, S Rives, M Boyer, H Bittencourt, P Bader, MR Verneris, HE Stefanski, GD Myers, M Qayed, BD Moerloose, H Hiramatsu, K Schlis, KL Davis, PL Martin, ER Nemecek, GA Yanik, C Peters, A Baruchel, N Boissel, F Mechinaud, A Balduzzi, J Krueger, CH June, BL Levine, P Wood, T Taran, M Leung, KT Mueller, Y Zhang, K Sen, D Lebwohl, MA Pulsipher, SA Grupp |
New England Journal of Medicine | 2018 |
Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products
K Cornetta, L Duffy, CJ Turtle, M Jensen, S Forman, G Binder-Scholl, T Fry, A Chew, DG Maloney, CH June |
Molecular Therapy | 2018 |
Engineered T lymphocytes eliminate lung metastases in models of pancreatic cancer
Q Sun, S Zhou, J Zhao, C Deng, R Teng, Y Zhao, J Chen, J Dong, M Yin, Y Bai, H Deng, J Wen |
Oncotarget | 2018 |
T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
JN Brudno, I Maric, SD Hartman, JJ Rose, M Wang, N Lam, M Stetler-Stevenson, D Salem, C Yuan, S Pavletic, JA Kanakry, SA Ali, L Mikkilineni, SA Feldman, DF Stroncek, BG Hansen, J Lawrence, R Patel, F Hakim, RE Gress, JN Kochenderfer |
Journal of Clinical Oncology | 2018 |
Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)
BD Santomasso, JH Park, D Salloum, I Rivière, J Flynn, E Mead, E Halton, X Wang, B Senechal, T Purdon, JR Cross, H Liu, B Vachha, , LM DeAngelis, D Li, Y Bernal, M Gonen, HG Wendel, M Sadelain, RJ Brentjens |
Cancer Discovery | 2018 |
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
S Haubner, F Perna, T Köhnke, C Schmidt, S Berman, C Augsberger, FM Schnorfeil, C Krupka, FS Lichtenegger, X Liu, P Kerbs, S Schneider, KH Metzeler, K Spiekermann, W Hiddemann, PA Greif, T Herold, M Sadelain, M Subklewe |
Leukemia | 2018 |
Current Status of Gene Engineering Cell Therapeutics
A Saudemont, L Jespers, T Clay |
Frontiers in immunology | 2018 |
Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
Z Wang, W Han |
Biomarker Research | 2018 |
Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia
MY Kim, KR Yu, SS Kenderian, M Ruella, S Chen, TH Shin, AA Aljanahi, D Schreeder, M Klichinsky, O Shestova, MS Kozlowski, KD Cummins, X Shan, M Shestov, A Bagg, JJ Morrissette, P Sekhri, CR Lazzarotto, KR Calvo, DB Kuhns, RE Donahue, GK Behbehani, SQ Tsai, CE Dunbar, S Gill |
Cell | 2018 |
CARs and other T cell therapies for MM: The clinical experience
S Danhof, M Hudecek, EL Smith |
Best practice & research. Clinical haematology | 2018 |
Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?
SK Tasian |
Therapeutic Advances in Hematology | 2018 |
CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
LN Zhang, Y Song, D Liu |
Journal of Hematology & Oncology | 2018 |
Chimeric Antigen Receptor-T Cell Therapy: Practical Considerations for Implementation in Europe
J Buechner, MJ Kersten, M Fuchs, F Salmon, U Jäger |
2018 | |
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
D Porter, N Frey, PA Wood, Y Weng, SA Grupp |
Journal of Hematology & Oncology | 2018 |
Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity
AJ Davenport, RS Cross, KA Watson, Y Liao, W Shi, HM Prince, PA Beavis, JA Trapani, MH Kershaw, DS Ritchie, PK Darcy, PJ Neeson, MR Jenkins |
Proceedings of the National Academy of Sciences | 2018 |
Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells
D Morita, N Nishio, S Saito, M Tanaka, N Kawashima, Y Okuno, S Suzuki, K Matsuda, Y Maeda, MH Wilson, G Dotti, CM Rooney, Y Takahashi, Y Nakazawa |
Molecular Therapy — Methods & Clinical Development | 2018 |
Producing proT cells to promote immunotherapies
J Singh, JC Zúñiga-Pflücker |
International Immunology | 2018 |
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites
A Titov, A Petukhov, A Staliarova, D Motorin, E Bulatov, O Shuvalov, SM Soond, M Piacentini, G Melino, A Zaritskey, NA Barlev |
Cell Death and Disease | 2018 |
Principles of adoptive T cell therapy in cancer
Ö Met, KM Jensen, CA Chamberlain, M Donia, IM Svane |
Seminars in Immunopathology | 2018 |
CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma
YP Park, L Jin, KB Bennett, D Wang, KM Fredenburg, JE Tseng, LJ Chang, J Huang, EK Chan |
Oral Oncology | 2018 |
Influence of various medium environment to in vitro human T cell culture
H Xu, N Wang, W Cao, L Huang, J Zhou, L Sheng |
In vitro cellular & developmental biology. Animal | 2018 |
Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy
S Rashdan, JD Minna, DE Gerber |
The lancet. Respiratory medicine | 2018 |
Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice
CA Pennell, JL Barnum, CS McDonald-Hyman, A Panoskaltsis-Mortari, MJ Riddle, Z Xiong, M Loschi, G Thangavelu, HM Campbell, MD Storlie, Y Refaeli, SN Furlan, MC Jensen, LS Kean, JS Miller, J Tolar, MJ Osborn, BR Blazar |
Molecular Therapy | 2018 |
Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia; Current Evidence, and Improving Outcomes Going Forward
JT Leonard, B Hayes-Lattin |
Current Hematologic Malignancy Reports | 2018 |
The promise of CAR T-cell therapy in aggressive B-cell lymphoma
R Nair, SS Neelapu |
Best practice & research. Clinical haematology | 2018 |
Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector
EL Smith, M Staehr, R Masakayan, IJ Tatake, TJ Purdon, X Wang, P Wang, H Liu, Y Xu, SC Garrett-Thomson, SC Almo, I Riviere, C Liu, RJ Brentjens |
Molecular Therapy | 2018 |
Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy
J Gauthier, CJ Turtle |
Current Research in Translational Medicine | 2018 |
Selection of Tumor-Specific Cytotoxic T Lymphocytes in Acute Myeloid Leukemia Patients Through the Identification of T-Cells Capable to Establish Stable Interactions With the Leukemic Cells: “Doublet Technology”
E García-Guerrero, LI Sánchez-Abarca, E Domingo, TL Ramos, JA Bejarano-García, JA Gonzalez-Campos, T Caballero-Velázquez, JA Pérez-Simón |
Frontiers in immunology | 2018 |
Single-cell technologies for profiling T cells to enable monitoring of immunotherapies
X An, N Varadarajan |
Current Opinion in Chemical Engineering | 2018 |
PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts
DC Bishop, N Xu, B Tse, TA OBrien, DJ Gottlieb, A Dolnikov, KP Micklethwaite |
Molecular Therapy | 2018 |
PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma
F Rataj, FB Kraus, M Chaloupka, S Grassmann, C Heise, BL Cadilha, P Duewell, S Endres, S Kobold |
Frontiers in immunology | 2018 |
Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma
J Zhang, LJ Medeiros, KH Young |
Frontiers in Oncology | 2018 |
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease
KC Pehlivan, BB Duncan, DW Lee |
Current Hematologic Malignancy Reports | 2018 |
Engineering a Dual Small Molecule Gated ZAP70 Switch in T Cells
NM Wong, WW Wong |
ACS Synthetic Biology | 2018 |
Selection of a novel CD19 aptamer for targeted delivery of doxorubicin to lymphoma cells
Y Hu, X Li, Y An, J Duan, XD Yang |
Oncotarget | 2018 |
Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy – Moving Target for Industry?
P Salmikangas, N Kinsella, P Chamberlain |
Pharmaceutical Research | 2018 |
Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors
AS Stein, G Schiller, R Benjamin, C Jia, A Zhang, M Zhu, Z Zimmerman, MS Topp |
Annals of Hematology | 2018 |
CAR T cells find strength in polyfunction
ML Davila |
Blood | 2018 |
Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy
JS Appelbaum, F Milano |
Current Hematologic Malignancy Reports | 2018 |
A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection
DJ Diamond, CL Rosa, F Chiuppesi, H Contreras, S Dadwal, F Wussow, S Bautista, R Nakamura, JA Zaia |
Expert Review of Vaccines | 2018 |
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
J Gust, A Taraseviciute, CJ Turtle |
CNS Drugs | 2018 |
The Modified Vaccination Technique
A Barabas, C Cole, Z Kovacs, E Kovacs, R Lafreniere |
Human vaccines | 2018 |
No free rides: management of toxicities of novel immunotherapies in ALL, including financial
T Jain, MR Litzow |
Blood Advances | 2018 |
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
MM Boyiadzis, MV Dhodapkar, RJ Brentjens, JN Kochenderfer, SS Neelapu, MV Maus, DL Porter, DG Maloney, SA Grupp, CL Mackall, CH June, MR Bishop |
Journal for ImmunoTherapy of Cancer | 2018 |
CAR T cells targeting α v β 3 integrin are effective against advanced cancer in preclinical models
L Wallstabe, A Mades, S Frenz, H Einsele, C Rader, M Hudecek |
2018 | |
No free rides: management of toxicities of novel immunotherapies in ALL, including financial
T Jain, MR Litzow |
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program | 2018 |
Are CAR T cells better than antibody or HCT therapy in B-ALL?
MA Pulsipher |
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program | 2018 |
Biological Consequences of MHC-II Expression by Tumor Cells in Cancer
ML Axelrod, RS Cook, DB Johnson, JM Balko |
Clinical cancer research | 2018 |
Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia
M Hefazi, MR Litzow |
Blood and Lymphatic Cancer: Targets and Therapy | 2018 |
A novel method to generate T-cell receptor–deficient chimeric antigen receptor T cells
T Kamiya, D Wong, YT Png, D Campana |
Blood Advances | 2018 |
Treatment of Older Patients with Acute Lymphoblastic Leukaemia.
Gökbuget N |
Drugs & Aging | 2018 |
[Anti-CD19 chimeric antigen receptors T cells for treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: three cases report and literatures review].
Yang F, Zhang J, Qiu HY, Wu Q, Kong DQ, Han JJ, Qi JQ, Han Y, Wu DP |
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi | 2018 |
CAR T cells: The future is already present.
Sánchez-Escamilla M, Yáñez San Segundo L, Urbano-Ispizua Á, Perales MÁ |
2018 | |
[Safety and efficacy of chimeric antigen receptor T cell in the treatment of elderly patients with hematological malignancies].
Liu D, Ke P, Huo L, Hu XH, Fu CC, Li CX, Huang HW, Xue SL, Qiu HY, Wu DP, Ma X |
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi | 2018 |
[An experimental study of CD4 targeted chimeric antigen receptor modified T cell with anti-lymphoma activity].
Chen GH, Huang HW, Wang Y, Liu HW, Xu LJ, Ma X, Xue SL, He XF, Wang Y, Gu B, Li CX, Qiu HY, Tang XW, Jin ZM, Miao M, Sun AN, Wu DP |
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi | 2018 |
我如何诊疗CAR-T细胞治疗相关细胞因子释放综合征
|
2018 | |
一种新的高亲和力的人源化抗CD19 CAR-T细胞的构建及体外功能验证
|
2018 | |
Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis.
Nagle K, Tafuto B, Palladino Kim L, Parrott JS |
Medical Oncology | 2018 |
Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia
Leahy AB, Elgarten CW, Grupp SA, Maude SL, Teachey DT |
Expert Review of Anticancer Therapy | 2018 |
Recent progress in improving the safety and efficacy of chimeric antigen receptor T cell therapy
Yang Y, Hu Y, Wang J, Huang H |
2018 | |
A dynamical systems perspective on chimeric antigen receptor T-cell dosing.
Toor AA, Chesney A, Zweit J, Reed J, Hashmi SK |
Bone marrow transplantation | 2018 |
Clinical and Immunological Responses after CD30-specific Chimeric Antigen Receptor redirected Lymphocytes
Carlos Ramos, Brandon Ballard, Huimin Zhang, Olga Dakhova, Adrian Gee, Zhuyong Mei, Mrinalini Bilgi, Meng-Fen Wu, Hao Liu, Bambi Grilley, Catherine M. Bollard, Bill Chang, Cliona Rooney, Malcolm Brenner, Helen Heslop, Gianpietro Dotti, Barbara Savoldo |
Journal of Clinical Investigation | 2017 |
Inhibition of AKT-signaling uncouples T-cell differentiation from expansion for receptor-engineered adoptive immunotherapy
Christopher Klebanoff, Joseph G. Crompton, Anthony Leonardi, Tori Yamamoto, Smita Chandran, Robert Eil, Madhusudhanan Sukumar, Suman Kumar Vodnala, Jinhui Hu, Yun Ji, David Clever, Mary Black, Devikala Gurusamy, Michael Kruhlak, Ping Jin, David Stroncek, Luca Gattinoni, Steven A. Feldman, Nicholas Restifo |
JCI Insight | 2017 |
Fine-tuning the CAR spacer improves T-cell potency
N Watanabe, P Bajgain, S Sukumaran, S Ansari, HE Heslop, CM Rooney, MK Brenner, AM Leen, JF Vera |
OncoImmunology | 2017 |
Trial Watch: Adoptively transferred cells for anticancer immunotherapy
C Fournier, F Martin, L Zitvogel, G Kroemer, L Galluzzi, L Apetoh |
OncoImmunology | 2017 |
Novel Immunotherapies for Multiple Myeloma
M DAgostino, M Boccadoro, EL Smith |
Current Hematologic Malignancy Reports | 2017 |
T memory stem cells in health and disease
L Gattinoni, DE Speiser, M Lichterfeld, C Bonini |
Nature Medicine | 2017 |
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma
A Heczey, CU Louis, B Savoldo, O Dakhova, A Durett, B Grilley, H Liu, MF Wu, Z Mei, A Gee, B Mehta, H Zhang, N Mahmood, H Tashiro, HE Heslop, G Dotti, CM Rooney, MK Brenner |
Molecular Therapy | 2017 |
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
JN Kochenderfer, RP Somerville, T Lu, V Shi, A Bot, J Rossi, A Xue, SL Goff, JC Yang, RM Sherry, CA Klebanoff, US Kammula, M Sherman, A Perez, CM Yuan, T Feldman, JW Friedberg, MJ Roschewski, SA Feldman, L McIntyre, MA Toomey, SA Rosenberg |
Journal of Clinical Oncology | 2017 |
CAR T-cell therapy for pancreatic cancer
CJ DeSelm, ZE Tano, AM Varghese, PS Adusumilli |
Journal of Surgical Oncology | 2017 |
Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective
I Rivière, M Sadelain |
Molecular Therapy | 2017 |
Immunotherapy in hematologic malignancies: past, present, and future
A Im, SZ Pavletic |
Journal of Hematology & Oncology | 2017 |
Therapeutic T cell engineering
M Sadelain, I Rivière, S Riddell |
Nature | 2017 |
Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains
L Alabanza, M Pegues, C Geldres, V Shi, JJ Wiltzius, SA Sievers, S Yang, JN Kochenderfer |
Molecular Therapy | 2017 |
Chimeric antigen receptor T-cell therapies for lymphoma
JN Brudno, JN Kochenderfer |
Nature Reviews Clinical Oncology | 2017 |
Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML
F Perna, SH Berman, RK Soni, J Mansilla-Soto, J Eyquem, M Hamieh, RC Hendrickson, CW Brennan, M Sadelain |
Cancer Cell | 2017 |
Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors
A Ghosh, I Politikos, MA Perales |
Current Opinion in Oncology | 2017 |
CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
A Ghosh, S Mailankody, SA Giralt, CO Landgren, EL Smith, RJ Brentjens |
Leukemia & Lymphoma | 2017 |
CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond
ZN Chang, YY Chen |
Trends in Molecular Medicine | 2017 |
Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies
KA Hay, CJ Turtle |
Drugs | 2017 |
An Update on the Use of Immunotherapy in the Treatment of Lymphoma
TU Marron, M Kalac, J Brody |
Current Hematologic Malignancy Reports | 2017 |
Adoptive T-Cell Therapy for Solid Tumors
O Yeku, X Li, RJ Brentjens |
American Society of Clinical Oncology Educational Book | 2017 |
A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia
SK Oda, AW Daman, NM Garcia, F Wagener, TM Schmitt, X Tan, AG Chapuis, PD Greenberg |
Blood | 2017 |
New development in CAR-T cell therapy
Z Wang, Z Wu, Y Liu, W Han |
Journal of Hematology & Oncology | 2017 |
Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells
L Qin, Y Lai, R Zhao, X Wei, J Weng, P Lai, B Li, S Lin, S Wang, Q Wu, Q Liang, Y Li, X Zhang, Y Wu, P Liu, Y Yao, D Pei, X Du, P Li |
Journal of Hematology & Oncology | 2017 |
Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
Z Wang, Y Guo, W Han |
Protein & Cell | 2017 |
Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies
A Rotolo, A Karadimitris, M Ruella |
Leukemia & Lymphoma | 2017 |
Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent
D Gomes-Silva, M Mukherjee, M Srinivasan, G Krenciute, O Dakhova, Y Zheng, JM Cabral, CM Rooney, JS Orange, MK Brenner, M Mamonkin |
Cell Reports | 2017 |
Development of T cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse
RG Dossa, T Cunningham, D Sommermeyer, I Medina-Rodriguez, MA Biernacki, K Foster, M Bleakley |
Blood | 2017 |
Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs
G Pittari, L Vago, M Festuccia, C Bonini, D Mudawi, L Giaccone, B Bruno |
Frontiers in immunology | 2017 |
Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy
R Urak, M Walter, L Lim, CL Wong, LE Budde, S Thomas, SJ Forman, X Wang |
Journal for ImmunoTherapy of Cancer | 2017 |
TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance
Y Yang, ME Kohler, CD Chien, CT Sauter, E Jacoby, C Yan, Y Hu, K Wanhainen, H Qin, TJ Fry |
Science Translational Medicine | 2017 |
The Principles of Engineering Immune Cells to Treat Cancer
WA Lim, CH June |
Cell | 2017 |
Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy
AD Fesnak, PJ Hanley, BL Levine |
Current Hematologic Malignancy Reports | 2017 |
Preclinical and clinical advances in transposon-based gene therapy
J Tipanee, YC Chai, T VandenDriessche, MK Chuah |
Bioscience Reports | 2017 |
Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells
DT MacLeod, J Antony, AJ Martin, RJ Moser, A Hekele, KJ Wetzel, AE Brown, MA Triggiano, JA Hux, CD Pham, VV Bartsevich, CA Turner, J Lape, S Kirkland, CW Beard, J Smith, ML Hirsch, MG Nicholson, D Jantz, B McCreedy |
Molecular Therapy | 2017 |
Chimeric antigen receptor engineered stem cells: a novel HIV therapy
A Zhen, MA Carrillo, SG Kitchen |
Immunotherapy | 2017 |
T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas: Sarcoma Immune Microenvironment
SM Pollack, Q He, JH Yearley, R Emerson, M Vignali, Y Zhang, MW Redman, KK Baker, S Cooper, B Donahue, ET Loggers, LD Cranmer, MB Spraker, YD Seo, VG Pillarisetty, RW Ricciotti, BL Hoch, TK McClanahan, E Murphy, WM Blumenschein, SM Townson, S Benzeno, SR Riddell, RL Jones |
Cancer | 2017 |
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
KG Anderson, IM Stromnes, PD Greenberg |
Cancer Cell | 2017 |
Fully human CD19-specific chimeric antigen receptors for T-cell therapy
D Sommermeyer, T Hill, SM Shamah, AI Salter, Y Chen, KM Mohler, SR Riddell |
Leukemia | 2017 |
Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice
MR Luskin, DJ DeAngelo |
Current Hematologic Malignancy Reports | 2017 |
Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults
RA Gardner, O Finney, C Annesley, H Brakke, C Summers, K Leger, M Bleakley, C Brown, S Mgebroff, K Spratt, V Hoglund, C Lindgren, AP Oron, D Li, SR Riddell, JR Park, MC Jensen |
Blood | 2017 |
Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities
AL Xia, XC Wang, YJ Lu, XJ Lu, B Sun |
Oncotarget | 2017 |
Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies
M Mamonkin, M Mukherjee, M Srinivasan, S Sharma, D Gomes-Silva, F Mo, G Krenciute, JS Orange, MK Brenner |
Cancer immunology research | 2017 |
Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf
M Ruella, SS Kenderian |
BioDrugs | 2017 |
Antigen receptor-redirected T cells derived from hematopoietic precursor cellslack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities
YV Caeneghem, SD Munter, P Tieppo, G Goetgeluk, K Weening, G Verstichel, S Bonte, T Taghon, G Leclercq, T Kerre, R Debets, D Vermijlen, H Abken, B Vandekerckhove |
OncoImmunology | 2017 |
Cells to prevent/treat relapse following allogeneic stem cell transplantation
AC Dietz, AS Wayne |
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program | 2017 |
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
FL Locke, SS Neelapu, NL Bartlett, T Siddiqi, JC Chavez, CM Hosing, A Ghobadi, LE Budde, A Bot, JM Rossi, Y Jiang, AX Xue, M Elias, J Aycock, J Wiezorek, WY Go |
Molecular Therapy | 2017 |
Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma
K Feng, Y Guo, Y Liu, H Dai, Y Wang, H Lv, J Huang, Q Yang, W Han |
Journal of Hematology & Oncology | 2017 |
CARs in the Lead Against Multiple Myeloma
M Ormhøj, F Bedoya, MJ Frigault, MV Maus |
Current Hematologic Malignancy Reports | 2017 |
Masked Chimeric Antigen Receptor for Tumor-Specific Activation
X Han, PD Bryson, Y Zhao, GE Cinay, S Li, Y Guo, N Siriwon, P Wang |
Molecular Therapy | 2017 |
Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis
MB Geyer, M Hsu, SM Devlin, MS Tallman, D Douer, JH Park |
Blood | 2017 |
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
G Wei, L Ding, J Wang, Y Hu, H Huang |
Experimental Hematology and Oncology | 2017 |
The Why, what, and How of the New FACT standards for immune effector cells
MV Maus, S Nikiforow |
Journal for ImmunoTherapy of Cancer | 2017 |
Genome variation across cancers scales with tissue stiffness – An invasion-mutation mechanism and implications for immune cell infiltration
CR Pfeifer, CM Alvey, J Irianto, DE Discher |
Current Opinion in Systems Biology | 2017 |
Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia
SK Tasian, SS Kenderian, F Shen, M Ruella, O Shestova, M Kozlowski, Y Li, A Schrank-Hacker, JJ Morrissette, M Carroll, CH June, SA Grupp, S Gill |
Blood | 2017 |
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib
CJ Turtle, KA Hay, LA Hanafi, D Li, S Cherian, X Chen, B Wood, A Lozanski, JC Byrd, S Heimfeld, SR Riddell, DG Maloney |
Journal of Clinical Oncology | 2017 |
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies
D Gomes-Silva, M Srinivasan, S Sharma, CM Lee, DL Wagner, TH Davis, RH Rouce, G Bao, MK Brenner, M Mamonkin |
Blood | 2017 |
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
DM ORourke, ML Nasrallah, A Desai, JJ Melenhorst, K Mansfield, JJ Morrissette, M Martinez-Lage, S Brem, E Maloney, A Shen, R Isaacs, S Mohan, G Plesa, SF Lacey, JM Navenot, Z Zheng, BL Levine, H Okada, CH June, JL Brogdon, MV Maus |
Science Translational Medicine | 2017 |
Recent developments in immunotherapy of acute myeloid leukemia
FS Lichtenegger, C Krupka, S Haubner, T Köhnke, M Subklewe |
Journal of Hematology & Oncology | 2017 |
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
SS Neelapu, S Tummala, P Kebriaei, W Wierda, C Gutierrez, FL Locke, KV Komanduri, Y Lin, N Jain, N Daver, J Westin, AM Gulbis, ME Loghin, JF de Groot, S Adkins, SE Davis, K Rezvani, P Hwu, EJ Shpall |
Nature Reviews Clinical Oncology | 2017 |
Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering
X Han, GE Cinay, Y Zhao, Y Guo, X Zhang, P Wang |
Molecular Therapy | 2017 |
Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors
TA Baeumler, AA Ahmed, TA Fulga |
Cell Reports | 2017 |
Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia
G Wei, J Wang, H Huang, Y Zhao |
Journal of Hematology & Oncology | 2017 |
Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts
J Hartmann, M SchüßlerLenz, A Bondanza, CJ Buchholz |
EMBO Molecular Medicine | 2017 |
Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells
MB Geyer, SH Manjunath, AG Evans, JH Park, ML Davila, CS Cutler, X Wang, Y Wang, B Senechal, I Rivière, M Sadelain, JL Liesveld, RJ Brentjens |
Leukemia & Lymphoma | 2017 |
Clinical trials of CAR-T cells in China
B Liu, Y Song, D Liu |
Journal of Hematology & Oncology | 2017 |
Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA + Metastatic Colorectal Cancers
C Zhang, Z Wang, Z Yang, M Wang, S Li, Y Li, R Zhang, Z Xiong, Z Wei, J Shen, Y Luo, Q Zhang, L Liu, H Qin, W Liu, F Wu, W Chen, F Pan, X Zhang, P Bie, H Liang, G Pecher, C Qian |
Molecular Therapy | 2017 |
Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells
M Ruella, M Klichinsky, SS Kenderian, O Shestova, A Ziober, DO Kraft, M Feldman, MA Wasik, CH June, S Gill |
Cancer Discovery | 2017 |
Driving better and safer HER2-specific CARs for cancer therapy
X Liu, N Zhang, H Shi |
Oncotarget | 2017 |
Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line
D Gomes-Silva, CA Ramos |
Biotechnology Journal | 2017 |
Integrating a 19F MRI Tracer Agent into the Clinical Scale Manufacturing of a T-Cell Immunotherapy
CF OHanlon, T Fedczyna, S Eaker, WD Shingleton, BM Helfer |
Contrast Media & Molecular Imaging | 2017 |
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
KA Hay, LA Hanafi, D Li, J Gust, WC Liles, MM Wurfel, JA López, J Chen, D Chung, S Harju-Baker, S Cherian, X Chen, SR Riddell, DG Maloney, CJ Turtle |
Blood | 2017 |
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia
KT Mueller, SL Maude, DL Porter, N Frey, P Wood, X Han, E Waldron, A Chakraborty, R Awasthi, BL Levine, JJ Melenhorst, SA Grupp, CH June, SF Lacey |
Blood | 2017 |
Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies
YT Png, N Vinanica, T Kamiya, N Shimasaki, E Coustan-Smith, D Campana |
Blood Advances | 2017 |
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types
C Lonez, B Verma, A Hendlisz, P Aftimos, A Awada, EV Neste, G Catala, JP Machiels, F Piette, JB Brayer, DA Sallman, T Kerre, K Odunsi, ML Davila, DE Gilham, FF Lehmann |
BMJ Open | 2017 |
Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
J Gust, KA Hay, LA Hanafi, D Li, D Myerson, LF Gonzalez-Cuyar, C Yeung, WC Liles, M Wurfel, JA Lopez, J Chen, D Chung, S Harju-Baker, T Özpolat, KR Fink, SR Riddell, DG Maloney, CJ Turtle |
Cancer Discovery | 2017 |
Fluorine-19 nuclear magnetic resonance of chimeric antigen receptor T cell biodistribution in murine cancer model
F Chapelin, S Gao, H Okada, TG Weber, K Messer, ET Ahrens |
Scientific Reports | 2017 |
Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells
N Mitwasi, A Feldmann, R Bergmann, N Berndt, C Arndt, S Koristka, A Kegler, J Jureczek, A Hoffmann, A Ehninger, M Cartellieri, S Albert, C Rossig, G Ehninger, J Pietzsch, J Steinbach, M Bachmann |
Oncotarget | 2017 |
Hematopoietic stem cell involvement in BCR-ABL1– positive ALL as a potential mechanism of resistance to blinatumomab therapy
I Nagel, M Bartels, J Duell, HH Oberg, S Ussat, H Bruckmueller, O Ottmann, H Pfeifer, H Trautmann, N Gökbuget, A Caliebe, D Kabelitz, M Kneba, HA Horst, D Hoelzer, MS Topp, I Cascorbi, R Siebert, M Brüggemann |
Blood | 2017 |
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
SS Neelapu, FL Locke, NL Bartlett, LJ Lekakis, DB Miklos, CA Jacobson, I Braunschweig, OO Oluwole, T Siddiqi, Y Lin, JM Timmerman, PJ Stiff, JW Friedberg, IW Flinn, A Goy, BT Hill, MR Smith, A Deol, U Farooq, P McSweeney, J Munoz, I Avivi, JE Castro, JR Westin, JC Chavez, A Ghobadi, KV Komanduri, R Levy, ED Jacobsen, TE Witzig, P Reagan, A Bot, J Rossi, L Navale, Y Jiang, J Aycock, M Elias, D Chang, J Wiezorek, WY Go |
New England Journal of Medicine | 2017 |
Infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy
JA Hill, D Li, KA Hay, ML Green, S Cherian, X Chen, SR Riddell, DG Maloney, M Boeckh, CJ Turtle |
Blood | 2017 |
Progress in adult ALL: incorporation of new agents to frontline treatment
J Leonard, W Stock |
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program | 2017 |
儿童急性髓系白血病靶向治疗进展
|
2017 | |
Understanding cytokine release syndrome.
Gödel P, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M |
Intensive Care Medicine | 2017 |
Adoptive T-Cell Therapy for Solid Tumors.
Yeku O, Li X, Brentjens RJ |
2017 | |
Is Disease-Specific Immunotherapy a Potential Reality for MDS?
Sallman DA, Davila ML |
Clinical Lymphoma, Myeloma & Leukemia | 2017 |
A Novel Strategy for Preventing Antigen-Loss Relapses after CD19-directed Immunotherapies
Marco Ruella, David Barrett, Saad S. Kenderian, Olga Shestova, Ted Hofmann, Jessica Perazzelli, Michael Klichinsky, Vania Aikawa, Farzana Nazimuddin, Miroslaw Kozlowski, John Scholler, Simon Lacey, Jan Melenhorst, Jennifer J.D. Morrissette, David A. Christian, Christopher A. Hunter, Michael Kalos, David Porter, Carl June, Stephan A. Grupp, Saar Gill |
Journal of Clinical Investigation | 2016 |
Targeted antibody-mediated depletion of CD19 CAR-T cells permanently reverses B cell aplasia
Paulina Paszkiewicz, Simon Fräßle, Shivani Srivastava, Daniel Sommermeyer, Michael Hudecek, Ingo Drexler, Michel Sadelain, Lingfeng Liu, Michael Jensen, Stanley R. Riddell, Dirk Busch |
Journal of Clinical Investigation | 2016 |
Longitudinal PET imaging demonstrates biphasic CAR-T cell responses in survivors
Yogindra Vedvyas, Enda Shevlin, Marjan Zaman, Irene Min, Alejandro Amor-Coarasa, Spencer Park, Susan Park, Keon-Woo Kwon, Turner Smith, Yonghua Luo, Dohyun Kim, Young Kim, Benedict Law, Richard Ting, John Babich, Moonsoo Jin |
JCI Insight | 2016 |
Recent advances in T-cell immunotherapy for haematological malignancies
RH Rouce, S Sharma, M Huynh, HE Heslop |
British Journal of Haematology | 2016 |
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies
M Sabatino, J Hu, M Sommariva, S Gautam, V Fellowes, JD Hocker, S Dougherty, H Qin, CA Klebanoff, TJ Fry, RE Gress, JN Kochenderfer, DF Stroncek, Y Ji, L Gattinoni |
Blood | 2016 |
Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells
HH van Acker, S Anguille, Y Willemen, JM van Bergh, ZN Berneman, E Lion, EL Smits, VF van Tendeloo |
Journal of Hematology & Oncology | 2016 |
A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies
TL Lu, O Pugach, R Somerville, SA Rosenberg, JN Kochenderfer, M Better, SA Feldman |
Human Gene Therapy Methods | 2016 |
Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination
A Redeker, R Arens |
Frontiers in immunology | 2016 |
Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
M Ruella, MV Maus |
Computational and Structural Biotechnology Journal | 2016 |
Engineered T cells: the promise and challenges of cancer immunotherapy
AD Fesnak, CH June, BL Levine |
Nature Reviews Cancer | 2016 |
Does it make sense to target one tumor cell chemotactic factor or its receptor when several chemotactic axes are involved in metastasis of the same cancer?
MZ Ratajczak, M Suszynska, M Kucia |
Clinical and Translational Medicine | 2016 |
Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells
MB Geyer, RJ Brentjens |
Cytotherapy | 2016 |
Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
CT Ellebrecht, VG Bhoj, A Nace, EJ Choi, X Mao, MJ Cho, GD Zenzo, A Lanzavecchia, JT Seykora, G Cotsarelis, MC Milone, AS Payne |
Science | 2016 |
Immunotherapy of non-Hodgkins lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells
CJ Turtle, LA Hanafi, C Berger, M Hudecek, B Pender, E Robinson, R Hawkins, C Chaney, S Cherian, X Chen, L Soma, B Wood, D Li, S Heimfeld, SR Riddell, DG Maloney |
Science Translational Medicine | 2016 |
Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol
XY Tang, Y Sun, A Zhang, GL Hu, W Cao, DH Wang, B Zhang, H Chen |
BMJ Open | 2016 |
Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART before the Horse
SS Kenderian, DL Porter, S Gill |
Biology of Blood and Marrow Transplantation | 2016 |
Toxicities of chimeric antigen receptor T cells: recognition and management
JN Brudno, JN Kochenderfer |
Blood | 2016 |
Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You
M Ruella, CH June |
Current Hematologic Malignancy Reports | 2016 |
Immunotherapy for acute lymphoblastic leukemia: from famine to feast
KL Davis, CL Mackall |
Blood Advances | 2016 |
Recent advances in T-cell engineering for use in immunotherapy
P Sharma, DM Kranz |
F1000Research | 2016 |
Immunotherapy for opportunistic infections: Current status and future perspectives
S Fuji, J Löffler, H Einsele, M Kapp |
Virulence | 2016 |
Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy
HR Mirzaei, H Mirzaei, SY Lee, J Hadjati, BG Till |
Cancer Letters | 2016 |
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
Y Hu, J Sun, Z Wu, J Yu, Q Cui, C Pu, B Liang, Y Luo, J Shi, A Jin, L Xiao, H Huang |
Journal of Hematology & Oncology | 2016 |
Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors
R Monjezi, C Miskey, T Gogishvili, M Schleef, M Schmeer, H Einsele, Z Ivics, M Hudecek |
Leukemia | 2016 |
Forecasting Cytokine Storms with New Predictive Biomarkers
RH Rouce, HE Heslop |
Cancer Discovery | 2016 |
Making urothelial carcinomas less immune to immunotherapy
JD Ramos, EY Yu |
Urologic Oncology: Seminars and Original Investigations | 2016 |
Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors
I Aldoss, RC Bargou, D Nagorsen, GR Friberg, PA Baeuerle, SJ Forman |
Leukemia | 2016 |
BCR-ABL–specific T-cell therapy in Ph + ALL patients on tyrosine-kinase inhibitors
P Comoli, S Basso, G Riva, P Barozzi, I Guido, A Gurrado, G Quartuccio, L Rubert, I Lagreca, D Vallerini, F Forghieri, M Morselli, P Bresciani, A Cuoghi, A Paolini, E Colaci, R Marasca, A Cuneo, L Iughetti, T Trenti, F Narni, R Foà, M Zecca, M Luppi, L Potenza |
Blood | 2016 |
New insights into effective targeted therapy for the treatment of adult acute lymphoblastic leukemia
X Thomas |
International Journal of Hematologic Oncology | 2016 |
Human Vaccines & Immunotherapeutics: News
|
Human Vaccines & Immunotherapeutics | 2016 |
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |